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Abstract 
Type 2 diabetes mellitus affects over 100 million people worldwide. It is characterized by 
various metabolic abnormalities such as insulin resistance, aberrant insulin secretion, 
hyperglycaemia and a cluster of cardiovascular risk factors, including increased oxidative 
stress. It is associated with microvascular complications and increased potential of 
macrovascular disease. The aim of the studies described in this thesis was to test the 
hypothesis that oxidant stress contributes to an altered vascular function and impaired 
insulin regulation in a pre-diabetic animal model- the obese Zucker rats. 
The first objective was to develop new methods to measure endothelial function in animal 
disease models. Firstly, without autonomic control - the in situ perfused hindquarters, and 
secondly, with autonomic control - the in vivo Doppler ear blood flow. 
The obese Zucker rat was shown to have increased oxidative stress, as measured by plasma 
8-epi-PGF2a,. It also had high insulin and glucose levels and impaired glucose disposal. 
Obese rats also had increased agonist-induced nitric oxide-dependent endothelial responses; 
these were further enhanced by insulin in a macrovascular preparation, but were impaired 
by insulin in a resistance vessel bed. 
Following dietary treatment with the antioxidants, the obese plasma insulin/glucose ratio 
was improved. However, vitamin E blunted the enhanced endothelial-dependent vasodilator 
responses, and decreased plasma levels of 8-epi-PGF2a. In contrast, pro-oxidant treatment 
with hydroquinone and buthionine-sulphoximine impaired the plasma insulin/glucose ratio, 
abolished endothelial hyperactivity but increased plasma 8-epi-PGF2a levels. Interestingly, 
fructose protected against pro-oxidant-induced increases in plasma 8-epi-PGF2a levels and 
further increases in glucose-induced plasma insulin. 
In summary the redox status in obese Zucker rats was modified with antioxidant and pro- 
oxidant treatment. This resulted in compensatory changes in glucose disposal and 
endothelial function. Impaired endothelial function may initiate "damage" especially in 
those individuals susceptible to syndrome X, leading to insulin insensitivity and vascular 
dysfunction in type 2 diabetes. 
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1.1 DIABETES MELLITUS 
Diabetes mellitus is a metabolic disorder affecting many millions of people worldwide. It is 
characterised by hyperglycaemia, glycosuria, polyuria, polydypsia and ketosis. The 
underlying fundamental nature of the disease is a relative or absolute deficiency of insulin 
activity, arising from an abnormality in the islets of Langerhans. 
Diabetes mellitus is classified into 2 groups. Type 1 develops in childhood it is 
characterised by a rapid onset of a severe syndrome. It is autoimmune in nature and occurs 
when ß-cells are destroyed and there is severe or an absolute insulin deficiency (Castano & 
Eisenbarth, 1990). The causes of type 1 diabetes are complex and still not completely 
understood. Type 1 diabetics are thought to have an inherited, or genetic, predisposition to 
the disease. It is theorized that this genetic predisposition may remain dormant until it is 
activated by an environmental trigger such as a virus or a chemical. This starts an attack on 
the immune system that results in the eventual destruction of the insulin producing (3-cells. 
1.1.1 Type 2 diabetes 
Type 2 diabetes is a condition affecting over 100 million people worldwide and accounts 
for 90-95 % of all diagnosed diabetic cases. This number is expected to double over the 
next 25 years. It develops later in life and is characterised by a gradual onset. Patients may 
have a long pre-diabetic phase with no glucose intolerance. This metabolic disorder is 
characterised by chronic hyperglycaemia and disturbances in carbohydrate, fat and protein 
metabolism. The disease typically exhibits defect(s) in insulin secretion and in many cases 
insulin resistance. Eventually the pancreatic ß-cells fail and low insulin secretion results in 
hyperglycaemia. Hyperglycaemia can then further progress the pre-existing (3-cell 
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dysfunction and more importantly increase the potential of macrovascular disease (Fuller et 
al., 1983) and microvascular complications (WHO, 1999). 
The genetic factors predisposing an individual to type 2 diabetes are still poorly understood. 
Direct evidence of genetic insulin abnormalities from single point mutations, such as 
Leprechaunism or Rabson-Mendenhall syndrome, are usually rare and severe. Studies in 
animal models have shown that the majority of defects are multiple. For example, the 
knockout mouse heterozygous for the insulin receptor or insulin receptor substrate-1 (IRS- 
1) is not insulin resistant yet mice heterozygous for both the insulin receptor and IRS-1 are 
insulin resistant (Consensus development conference on insulin resistance, 1998). Indirect 
evidence for genetic susceptibility to type 2 diabetes comes from family and ethnic 
assessments. Pima Indians in Arizona have the highest prevalence in world (-35 %), while 
Melanesians in New Guinea demonstrated low prevalence (-0%) (King & Zimmet, 1988). 
The strongest evidence comes from identical twin studies where there is almost complete 
concordance for type 2 diabetes in monozygote twins (Newman et al., 1987; Medici et al., 
1999). The prevalence of type 2 diabetes in developing countries has given rise to the 
thrifty gene hypothesis (Neel, 1962). It is thought that the genetic trait which enables an 
individual to store and mobilise energy efficiently during times of hunting and gathering 
may improve survival in times of famine. However these genetic traits combined with 
today's sedentary lifestyles and increased dietary fat and carbohydrates, leads to obesity. 
And indeed as the risk factors - age, obesity, sedentary lifestyle and intra-abdominal fat 
increase, they correlate to the development of type 2 diabetes (Banerji et al., 1995). More 
recent studies have suggested a thrifty phenotype hypothesis (Hales et al., 1992), as poor 
foetal and early post-natal nutrition results in impaired long-term development of the 
endocrine pancreas and a greater susceptibility to type 2 diabetes. Gestational diabetes 
sometimes called type 4 diabetes is a condition where glucose intolerance is first 
recognised during pregnancy. However, in most patients it cannot be established if the 
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onset of diabetes occurs prior to or during pregnancy. Gestational diabetes is thought to 
develop in response to the production of the placental hormones progesterone (Branisteanu 
& Mathieu, 2003), cortisol, prolactin, human placental lactogen, and oestrogen as they have 
been shown, in animal models, to influence n-cell function and/or the peripheral tissue 
sensitivity to insulin (Kuhl, 1998). There is also an increased risk of hypertension and pre- 
eclampsia especially when the diabetes is poorly controlled. Recent studies have shown a 
correlation with the future development of type 2 diabetes (Verma et al., 2002) in women 
who previously had gestational diabetes. Type 3 diabetes according to etiologic 
classification includes many specific types of diabetes, such as genetic defects of ß-cell 
function or insulin action, diseases of the exocrine pancreas, endocrinopathies, drug or 
chemically-induced changes, infection-induced changes, and other genetic syndromes 
sometimes associated with diabetes (Report of the Expert Committee on the Diagnosis and 
Classification of Diabetes Mellitus, 2000). 
1.1.2 Syndrome X 
Syndrome X is a metabolic disorder where a number of type 2-diabetes risk factors 
including obesity, hypertension, glucose intolerance and hyperinsulinemia are clustered 
together (Reaven, 1988). It has been proposed that syndrome X may reflect a number of 
abnormalities or just a single abnormality. It is not known if insulin resistance is a 
consequence of the other disorders such as hypertension or hyperlipidaemia rather than 
itself a cause. Insulin resistance and /or hyperinsulinaemia have been shown to be 
predictors of type 2 diabetes. There is also evidence for a neurohormonal mechanism, 
including an endocrine role for adipocytes (Chan et al., 2001). The distribution and 
deposition of adipose tissue is under the control of pituitary hormones such as the sex 
steroids, growth hormone, and the pituitary-adrenal axis. Interestingly, studies have 
suggested that increased prevalence of psychosocial stress factors is associated with visceral 
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distribution of body fat and is associated with changes in the pituitary hormone levels 
(Bjorntorp, 1991). 
The obese Zucker has the clustered abnormalities characteristic of syndrome X and can 
therefore be used as a model of insulin resistance and of the pre-diabetic state (Maher et al., 
1995). It is also therefore a good model to study insulin resistance and the effects of 
oxidant stress on endothelial function. The use of diet and pharmacological interventions 
was studied to improve and further impair vascular function in this thesis as the decline of 
endothelial function may contribute to early disease and is certainly involved in frank 
disease complications. 
1.2 INSULIN 
Insulin is composed of 2 peptide chains (A-chain, 21 amino acids and B, 30 amino acids) 
linked by 2 disulphide bridges. Proinsulin is synthesised in the ß-cells of the islets of 
Langerhans in the pancreas. It is then cleaved to form insulin and the inactive C-peptide. 
Uncleaved proinsulin, insulin and the C-peptide are packed into granules and released 
together into the circulation. Proinsulin has about 10% of the biological activity of insulin 
whereas the C-peptide is inactive. The half life of insulin in the plasma is no more than a 
few minutes. Most tissues have the ability to destroy insulin by enzymatic disruption. The 
enzyme glutathione insulin transhydrogenase catalyses the reduction and cleavage of 
disulphide bonds, liberating the separate A and B chains of insulin. At the same time 
reduced glutathione and NADPH are oxidised to glutathione and NADP. 
The major stimulus for insulin synthesis and secretion is the elevation of blood glucose 
concentration as the islet cells are freely permeable to glucose. The action of glucose on 
insulin secretion is biphasic - first pre-formed insulin is rapidly secreted followed by a 
20 
slower prolonged response, which is dependent on de novo insulin synthesis (DeFronzo et 
al., 1979). This acute first phase of insulin secretion is reduced or absent in diabetic patients 
(Brunzell et al., 1976). Interestingly, studies using human (3-cells in vitro have shown that 
their incubation with free fatty acids causes impairment of this first phase response (Lupi et 
al., 2002). The release of insulin can also be stimulated by fructose. More importantly, 
orally ingested food is a greater stimulus for insulin secretion, due to gastrointestinal 
hormones release which potentiates secretion. The ß-cells are innervated with 
noradrenergic and cholinergic nerve fibres and adrenaline and noradrenaline act on a- 
adrenoceptors to inhibit insulin release. It is thought that neural control is involved in the 
fine control of insulin release. 
Insulin is a powerful pleuripotent anabolic hormone that binds a highly regulated and 
specific glycoprotein receptor present on the cell surface. Following binding, the receptor is 
autophosphorylated on multiple tyrosine residues. This causes activation of receptor kinase 
and tyrosine phosphorylation of a family of insulin receptor substrate (IRS) proteins. The 
IRS proteins then produce a series of protein-protein interactions that transmit signals from 
the receptor to cascade into the cell compartments. The final cellular effects being glucose 
uptake into all types of muscle, adipose tissue, leukocytes, fibroblasts, the lens of the eye, 
the aqueous humour, the pituitary gland and the liver. The glucose taken up under the 
influence of insulin is either utilised as fuel or converted to glycogen (Fig. 1.1). Insulin also 
promotes the uptake of K+, amino acids and stimulates protein synthesis particularly in 
skeletal muscle. The action of insulin on adipocytes allows the uptake of glucose which is 
then available for synthesis into fatty acids and glycerol-3-phosphate and thence into 
triglycerides. However insulin also depresses lipolysis and consequently free fatty acid 
release. In addition, in response to insulin, adipose tissue in turn, releases various 
modulators of insulin secretion and insulin action, including leptin, tumour necrosis factor- 
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Figure 1.1 Metabolic effects of insulin in the liver, smooth muscle cells 
(SMCs) and adipose tissue. The illustration is adapted from flesh and 
bones. com Baynes: Medical Biochemistry. 
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1.2.1 Hyperinsulinaemia 
Hyperinsulinaemia is an early compensatory response to insulin resistance; it is also 
considered to be the core defect underlying long term complications of type 2 diabetes. In 
addition to environmental factors such as increased levels of glucose and free fatty acids, 
hyperinsulinaemia potentially arises from a number of abnormalities such as abnormal 
insulin or insulin antibodies (Shimoyama et al., 1989), glycosylation of receptors, mutation 
of the insulin receptor (Krook et al., 1996), deficiency of glucose transporter (GLUT) 
molecules (Petersen et al., 2002) or abnormal signal transduction and phosphorylation 
reactions at the post receptor level.. Pre-diabetic conditions show increased levels of insulin 
to make up for the lack of insulin sensitivity - glucose tolerance is maintained in the normal 
range by this increased insulin secretion. However, this increased insulin secretion 
eventually leads to ß-cell failure and type 2 diabetes. This glucose-insulin relationship is 
clinically important, but it also important to recognise that insulin resistance applies to lipid 
and protein metabolism, gene expression and most interestingly, endothelial function 
(Consensus development conference on insulin resistance, 1998). 
Insulin resistance per=se independent of hyperglycaemia is thought not to have a role in 
diabetic complications such as retinopathy, nephropathy or neuropathy. However, there is 
evidence to suggest it increases susceptibility to macrovascular disease and atherosclerosis. 
In addition to increasing triglycerides, it is also implicated in changes in endothelium- 
dependent function, which will be discussed later in this chapter. 
Studies in individuals have shown that type 2 diabetes indices can be improved with insulin 
sensitizer drugs such as Metformin or thiazolidinediones. Metformin enhances the action of 
insulin, causing suppression of hepatic glucose output and improvement in peripheral 
glucose utilisation. The precise mechanism of action of metformin remains unclear, but 
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may be by interruption of the mitochondrial oxidative processes in the liver and correction 
of abnormalities of intracellular Ca2+ metabolism in insulin-sensitive tissues (liver, skeletal 
muscle, and adipocytes) and cardiovascular tissue (Kirpichnikov et al., 2002). Troglitazone 
is a thiazolidinedione, an insulin sensitizer, and enhances the insulin-stimulated peripheral 
glucose disposal. Troglitazone acts on the peroxisome proliferator activated receptor y 
(PPARy), a member of the nuclear-hormone-receptor family (PPAR (x, S, and y). After 
binding, the activated complex translocates to the nucleus and binds cognate promoter 
elements, that in turn upregulate expression of genes. How PPARs improve insulin 
sensitivity remains unclear but is likely to involve regulation of genes involved in the 
increased hydrolysis of triglycerides, decreased synthesis of fatty acids and triglycerides, as 
well as increased glucose uptake via the insulin sensitive transporter GLUT4. Studies into 
the molecular basis of insulin resistance have recently shown two loss-of function 
mutations of PPARy to be associated with severe insulin resistance in type 2 diabetes 
patients (Barroso et al., 1999). However studies in heterozygous PPARy +/- mice show 
decreased insulin levels, enhanced glucose disposal rate and a reduction in PPARy 
receptors in peripheral and hepatic tissues. This suggests that PPARs may act to dampen 
the action of insulin and promote insulin resistance and that thiazolidinediones may act as 
partial agonists or antagonists (Olefsky, 2000). In addition to the pharmacological 
interventions there are many natural ligands of PPARs. Endogenous ligands include fatty, 
arachidonic and linoleic acids, many eicosanoids, and oxidised and native low density 
lipoprotein (LDL). Exogenous activators of PPAR include thiazolidinediones (increases 
insulin sensitivity), fibrates (lowers cholesterol) and indomethacin (anti-inflammatory). As 
PPAR has a large binding pocket and has many low affinity endogenous ligands, it has 
been proposed that PPAR may be acting as a lipid sensor. 
The function of insulin receptors present on the endothelium is also unclear and they were 
initially thought to facilitate the transport of insulin across the vascular barrier and into the 
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subendothelial space (Bar et al., 1978). However insulin also regulates endothelial-derived 
mediators involved in vasodilation, mitogenesis and, more controversially, 
vasoconstriction. Many studies have now demonstrated a vasodilator action by insulin 
(Liang et al., 1982; Baron et al., 1993) through the stimulated release of nitric oxide (NO) 
by the endothelium (Steinberg et al., 1994). However insulin has also been shown to induce 
vasoconstriction (Edwards & Tipton, 1989), through both sympathetic mediators (Henrion 
& Laher, 1994), and via the release of endothelin-1 from endothelial cells (Hattori et al., 
1991). Insulin may also increase blood pressure by prompting salt and water retention via 
sympathetic nervous system. 
1.3 THE ENDOTHELIUM 
The vascular endothelium is an endocrine organ that maintains blood flow by regulation of 
vascular tone. It was once thought to be a simple barrier between blood borne substances 
and the underlying smooth muscle cells. However it is now known to be important in 
control of local homeostasis (prevention of fibrinolysis, platelet activation and inhibition, 
thrombogenesis) and maintenance of smooth muscle contractile phenotype. Vasoregulation 
by the endothelium is induced by detection of receptor ligands, such as neurotransmitters 
from sympathetic and non-adrenergic non-cholinergic innervation; or systemically 
circulating substances, such as catecholamines; or local autocoids, such as kinins. In 
addition, mechanical stimulation, such as shear stress evoked by blood flow, induces 
endothelium-dependent vasodilation. The endothelium is a facilitator of insulin transport 
from the circulation to vascular smooth muscle cells but more importantly mediates an 
insulin-induced vasodilation, a function shown to be reduced in type 2 diabetic patients 
(Karasu & Altan, 1993). 
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The endothelium mediates vasoregulation through the release of substances including 
prostaglandin's, endothelin's, endothelium-derived hyperpolarising factor(s) (EDHFs) 
(Moncada & Vane, 1979; Rubanyi et al., 1985; Rubanyi & Vanhoutte, 1985) and, most 
importantly, NO (Furchgott & Zawadski, 1980; Palmer et al., 1987). NO, prostacyclin and 
EDHF regulate local blood flow to regional organs and microcirculation and thereby 
contribute to the overall regulation of vascular tone (Moncada et al., 1988). Endothelin acts 
to increase the overall tone of the vasculature in opposition to NO and can contribute to 
regulatory mechanism that can control the release of vasoactive substances including NO. 
Studies of vascular dysfunction in type 2 diabetes show impaired NO (Williams et al., 
1996) and prostacyclin (Umeda et al., 1989; Jennings, 1994) mediated vasodilation as well 
as increased vasoconstriction by endothelin (Laurenti et al., 1997). In addition, studies in 
the obese Zucker rat in vitro have shown impaired EDHF vasorelaxation (Kaw et al., 
1999). The endothelium derived vasodilators NO, prostanoids and EDHF will be discussed 
in more detail below as they have been shown to be important mediators that are affected 
by diabetes. 
1.3.1 Nitric Oxide (NO) 
In 1980 Furchgott and Zawadski discovered that the endothelium released a factor that 
caused relaxation of the underlying vascular smooth muscle. It was later in 1987 this 
endothelium derived relaxing factor (EDRF) was identified as NO (Palmer et al., 1987). 
NO is a potent biological modulator acting as a vasodilator, neurotransmitter and anti- 
microbial effector molecule depending on the cell type and situation in which it is 
produced. Many cell types have been shown to produce NO including macrophages, 
hepatocytes, epithelial cells, smooth muscle cells, cardiac myocytes, neurons and 
endothelial cells (Salter et al., 1991). 
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NO is continually released from the endothelium, and contributes to a basal vascular tone 
(Moncada et al., 1988). The shear stress on the endothelium evoked by blood flow, and 
receptor ligand stimulation (such as acetylcholine (ACh) or bradykinin) stimulates NO- 
mediated vasodilation (Fig. 1.2). Endothelial stimulation causes an influx of intracellular 
Ca2+ (see review Furchgott, 1984) that triggers the activity of a Cat /calmodulin-dependent 
(Busse & Mulsh, 1990, Lopez-Jaramillo et al., 1990) constitutive enzyme NO synthase 
(eNOS) (Palmer et al., 1989 & Pollock et al., 1991). NOS enzyme contains two distinct 
structural domains with oxygenase and reductase activity. The oxygenase contains heure, 
while the reductase domain binds flavin mononucleotide (FMN), flavine adenine 
dinucleotide (FAD), and nicotinamide adenine dinucleotide phosphate (NADPH). Linking 
these domains is a binding site for the cytosolic protein calmodulin. When intracellular 
Ca 2+ increases, calmodulin associates with eNOS thereby facilitating electron flow between 
the two regions. Localisation of electron in the oxygenase domain enables the transfer of 
electrons to other substrates such as 02 leading to formation of OZ ' rather than NO 
(Vasquez-Vivar et al., 2003). However in the presence of tetrahydrobiopterin (BH4) a 
ubiquitous metabolite that serves as a NOS cofactor, the enzyme binds L-arginine cleaving 
the terminal guanidino nitrogen atom (Palmer et al., 1988) in the presence of molecular 
oxygen to form NO and the co-product L-citrulline (Palmer & Moncada, 1989). NO can 
then diffuse rapidly over short distances into neighbouring cells to exert its effect. NO is 
the endogenous activator of the enzyme soluble guanylyl cyclase (Murad et al., 1978), 
which via generation of cyclic cGMP (Ignarro et al., 1987) increases extrusion of Cal' from 
the cytosol and decreases the proportion of myosin light chain-dependent myosin activation 
(Hathaway et al., 1985), resulting in vasorelaxation. Additionally NO can activate K+ 
channels (Bolotina et al., 1994) to cause vasorelaxation through a hyperpolarising 


















Figure 1.2 The nitric oxide pathway. Stimulation of the Muscarinic-3 (M3) receptors 
with acetylcholine (ACh) leads to the increase in intracellular Ca 2+ which in turn stimulates 
NOS to produce NO. Alternatively sodium nitroprusside (SNP) donates NO to directly 
stimulate soluble guanylyl cyclase (sGC) in the smooth muscle cells. 
The half life of NO is a few seconds, before it is oxidised to the stable products nitrite 
(NO2) and nitrate (NO3), and then excreted. In plasma and water, NO is oxidised to NO2 
which is stable for hours, whereas in whole blood NO2 is rapidly converted to NO3. Thus, 
basal NO2 levels in human blood are low (3 µM) and NO3 levels much greater (30 µM). 
NO is can also be sequestered by a diverse group of compounds including haemoglobin, 
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dithiothreitol, hydroquinone (Griffith et al., 1984), Fe2+ (Gryglewski et al., 1986) and 
pyrogallol (Moncada et al., 1986). The action of most of these compounds can be attributed 
to their binding of NO, resulting in its detoxification or the production of 02'* (Beckman et 
al., 1990). 
Endothelial dysfunction and type 2 diabetes: the role of NO. A role for NO in type 2 
diabetes and its complications is still uncertain. Many studies measuring forearm blood 
flow in type 2 diabetic patients have shown impaired endothelium-dependent responses. 
However, studies with uncomplicated type 2 diabetic patients showed no difference in basal 
or agonist stimulated NO (Avogaro et al., 1997). This indicates that the endothelial 
dysfunction observed in many patients with type 2 diabetes may be the complicating factors 
of the disease rather than a causative underlying endothelial dysfunction. Interestingly, 
LDL and dyslipidaemia have been associated with abnormal endogenous NO release 
(O'Brien et al., 1997; Watts et al., 1996). Similarly, levels of nitrite/nitrate, were raised in 
type 2 diabetic patients (Catalano et al., 1997). This suggests reduced bioavailability of 
NO, possibly due to an increased oxidant status in type 2 diabetic patients (Gopaul et al., 
1995). In contrast, blood flow studies in animals with early diabetes show an increased 
formation of endothelial-derived NO (Corbett et al., 1992; Tilton et al., 1993). Studies in 
obese Zucker rats have shown enhanced endothelial-dependent relaxation in young rats (8- 
13 weeks) (Sexl et al., 1995; Laight et al., 1998; Andrews et al., 2000). However, this 
enhancement diminishes with age (Sexl et al., 1995). These studies can be explained by 
overcompensation of the NO pathway early in the disease process. The overcompensation 
then either diminishes or the production of reactive oxygen species (ROS) increases, 
leading to less NO synthesis or greater NO quenching. Currently there is no clear evidence 




Prostanoid is a general term used for the compounds derived from prostanoic acid. These 
include prostaglandins, prostacyclin and thromboxanes. This large family of mediators has 
diverse biological activities, ranging from regulation of blood pressure and smooth muscle 
contractility, to mediation of inflammatory responses. Similarly, prostanoid receptor 
specificity and regulatory functions are also complex. 
The production of vascular prostaglandins is by de novo synthesis following binding of 
agonists such as bradykinin, histamine, angiotensin II, thrombin and even cytokines to their 
respective cognate receptor. Initially, arachidonic acid is removed from the membrane 
phospholipids by the enzyme phospholipase A2 (Lands & Samuelsson, 1968; Vonkeman & 
Van Dorp, 1968). Metabolism of free arachidonic acid is then initiated through the 
cyclooxygenase (COX) pathway (Needleman et al., 1986), which catalyses the oxygenation 
and peroxidation reactions of free arachidonic acid to first create PGG2 and then PGH2. 
COX has 2 catalytic components; bis-oxygenase and hydroperoxidase, which catalyse the 
formation of PGG2 and PGH2 respectively. 
Endothelial dysfunction and type 2 diabetes: the role of prostanoids. The vasodilator 
prostacyclin (PGI2) and the vasoconstrictor thromboxane (TxA2) have been implicated in 
endothelial dysfunction associated with type 2 diabetes. PGI2 is a potent vasodilator 
generated mainly by the endothelium. It acts via the inhibition of adenylyl cyclase to 
increase levels of cAMP. In smooth muscle this leads to phosphorylation of cAMP- 
dependent protein kinase, thereby inactivating the myosin light chain kinase required for 
contraction. The prostanoid balance is impaired in type 2 diabetes, where levels of PGI2 are 
reduced (Umeda et al., 1989), and TxA2 levels are increased. 
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1.3.3 Endothelium derived hyperpolarising factor (EDHF) 
In 1988 Taylor and Weston suggested that there was an additional factor involved in 
endothelial-dependent relaxation other than EDRF. This factor was termed EDHF as it 
caused relaxation by increasing the membrane potential of the muscle cells. Bioassay 
experiments suggested that EDHF acted by opening K+ channels in vascular smooth 
muscle, to cause hyperpolarisation (Mombouli et al., 1996). EDHF is a diffusible factor 
whose identity is still controversial. Indeed it may represent a family of factors including 
NO. Non-prostanoid products of the metabolism of arachidonic acid remain particularly 
appealing candidates as EDHFs because as products of phospholipase A2 they would be 
expected to be released in response to elevated endothelial cell Ca2+ levels. Specifically, the 
three major candidates are the epoxyeicosatrienoic acids (cytochrome P450 metabolites of 
arachidonic acid), K+ itself and H202. Electrical coupling through myoendothelial gap 
junctions serves to conduct electrical changes from the endothelium to the smooth muscle 
and may mediate or propagate hyperpolarisation. 
Vascular smooth muscle cell hyperpolarisation may be initiated by several autacoids and 
hormones including ACh, histamine, bradykinin, substance P, ADP, and endothelin. 
Interestingly, the hyperpolarisation of the smooth muscle caused by EDHF usually precedes 
and is more transient than the accompanying relaxation induced by other endothelium- 
dependent mediators. Endothelial cells themselves are also hyperpolarized by agents that 
cause endothelium-dependent hyperpolarisation, an event that has been attributed to the 
opening of Cat+-dependent K+ channels on the endothelial cell membrane in response to the 
increase in cell Cat+. 
Electrophysiological studies show that endothelium-dependent hyperpolarisation of 
vascular smooth muscle cannot be prevented by NOS and COX inhibition (Feletou & 
Vanhoutte, 1996; Mombouli & Vanhoutte, 1997). Studies of large arteries have shown that 
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membrane repolarization in the presence of NOS and COX inhibitors accounts for 20-25 % 
relaxation. However, studies in smaller arteries show EDHF may be responsible for up to 
80 % of the total relaxation potential. In human coronary vessels and animal vessels it has 
been shown that the importance of EDHF increases as the arterial diameter decreases in 
size (Urakami-Harasawa et al., 1997). This suggests that EDHF has a role in peripheral 
vascular resistance and local haemodynamics. 
Endothelial dysfunction and type 2 diabetes: the role of EDHF. Elevated NO has been 
shown to induce an impairment of the EDHF pathway (Bauersachs et al., 1996) through a 
cGMP-dependent mechanism. The observed decrease of EDHF-mediated dilation by NO 
would suggest that under conditions of impaired NO release there would be an enhanced 
formation of EDHF. Therefore, in pathophysiological states such as hypercholesterolemia, 
hypertension, arteriosclerosis, and diabetes, which are associated with decreased 
bioavailability of endothelium-derived NO, EDHF formation may be of much greater 
importance than under physiological conditions. Indeed, in a rabbit model of 
hypercholesterolemia, endothelium-dependent hyperpolarisation, mediated via opening of 
Cat+-activated KK channels, maintains endothelium-dependent dilation in response to ACh 
prior to development of atherosclerosis. Moreover, in the same model, an enhanced 
synthesis of cytochrome P450-derived epoxyeicosatrienoic acids, products that activate 
Cat+-activated K+ channels, have been described (Pfister et al., 1991). Other studies have 
shown that endothelium-dependent hyperpolarisation is reduced in mesenteric arteries from 
streptozotocin-induced diabetic rats when compared to age-matched controls (Fukao et al., 
1997). 
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1.4 OXIDANT STRESS AND OTHER DISEASE MEDIATORS 
Oxidative stress is the end result of an imbalance between pro-oxidants, including ROS and 
antioxidant defences, a condition that may result from excess ROS generation or 
suppressed antioxidant activity. 
1.4.1 Reactive Oxygen Species (ROS) 
ROS are defined as reactive metabolites of oxygen (Halliwell & Gutteridge, 1989). 
Superoxide (02"'), hydroxyl radical (OH') and hydrogen peroxide (H202) are referred to as 
ROS, and can react with biological molecules. The major source of ROS is OZ ' from cell 
respiration generated by leakage from the mitochondrial electron transport chain and 
endoplasmic reticulum. Other sources include COX, NADPH oxidation, xanthine oxidase 
and uncoupled eNOS. The most reactive ROS is OH', it has an extremely short half life and 
will attack all molecules in its vicinity. Although somewhat less reactive Of, is involved in 
a number of biological processes and can combine with other molecules to generate 
compounds with higher reactivity, such as peroxynitrite (ONOO"). 
At low concentrations 02"' acts as an intracellular signalling molecule (Burdon & Rice 
Evans, 1989). It may also help to regulate vascular reactivity by quenching NO. The 
reaction of OZ ' with NO produces ONOO-, another potent oxidant that appears to contribute 
to some of the damaging effects of radicals (Beckman & Koppenoe, 1996); as has been 
seen in studies of type 2 diabetes patients (Ceriello et al., 2001). ONOO" can cross cell 
membranes and is capable of causing oxidative damage to a wide area. In principle, the 
relative physiological effects of NO can change depending on the availability of Of, with 
the result that impaired vascular reactivity would be a consequence of increasing oxidant 
levels. Other changes include increased monocyte adhesion to the endothelium, ultimately 
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leading to the generation of atherosclerotic lesions. At higher concentrations, ROS are able 
to modify the structure and function of proteins by causing cross-linking or fragmentation. 
Since up to 2% of inspired oxygen may be converted to ROS, it is essential there are 
mechanisms available to remove them. The endothelium's physiological defence 
mechanisms for ROS include superoxide dismutase (SOD), catalase and glutathione 
peroxidase (GPx), glutathione S-transferase and vitamin E (Halliwell & Gutteridge, 1989). 
SOD catalyses the dismutation of 02 ' to H202, which is catalysed to H2O by GPx or 
catalase. Antioxidants can be lipophilic, such as vitamin E, or hydrophilic, such as vitamin 
C, uric acid and plasma proteins. Vitamin E acts as a chain breaking antioxidant that 
defends the cell against ROS by scavenging radicals present in membranes and lipoproteins 
as it binds and captures peroxyl radicals (chain reaction intermediates) and thus breaks the 
lipid peroxidation chain reaction. Vitamin C is a water-soluble reducing agent that 
scavenges 02 ' and OH', part of its action appears to be the replenishment of vitamin E. 
Markers of oxidant stress are indicative of increased levels of ROS. By using end products 
of lipid peroxidation (Fig. 1.3), a number of methods can be employed to assess oxidative 
stress in plasma and tissue. These include measurement of thiobarbituric acid reactive 
substances (TBARS), or more specifically malondialdehyde (MDA; an aldehyde product of 
lipid peroxidation). However, these simple methods lack specificity and/or sensitivity, or 
are generally unreliable (Halliwell & Grootveld, 1987). F2-Isoprostanes are a series of 
prostaglandin-like compounds which are now established as reliable and sensitive markers 
of lipid peroxidation (Morrow et al., 1999). They are derived from arachidonic acid largely 
by an enzyme-independent, free radical catalysed peroxidation (Morrow et al., 1990). They 
are also likely to be formed in situ on phospholipids from which they are subsequently 
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Figure 1.3 The mechanism of lipid peroxidation. There are 3 
characteristic phases of lipid peroxidation: Initiation, Propagation and 
Termination. 
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also appear to have some biological properties (see chapter 4). In the cell membrane these 
F2-isoprostanes can distort fluidity and integrity, hence interfering with normal 
physiological processes (Morrow et al., 1992). Finally, another useful marker of oxidative 
stress measurement is total antioxidant status (TAOS) which may represent an overall 
picture as it assesses the sum of the antioxidant activity (Laight et al., 1999A). 
Metabolism itself may give rise to the production of ROS through increased respiratory 
chain leakage. However, studies have also shown decreased antioxidant status following a 
meal high in carbohydrate and fat (Ceriello et al., 1998). This decrease in antioxidant status 
was worse in diabetic patients. It was postulated that ROS could be generated from non 
enzymic glycation and glucose oxidation, or from the imbalance of NADH to NAD+ ratio 
that is linked to the activation of the sorbitol pathway. Post prandial ROS generation may 
therefore play an important factor in obesity where there is prolonged and more frequent 
exposure to post prandial-induced oxidative stress. Post prandial hyperglycaemia may 
contribute to the development of diabetic complications as these bouts of abnormal glucose 
metabolism and advanced glycation end product (AGE) generation would be greater in the 
diabetic than the controls (Ceriello et al., 1998). 
Endothelial dysfunction and type 2 diabetes: the role of ROS. Markers of oxidant stress 
are raised in type 2 diabetes (Gopaul et al., 1995). Furthermore, a reduction of antioxidant 
defences, such as SOD and catalase has also been observed in both diabetic patients 
(Collier et al., 1990; Vijayalingam et al., 1996) and pre-diabetic rats (Frisbee & Stepp, 
2001). Furthermore, the total antioxidant status in the plasma of the pre-diabetic rats was 
shown to be decreased (Gunnarsson et al., 1998). Other studies have shown significant 
improvement in insulin action in type 2 diabetic patients following antioxidant treatment 
with vitamin E or vitamin C (Paolisso et al., 1993; 1994). It is known that increased oxidant 
stress causes cell damage (Halliwell, 1994) and even cell death. Increased oxidant stress in 
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type 2 diabetes may contribute to its complications and more importantly be involved in the 
primary onset of the disease itself. Oxidant stress can further contribute to the disease 
progression in type 2 diabetes by altering the balance of mediators involved in vascular 
regulation. It is known that 02 ' can react with NO causing impaired relaxation, in addition 
to producing ONOO", a that radical will elicit endothelial cell damage and prevent any 
further release of NO from that cell. The decreased availability of endogenous antioxidants 
in the diabetic patient ultimately means that more free radicals can potentially react with 
NO and impair vascular function. This impaired vascular function may in turn promote 
progression of the diabetic disease and enhance its complications (discussed later in this 
chapter). 
1.4.2 Other mediators of type 2 diabetic disease 
Other mediators such as leptin, TNFa and the enzyme beta-hydroxysteroid dehydrogenase 
(113 -HSD) are described in more detail in this chapter as they have been implicated in 
type 2 diabetes and the obese Zucker rat pathology. 
Leptin is a product of the ob gene (Friedman et al., 1991). It is a plasma protein 
approximately 16 kDa in mass and is secreted from adipose tissue. The leptin receptor is a 
member of the cytokine family of receptors that are expressed in the hypothalamus, T- 
lymphocytes and more interestingly on vascular endothelial cells (Sierra-Honigmann et al., 
1998). The obese Zucker rat phenotype is due to a mutation in the leptin receptor (OB-R) 
gene. Leptin acts at hypothalamic receptors to signal increases in the lipid content of the 
adipocytes, causing satiety and hence a decrease in food intake and an increase in 
thermogenesis. It is thought to reduce or stop feeding by inhibiting the potent stimulant for 
feeding, neuropeptide Y (NPY). It has been shown in animals that NPY production can be 
suppressed by leptin (Stephens et al., 1995). Decreased NPY activates the sympathetic 
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nervous system and stimulates thermogenesis in brown fat. In contrast, if animals do not 
have any leptin, the NPY system is completely unrestrained, leading to hyperphagia and 
hence obesity. Interestingly, obesity in humans appears to be frequently associated with 
high levels of leptin, so called hyperleptinaemia - suggestive of leptin resistance rather than 
leptin deficiency in these individuals. This resistance may be due to impaired transport of 
leptin through the blood brain barrier, or a receptor defect, and/or post receptor failure. 
Leptin also decreases insulin secretion from ß-cells and regulates insulin signalling. 
Circulating levels of leptin correlate with percentage body fat and fasting insulin 
concentrations in humans. This makes leptin a possible marker of obesity and the insulin 
resistance syndrome. 
Identification of leptin receptors on the endothelium suggested a vasoactive role for leptin. 
Leptin has been shown to cause increased blood pressure by increasing sympathetic 
nervous activity (Dunbar et al., 1997). However, Frühbeck (1999) showed leptin also 
induced a hypotensive effect in sympathectomised rats by a NO-dependent mechanism. 
Further investigation showed a direct vasoactive effect by leptin through its functional 
receptor on the endothelium (Lembo et al., 2000). Leptin also caused vasorelaxation in rat 
conduit (aorta) and resistance (mesentery) vessels through NO and EDHF -dependent 
mechanisms respectively. As resistance vessels are thought to be have a dominant role in 
blood pressure homeostasis (Mulvany, 1993), leptin may have a role in the maintenance of 
blood pressure. In addition, leptin is able to inhibit NPY, which has also been shown to 
have potent vasoconstrictor properties. Studies have show leptin to increase ROS in human 
endothelial cells, an effect associated with JNK/SAPK-dependent pathway. 
TNFa is a 17-kDa soluble plasma protein secreted from macrophages, monocytes, smooth 
muscle cells and adipose tissue. It is a proinflammatory cytokine that has been implicated 
in the pathogenesis of many inflammatory disorders where it acts to enhance the 
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inflammatory cascade and to activate macrophages to produce ROS. More recently, TNFa 
has been implicated in obesity, insulin resistance, and type 2 diabetes. Studies have shown 
an inverse correlation between TNFa levels and both fasting glucose and glucose disposal 
in normal subjects and those with impaired glucose tolerance (Miyazaki et al., 2003). The 
study also explained that this correlation is not present in type 2 diabetic subjects and 
suggested that TNFa may be implicated in the onset of the insulin resistance syndrome but 
not in the deterioration of peripheral resistance in the later disease. Animal studies in the 
obese Zucker rat have shown increased plasma TNFa levels, and that neutralization of 
TNFa in vivo, by an infusion of soluble TNFa receptor-IgG protein, significantly 
increased peripheral insulin-stimulated glucose disposal (Hotamisligil et al., 1993). It is 
thought that TNFa can potently cause insulin resistance by accelerating lipolysis. This may 
occur by suppressing the expression of genes that encode proteins that would normally 
regulate fatty acid uptake or lipogenesis. It is the resultant release of free fatty acids from 
adipocytes that then block insulin sensitive pathways. Indeed, reduction in both circulating 
free fatty acid and insulin levels in obese Zucker rats has been reported following TNFa 
inhibition by infusion of neutralizing TNF antibodies (Morin et al., 1997). TNFa 
concentrations were decreased in studies using the PPARy agonist, troglitazone. In these 
studies troglitazone increased the number of small adipocytes and decreased the number of 
large adipocytes in white adipose tissues of obese Zucker rats. The authors suggest this may 
be an important mechanism by which increased expression levels of TNFa and higher 
levels of plasma lipids are normalized, leading to alleviation of insulin resistance (Okuno et 
al., 1998). 
11/3-HSD consists of 2 distinct isoenzymes (type 1 and 2) with contrasting functions. 11 ß- 
HSD2 is an exclusive 11 ß-dehydrogenase that acts in aldosterone target tissues such as the 
kidney, colon and sweat glands. It functions as a potent dehydrogenase that rapidly 
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inactivates cortisol so that aldosterone can selectively access the otherwise nonselective 
mineralocorticoid receptors. In contrast, 11 ß-HSD 1 is a predominant 11 ß-reductase in vivo 
that acts in many tissues such as the liver, adipose tissue, brain, and lung, to increase local 
intracellular cortisol concentrations and thereby maintain exposure to its receptors. As 11ß- 
HSD 1 is an enzyme that regenerates cortisol from inactive cortisone, it is a factor capable 
of producing obesity and type 2 diabetes. The metabolic syndrome X and Cushing's 
syndrome show similar symptoms including, hypertension, central obesity, glucose 
intolerance, insulin resistance and dyslipidaemia. However, plasma cortisol is not elevated 
in syndrome X. However recent evidence has shown increased intracellular cortisol 
concentrations in adipose tissue in obese humans and Zucker rats (Rack et al., 2001). 
Interestingly, in these studies also show decreased levels of cortisol in both liver and 
plasma samples - 11ß -HSD1 is the enzyme responsible for these tissue specific variations 
in intracellular cortisol concentrations. Recent animal studies have certainly provided 
greater evidence for the involvement of 11ß-HSD1 in the development of syndrome X. 
Transgenic mice over-expressing 1113-HSD1 selectively in adipose tissue developed obesity 
and showed increased levels of corticosterone in their adipose tissue. Moreover, the mice 
also exhibited pronounced insulin-resistant diabetes, hyperlipidaemia, and hyperphagia, 
despite having hyperleptinaemia (Masuzaki et al., 2001). In vascular experiments, it has 
been reported that 1113-HSD1 may play an important role in regulating inflammatory 
responses in the artery wall. 113-HSD1 was shown to be expressed in human aortic smooth 
muscle cells. Treatment of the cells with cytokines, IL-1 ß or TNFa caused a time and dose- 
dependent increase of 11(3-HSD1 mRNA levels, and an increased conversion of cortisone 
to cortisol (Cai et al., 2001). This is of particular interest as levels of TNFa are elevated in 
human obesity, and indeed the Zucker rat, and have been associated with insulin resistance. 
Specific inhibition of llß-HSD1 would help to understand aspects of the pathogenesis of 
syndrome X and may lead to new therapeutic perspectives. 
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1.5 HYPERGLYCAEMIA 
Hyperglycaemia results from ineffective clearance of glucose. Glucose levels are elevated 
in the plasma, interstitial fluid and in cells where glucose uptake is not insulin-dependent, 
such as nerve, glomerulus, retina and lens cells. Persistent hyperglycaemia is clearly a 
major risk factor for type 2 diabetes complications (DCC trial, 1993). The development of 
endothelial dysfunction in arteries exposed to hyperglycaemia (Valentoric et al., 1985; 
Tesfamarian et al., 1990) involves increased formation of AGEs, increased glucose flux 
through the aldose reductase pathway and activation of protein kinase C (PKC) (Nishikawa 
et al., 2000). 
Polyol Pathway. In endothelial cells and cells independent of insulin for glucose uptake, 
glucose is metabolised by the sorbitol (polyol) pathway. Aldose reductase is an enzyme that 
converts glucose to sorbitol. Glucose is reduced by aldose reductase, generating NADP', a 
competitor of glutathione, (Gonen & Dvornik, 1995) and sorbitol, which accumulates 
intracellularly as it does not easily cross cell membranes (Taylor & Agius, 1998) (Fig. 1.4). 
Aldose Sorbitol 
reductase dehydrogenase 
D-glucose D-Sorbitol D-fructose 
NADPH NADP+ NAD+ NADH 
Figure 1.4 Metabolism of glucose via the sorbitol (polyol) pathway. 
The polyol pathway is a series of enzymatic reactions in the synthesis of fructose. 
Normally, aldose reductase has a low affinity for glucose and little glucose substrate enters 
the polyol pathway. However during hyperglycaemia, this pathway is activated because the 
KM of glucose for aldose reductase is high (70 mM). Hyperglycaemia forces intracellular 
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glucose accumulation, particularly in tissues such as the retina where glucose entry is 
independent of insulin. The excess glucose is largely metabolized by aldose reductase. It is 
this increased flux of glucose metabolised through the polyol pathway that is associated 
with diabetic abnormalities. Hyperglycaemia also leads to de novo synthesis of 
diacylglycerol (DAG), which activates PKC. DAG-PKC is important in the signalling 
pathways regulating vascular cell permeability and contractility (Koya & King, 1998). It is 
possible that PKC activation may cause vasoconstriction by increasing endothelin-1 
expression in retinal cells (Koya & King, 1998). 
AGE. Formation of AGEs occurs by non-enzymatic glycosylation or glycation of glucose, 
fructose or their phosphates to a protein or lipid. Hence the production of AGE is increased 
with hyperglycaemia. The reaction occurs between the aldehyde oxygen or keto oxygen 
and an exposed amino group. The resultant Schiff base then undergoes a number of 
chemical reactions (rearrangements) leading to the cross linking of proteins. AGEs can 
cross-link with plasma components and cell surface receptors, which in turn may lead to 
abnormalities in receptor recognition and enzyme activity. Proteins in contact with the 
blood are most vulnerable to glycation, and smaller blood vessels may be at particular risk 
as they have a long replacement time - this can lead to endothelial dysfunction and 
secondary complications. Investigations in vitro have shown glycosylation is proportional 
to the incubation time and glucose concentration, suggesting increased hyperglycaemia for 
longer duration will cause more damage associated with diabetic complications. A marker 
for glycaemic control is glycosylated haemoglobin Alc (HBAlc). Glucose binds 
irreversibly to haemoglobin and HBAlc is proportional to the concentration of glucose in 
the blood. Since red blood cells have a lifespan of approximately 90 days, the HBA1c test 
is a very useful method to assess control of glycaemia in patients. Specific receptors for 
AGE (RAGE) are also expressed in a number of cell type including monocytes, 
macrophages endothelial cells, smooth muscle cells and neuronal cells. RAGE expression 
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is potentiated by hyperglycaemia and TNFa. The binding of AGE to RAGE causes 
activation of endothelial cells to produce inflammatory mediators including cytokines and 
adhesion molecules. AGEs accumulate in the extracellular matrix proteins during the 
physiological process of aging, however earlier and more rapid accumulation of AGE 
occurs in type 2 diabetic patients. Significant correlation has been shown between AGE 
deposition and severity of diabetic complications (Wautier & Guillausseau, 2001). 
Importantly, AGEs have been shown to quench NO both in vitro and in vivo and thus 
contribute to endothelial vascular impairment (Bucala et al., 1991). It has been shown that 
AGE causes microvascular, retinal and glomerular and nerve lesion that can be prevented 
with aminoguanidine (inhibitor of AGE formation). In addition, other studies have shown 
that recombinant RAGE prevented hyperpermeability and vascular lesion. Glycation of 
oxidised lipids and lipoproteins further increases their atherogenicity and may, at least in 
part, explain why diabetics have increased risk for cardiovascular disease. 
1.5.1 Diabetic Complications 
The contributory risk factors to the development of diabetic complications include - age, 
poor glycaemic control, duration of diabetes, and abnormal lipid metabolism. Current 
evidence suggests that each late complication of diabetes arises following a sequence of 
progressive changes to an individual organ or system, and hyperglycaemia is the common 
insult initiating the early complication. The four major pathways of glucose metabolism 
involved in the development of diabetic complications include: 1. Increased polyol pathway 
activity leading to sorbitol and fructose accumulation, NAD(P)H-redox imbalances, and 
changes in signal transduction; 2. Non-enzymatic glycation of proteins yielding AGEs; 3. 
Activation of PKC thereby initiating a cascade of stress responses, and 4) Increased 
hexosamine pathway flux (Fig. 1.5). In the diabetic state increases in polyol pathway 
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system of for increased 0' accumulation and progressive cellular dysfunction (Feldman, 
2003). It is estimated that by improving blood glucose levels in the diabetic patient that the 
risk of diabetic retinopathy can be improved by as much as 50 % and nephropathy damage 
33%. 
Retinopathy. The majority (90 %) of diabetic patients present evidence of retinopathy 
within 15 years of disease onset. Retinopathy is a well studied complication of diabetes as 
the retina and its vasculature can be easily accessed and assessed on a regular basis over the 
duration of the disease. It is usually graded according to severity. There are three main 
stages; background diabetic retinopathy, maculopathy, and proliferative diabetic 
retinopathy. Abnormalities of the vascular bed are early characteristics of background 
diabetic retinopathy. These abnormalities include capillary dilation (leading to capillary 
leakage), capillary closure and microaneurysms. The macula area of the retina remains 
unaffected at this stage. However, diabetic changes including haemorrhage, abnormal blood 
vessels and lipid rich exudates in the eye are a warning sign that more severe disease may 
develop. If the macula area, containing light sensitive cells, becomes involved 
(maculopathy) central vision gradually worsens. Maculopathy is essentially caused by the 
leakage of fluid, protein and fats into the retina, damaging the retinal cells, and eventually 
leading to ischaemia. As the eye condition progresses, ischemia causes the need for 
neovascularisation and the progression to proliferative diabetic retinopathy. The blood 
vessels that develop are weak and grow on the surface of the retina and into the vitreous 
gel, and cause the basement thickening of retinal blood vessels that is thought to occur 
following the breakdown of the endothelial barrier, the degeneration of endothelial cells 
and pericytes, and the successive generation of replacement endothelial cells. Pericyte loss 
may impair blood flow regulation further as pericytes have been shown to have contractile 
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properties. This thickening of the retinal blood vessels eventually forms fibrous tissue 
which can distort the retina, leading to retinal detachment. 
The probable factors proposed in the pathogenesis of retinopathy are increased polyol 
pathway activity, non enzymic glycation of structural proteins and enhanced mechanical 
force delivered to the vessel by rigid red blood cells. The resultant changes in endothelial 
cells include decreased NO levels, and enhanced activity of the vasoconstrictors endothelin- 
1 and angiotensin II which pushes the vessels towards constriction and retinal ischemia. In 
addition, glycation of haemoglobin can reduce the oxygen capacity of red blood cells and 
lead to hypoxia. Hypoxia alters vessel permeability and facilitates the release of angiogenic 
factors. Vascular endothelial growth factors (VEGFs) and their receptors VEGFR-1, 
VEGFR-2, and VEGFR-3, control pathological angiogenesis and increase vascular 
permeability and have been shown to be over expressed in diabetic retinopathy (Witmer et 
al., 2003). In addition, AGEs binding to their receptors will activate endothelial cells to 
produce cytokines, and express adhesion molecules and tissue factor. 
Neuropathy. It has been estimated that 20 to 40 % of diabetics develop neuropathy, the risk 
of which increases by 15 % for every 1% rise in HbAlc. Diabetic neuropathy is a 
progressive disease caused by deterioration of nerves which results in peripheral and 
autonomic nerve dysfunction. Nerve damage caused by diabetes generally occurs over a 
period of years and may lead to problems with internal organs including the digestive tract 
and sexual organs. Diabetic neuropathy can be divided into three groups: 1. diffuse 
(peripheral) neuropathy (affects the legs, feet, arms, hands). 2. diffuse (autonomic) 
neuropathy (affects the heart, digestive system, sexual organs, urinary tract, sweat glands). 
3. focal neuropathy (eyes, probably due to pressure damage). 
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It is the peripheral nervous system that is most commonly affected and sensory nerve fibres 
are usually the first affected. They show a reduction in the conduction velocity, together 
with reduced amplitude and increased temporal dispersion of the action potential. 
Neurophysiological studies have also shown reduced motor and sensory nerve conduction 
in ischemic nerves. Nerve biopsies obtained from diabetic patients have shown axonal 
degeneration and regeneration, demyelination and remyelination, and capillary closure. In 
addition, the extent of damage was correlated to severity of disease. These impaired neural 
functions and loss of neurotrophic support, can eventually mediate apoptosis of neurons, 
Schwann cells, and the glial cells of the peripheral nervous system. 
The precise mechanisms causing nerve damage still needs to be established. Possible 
causes include osmotic swelling secondary to intracellular sorbitol accumulation; this is 
known to cause functional and morphological alterations in the diabetic nerve, also 
myoinositol depletion leading to reduced Na' KK ATPase activity, and increased 
intracellular Na' levels that in turn slow nerve conduction velocity. It is known that RAGEs 
can modulate cell activation, growth related mediators and cell proliferation. Therefore in 
neuropathic complications AGE contributes to reduced nerve perfusion, and endoneural 
hypoxia changes in nerve microvascular including basement membrane thickening, pericyte 
degeneration and endothelial cell hyperplasia. Studies into nerve growth factor (NGF) have 
shown it was decreased in diabetic subjects. However, further investigations into its 
potential as a causative factor of neuropathy are disappointing, as the results from recent 
clinical trials failed to prove efficacy (Apfel, 2002). More recently, the Hedgehog Family 
(Sonic, Desert and Indian) of proteins which play a key role in the formation, maintenance 
and repair of a number of tissues, including the nervous system and cartilage, was shown to 
have reduced mRNA expression in the peripheral nerve of maturing diabetic rats. These 
studies showed that treatment with a sonic hedgehog-IgG fusion protein fully restored 
motor- and sensory-nerve conduction velocities and maintained the axonal calibre of large 
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myelinated fibres (Calcutt et al., 2003). Other studies in animal have shown that antioxidant 
treatment can prevent or reverse the hyperglycaemia-induced nerve dysfunction, possibly 
via correction of nutrient blood flow (van Dam, 2002). 
Nephropathy. The prevalence of diabetic nephropathy is 5- 60 % of type 2 diabetics 
depending on ethnic origin (Caucasians 5- 10 %, African Americans 10 - 20 %, Pima 
Indians 60 %). Nephropathy is defined by persistent albuminuria, a declining glomerular 
filteration rate (GFR) and rising blood pressure. The earliest clinical evidence of 
nephropathy is the appearance of low levels of albumin (microalbuminuria) in the urine, 
referred to as incipient nephropathy. Once overt nephropathy occurs, without specific 
interventions, the GFR gradually falls. Albuminuria is due to glomerular capillary damage 
and reflects generalised damage to microcirculation and large vessels. Microalbuminuria is 
due to increased permeability of glomerular capillaries, probably due to raised pressure. 
Hypertension, also a complication of diabetes, accelerates the rates at which albuminuria 
increases and GFR declines. Proteinuria itself can lead to low albumin levels and peripheral 
oedema. 
The proposed mechanisms involved in the progression of nephropathy again involve 
increased activity of the polyol pathway. This increased polyol pathway activity impairs 
myoinositol metabolism in the tissues in which intracellular glucose concentrations are not 
regulated by insulin. Myoinositol is required to maintain synthesis of phosphatidylinositol, 
whose rapid turnover regulates a major component of tissue Na' K+ ATPase activity. 
Studies have shown that myoinositol supplementation and aldose reductase therapy 
improve glomerular function and increase nerve conduction velocity (Goldfarb et al., 
1991). Another mechanism of damage is glycation of albumin, which has been shown to 
modulate signal transduction and induce alterations in renal glomerular cells that contribute 
to the development of diabetic nephropathy. 
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Macrovascular disease. Diseases of the large arteries are responsible for over 50 % of 
diabetic deaths. Peripheral vascular disease is the name of the group of problems caused by 
inflammation and structural damage in the blood vessels. One of the major diseases in this 
group is atherosclerosis. Atherosclerosis is caused by fatty build up inside the artery walls 
over time which can lead to occlusion and restriction of blood flow. In early 
atherosclerosis, monocytes adhere to the endothelium and migrate into the intima in a three 
stage process (rolling, activation and transmigration). This process is mediated by selectins 
and adhesion molecules on the endothelium, such as ICAM-1 and VCAM-1. The selectins 
and adhesion molecules first cause the monocytes to slow, then their adhesion to the 
endothelium, followed by their migration through the intercellular junctions into the sub- 
endothelial space. Hyperglycaemia has been shown to increase monocyte binding in human 
aortic endothelial cells (Kim et al., 1994), More recently, insulin resistance and adiposity 
was shown to correlate with acute-phase reaction and soluble cell adhesion molecules in 
type 2 diabetes (Leinonen et al., 2003). The monocytes differentiate into macrophages and 
accumulate lipid to form foam cells. The lipid laden foam cells form the characteristic fatty 
streaks of early the atherosclerotic lesion. Production of growth factors and cytokines by 
foam cells then initiate the migration of smooth muscle cells from media into the intima 
and their proliferation. The advanced lesion consists of an extracellular lipid core and a 
thick fibrous structure in the lumen, this type of lesion narrows the artery. Finally the 
complicated plaque can fissure and rupture to cause myocardial infarction or stroke. 
The vascular imbalance of vasoregulators such as NO and Of ' contribute to the disease 
progression from diabetes to atherosclerosis. NO has potent vasoprotective effects 
including inhibition of vascular smooth muscle cell proliferation, lipid peroxidation, and 
monocyte adhesion to endothelial cells - all of which are important in the prevention of 
49 
atherosclerotic disease progression. In addition, NO inhibits platelet adhesion and 
thrombogenesis, an important factor in the prevention of myocardial infarction and stroke 
in the later stage of atherosclerosis. The decreased NO availability in frank diabetes may 
also contribute to hypertension, especially in individuals with atherosclerosis arterial 
narrowing. Finally, NO counterbalances other vasoconstrictors such as endothelin, 
angiotensin II and more relevant to this thesis, OZ '. 
1.6 ANIMAL MODELS OF TYPE 2 DIABETES 
The term model refers to a reproduction of a system on a different scale. The advantage of 
an animal model of disease is analysis of metabolic or physiological parameters not or not 
easily accessible in humans, including tissue biopsy (Renold et al., 1988). There are many 
different types of animal models available that provide routes of investigation into diabetes. 
Some of the animal models available include; the immune related BB rat and NOD mouse; 
the NIDD-IDD transition db/db mouse; the low insulin secretion NON mouse; the nutrient- 
dependent sand rat or spiny mouse; the genetically selected Goto-Kakizaki (GK) rat, and 
the obesity related ob/ob mouse, Otsuka-Long-Evans Tokushima Fatty Rat (OLEFT) and 
fa/fa rats. In addition, diabetes can be chemically induced in normal rats, such as the Wistar 
rat, by using drugs that are toxic to the pancreatic ß-cells, such as alloxan and streptotocin 
(STZ). None of these models are identical to the human syndrome, but all have mechanisms 
that cause type 2 diabetic and type 1-like disease. The mechanism and progression of 
disease is worth investigation as its presence in one system helps the understanding of 
another system. This is especially fitting in understanding a polygenic disease such as type 
2 diabetes. 
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1.6.1 The obese Zucker "fatty" rat (fa/fa) 
The Zucker "fatty" rat (faffa) (Fig. 1.6) is model of obesity, insulin resistance and pre-type 
2 diabetes, resulting from a cross between Sherman and Merck rats (Zucker and Zucker, 
1961). The homozygous phenotype Zucker (fa/fa) rat exhibits obesity is due to a single 
missense mutation at codon 269 (glutamine to proline) of the leptin receptor (OB-R) gene. 
This reduces the expression of the leptin receptor on the cell surface leading to marked 
intracellular retention, decreased leptin binding and diminished signal transduction. The 
non-obese genotypes with the (fa) gene are appropriate age matched controls for the obese 
(fa/fa) Zucker rat, as levels of glucose metabolism in fat cells are the same (Cleary & 
Phillips, 1996). 
The obese Zucker rat (faffa) has several endocrine abnormalities that accompany its obesity 
including hyperleptinaemia, hyperphagy, hyperinsulinaemia, insulin-resistance, 
hyperglycaemia and hypercholestrolaemia. However it does not appear to develop 
atherosclerosis spontaneously. Other endocrine disorders include depressed pituitary 
growth hormone secretion, hypothyroidism, oversecretion of glucagon, abnormal regulation 
of the thermogenic process, and reproductive dysfunction. The marked insulin resistance 
concomitant to hyperinsulinaemia may account for the reported normoglycaemia of these 
animals. It is interesting that administration of corticosterone to normal rodents caused 
hyperphagia, hyperinsulinaemia, increased energy efficiency, increased lipid, but decreased 
protein deposition. This demonstrates the importance of leptin and the hypothalamic- 
pituitary axis in this disease model and its role in type 2 diabetes. The prevalence of 
psychosocial stress factors and their association with increased body fat (mentioned earlier 
(Bjorntorp, 1991)) was studied in lean and obese rats using fluoxetine (a serotonin reuptake 
inhibitor). Fluoxetine administration caused a reduction in NPY levels and NPY secretion 
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Figure 1.6 Comparison of the size of the lean and obese Zucker rat 
littermates at 13 weeks-old 
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in the hypothalamus, resulting in hypophagia and weight loss (Dryden et al., 1996). The 
pathological progression in the Zucker rat has been proposed as a central nervous system 
(CNS) and autonomic nervous system (ANS) disorder that results in insulin oversecretion 
and dysregulation of insulin counter regulatory hormones; insulin being the main driving 
force in bringing about insulin resistance in the skeletal muscle. A state of insulin resistance 
is seen in the obese Zucker liver skeletal muscles, whereas white adipose tissue is normal or 
even hyper sensitive to the effects of insulin thus contributing to the development of 
obesity (Penicaud et al., 1987). 
1.7 AIMS AND OBJECTIVES 
Oxidant stress has been associated with type 2 diabetes. For example, both decreased NO 
and increased in O2 ' plasma levels have been reported. If the NO/ 0' balance is perturbed 
vascular dysfunction can result. Similarly, oxidant stress may enhance insulin resistance. 
The initial aim of the studies described in this thesis was to characterise the relationship 
between oxidant stress, endothelial function and insulin resistance. To assess these 
relationships, new methods to measure endothelial function in animal disease models 
needed to be developed. Firstly, the in situ perfused hindquarters would allow direct 
measurement endothelial function without autonomic nervous control and blood. In 
addition to it being a large vascular area which is insulin sensitive. Secondly, was to 
develop an in vivo model to assess endothelial function with autonomic control using 
Doppler ear blood flow measurements. These models could provide data that could be 
extrapolated to isolate peripheral effects in particular endothelium-dependent effects of the 
pharmacological interventions in vivo. Endothelial function and oxidant stress could then to 
be investigated in the obese Zucker rat -a model of insulin resistance. This model provided 
information on the presence of endothelial dysfunction and oxidant stress in a pre-diabetic 
model. This being of interest, in that it is known that oxidants contribute to the 
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complications associated with type 2 diabetes, but their causative role is less clearly 
understood. Similarly, endothelial dysfunction is certainly a symptom of type 2 diabetic 
disease but it having a causative role in early disease is not clear. 
Once oxidant stress, endothelial dysfunction and insulin resistance were understood to exist 
in the obese Zucker rat, the next aim was to test the hypothesis that increasing oxidant 
stress contributes to an altered vascular function and impaired insulin regulation. Thus, 
oxidant stress contributes to the disease progression in the obese Zucker rat. This aim was 
tested by increasing the oxidant stress levels by chronic administration of pro-oxidants to 
the rats. The obese Zucker rat already exhibited increased plasma levels of the oxidant 
stress marker 8-epi PGF2a. In addition, fructose a natural dietary ingredient could additively 
increase production of oxidant stress by another mechanism, pushing this pre-diabetic 
syndrome to a later stage of diabetic disease. The deterioration of endothelial function and 
insulin resistance would provide evidence for the capability of oxidant stress to worsen type 
2 diabetic disease. Finally, further evidence for the role of oxidant stress and endothelial 
dysfunction in pushing the insulin resistant syndrome to frank diabetes was to test the 




General Methods and Materials 
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2.1 MATERIALS 
Solvents were obtained from Rathburn Chemicals Ltd, (Walkerburn, UK). All other 
chemicals were obtained from Sigma Chemical Co. (Poole, Dorset, UK) unless otherwise 
stated below. 
Thiopentone sodium (Intraval sodium) and sodium pentobarbitone (National Veterinary 
Supplies, Stoke on Trent, UK); CaC12 (BDH); 8-epi-PGF2a, (Cayman chemical company, 
Ann Arbor Michigan, USA); 8-epi-PGF2a radioimmunoassay (RIA) (Oxford biomedical 
Research, Oxford, MI, USA); Evans Blue (Boehringer Ingelheim, Heidelberg, Germany); 
Fructose (fructofin C, Forum Products, Surrey, UK); Human recombinant insulin and 
NADPH (Boehringer Mannheim Biochemica, Germany); Insulin radioimmunoassay (RIA) 
(Linco Research Inc. St. Charles, Missouri, USA). 
2.2 GENERAL METHODS 
2.2.1 Perfusion of the rat hindquarters in situ 
Male Wistar rats (250-350 g) were anaesthetised with pentobarbitone sodium (60 mg kg-1 
i. p. ) and heparin (200 U kg") administered via the tail vein. A midline laporatomy was 
performed and the intestines displaced to reveal the abdominal aorta and vena cava. The 
aorta was ligated and then cannulated for perfusate inflow at the bifurcation point of the 
common iliac arteries. The vena cava was cannulated at the same point to allow perfusate 
outflow (effluent). The abdominal incision was then closed with clips and the animal 
exsanguinated. The temperature of the hindquarters was monitored via a rectal probe and 
maintained at 37°C by a homeothermic blanket. The hindquarters were perfused in an open 
circuit with physiological salt solution (PSS) warmed to 37°C and gassed with 95 % 02 and 
5% CO2. The composition of the PSS in (mM): NaCl 133, KCl 4.7, NaH2PO4 1.35, 
NaHCO3 16.3, MgSO4 0.61, CaC12 2.52, and d-glucose 7.8. PSS was perfused at a constant 
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flow of 7 mL min 1. The changes in perfusion pressure, reflecting changes in vascular 
resistance, were measured by a pressure transducer and continuously recorded using a 
MacLab system (Hastings, Sussex, U. K. ). A stabilisation time of 20 min was allowed 
before proceeding with experimental protocols. The delivery of drugs was via an injection 
port proximal to the peristaltic pump (Fig. 2.1). The initial validation studies performed 
with this method are included in chapter 3. 
In agonist stimulated endothelial function studies, Phe eliciting approximately 85 % of the 
maximal response (Zucker obese and lean: 100 nmol min-) was infused at t=20 min to 
provide sub-maximal pre-constriction. After a stabilisation of induced vascular tone, bolus 
doses of ACh (0.001-30 nmol; 10-30 µl) or sodium nitroprusside (SNP) (0.001-100 nmol; 
10-30 µl) were injected to construct vasodilator dose response curves. 
In separate experiments, the effect of NG-nitro-L-arginine methyl ester (L-NAME) on an 
ACh (0.001-30 nmol) dose response curve was assessed in hindquarters preparations pre- 
constricted with Phe (100 nmol) at t=20 min. L-NAME (2.1 µmol equivalent to 300 µM) 
(Rees et al., 1990) was added to the PSS of the treated preparations at t=0 min. After a 
stabilisation of induced vascular tone, bolus ACh was administered. 
In experiments assessing the acute action of insulin, hindquarters were exposed to insulin 
(100 nM) or its vehicle BSA (0.1 %) for 20 min. Then the hindquarters were pre- 
constricted with Phe (300 nmol). After the constriction was stabilised, endothelium- 
dependent vasodilation to ACh (0.001-30 nmol), and endothelium-independent vasodilation 
to SNP (SNP, 0.01-100 nmol), were assessed in separate preparations. In other 
preparations, constriction to Phe (0.001-10 nmol) was assessed following a 20 min pre- 
treatment with human insulin (100 nM) or its vehicle in the presence or absence of 
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In experiments in the Zucker rat, SNP (100 nmol) was injected to construct vasodilator 
dose response curves with respect to SNP (as an internal control and an estimation of the 
total vasodilation ability of the preparation). 
2.2.2 Haemodynamic measurements in vivo 
Blood pressure. Male Wistar rats were anaesthetised with thiopentone sodium (Intraval®, 
120 mg kg'', i. p. ). The trachea was cannulated to facilitate respiration and the rectal 
temperature was maintained at 37°C. The right carotid artery was cannulated and connected 
to a pressure transducer (SensoNor 840, Norway) for the measurements of mean arterial 
blood pressure (MAP) and heart rate (HR). These were recorded for the duration of the 
experiment and displayed on a MacLab 16s recording system (AD Instruments, London, 
UK). The jugular vein was cannulated for the bolus administration of drugs. Following 
surgery, a 30 min period of stabilisation was allowed before recording baseline 
haemodynamic parameters. 
ACh (0.01-10 nmol kg" Lv. ) and SNP (1-100 nmol kg" Lv. ) bolus doses were administered 
to assess vasodilation and changes in blood flow mediated by endogenous or exogenous 
NO respectively. Vasoconstrictor reactivity was assessed in vivo by construction of a dose 
response curve to bolus doses of Phe (0.1-100 nmol kg-1 i. v. ). The vasodepressor activity 
and changes in blood flow are plotted as the percentage drop or rise in MAP. 
2.2.3 Analysis of blood volume. 
Blood volume was assessed according to a procedure described by (Bianchi et al., 1981). 
Evans blue (200 µL of 15 g 1; 1) solution was administered via the jugular vein. At t=5 min 
after the injection, blood samples were taken. The haematocrit or packed cell volume 
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(PCV) was determined in duplicate, and blood was centrifuged at 15,000 rpm for 5 min to 
derive the plasma. Evans Blue (0.5-32 mg L'1) standard curve was constructed and distilled 
water diluted plasma samples (1: 10) were read at 621 nM in a spectrophotometer 
(Shimadzu UV-160). The plasma volume was calculated by the formula: Plasma volume 
(cm3) = (Absorbance of standard / Absorbance of sample) x 10, where the standard is 3 mg 
of Evans blue in 10 cm3 plasma diluted (1: 10). The use of a single blood sample for the 
determination of plasma is well accepted (Bianchi et al., 1981). Total blood volume was 
determined from the equation: Blood volume (cm3) = Plasma volume x 100/100 - (PCV x 
0.95), where 0.95 is the correction factor to obtain true cell percentage (total body PCV). 
2.2.4 Glucose tolerance test (g. t. t. ) 
Rats deprived of food for 16-20 hours were anaesthetised with thiopentone sodium (120 mg 
kg-1, i. p. ). The trachea was cannulated to facilitate respiration. The carotid artery and 
jugular vein were cannulated for blood sampling and the administration of drugs 
respectively. After a stabilisation time of 30 min following surgery a basal sample of blood 
(500 p. L) was collected in EDTA (10 mg ml-1 blood) to determine basal levels of glucose 
and insulin. The volume of blood lost in sampling was replaced with an equal volume of 
saline. A D-glucose solution (0.5g kg-1) was administered as a bolus dose over 10 sec. 
Blood samples were then collected at times 1,3,6,12,24 min post glucose bolus. The 
blood was centrifuged at 15,000 rpm for 3 min at 4°C and the plasma frozen in liquid 
nitrogen and stored at -70°C. 
2.2.5 Collection of plasma for analysis of 8-epi-PGF2a 
Rats deprived of food for 16-20 hours were anaesthetised with pentobarbitone sodium (60 
mg kg-1, i. p. ) and exsanguinated by the removal of blood through the abdominal aorta. 
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Blood was collected into a syringe containing sodium citrate (3.8 % w. v'1), indomethacin 
(15 µM) and butylated hydroxytoluene (BHT) (20 µM). This was then centrifuged at 
15,000 rpm for 3 min at 4°C to derive plasma. The plasma was further treated with BHT 
(20 µM) and immediately frozen in liquid nitrogen and stored at -70°C. 
2.2.6 Extraction of 8-epi-PGF2afrom plasma 
Plasma was mixed with a Folch solution (CHC13: MeOH, 2: 1) containing MgCl (0.43 %). 
The samples were then centrifuged at 1000 rpm for 3 min to separate the water, protein, and 
organic layers. The organic layer containing the isoprostanes was evaporated to dryness 
under N2 and reconstituted in MeOH. The samples were incubated for 30 min at 37°C with 
KOH (15 %) to isolate the total isoprostane content from the cell membranes into solution. 
The sample solution was later neutralised with water (pH 3). 
The samples were applied to a C18 sep-pak cartridge that had been preconditioned with 
MeOH then water (pH 3). After sample addition, the column was washed with water (pH 3) 
and heptane and eluted with ethyl acetate and heptane (1: 1). Sodium sulphate was added to 
the eluent to remove excess water. A Silica sep-pak column was preconditioned with 
McOH then ethyl acetate, before the eluate from the C18 Sep-pak was loaded. The column 
was washed with ethyl acetate: methanol (1: 1), and the final eluate was evaporated under 
N2 then reconstituted in the immunoassay dilution buffer (supplied by Oxford biomed). 
2.2.7 Measurement of 8-epi-PGF2a by Enzyme Immunoassay and GCMS 
The EIA kit (EA 84) was purchased from Oxford biomedical Research. The assay is based 
on the competition between free 8-epi-PGF2a,, in the standards or samples, competing with 
8-epi-PGF2a, linked to horseradish peroxidase (HRP) for a limited number of sites on a 8- 
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epi-PGF2a, -specific polyclonal antibody coated on a microtitre plate. The HRP enzyme 
activity results in colour development proportional to the amount of 8-epi-PGF2a linked to 
HRP that is bound and inversely proportional to the amount of free 8-epi-PGF2a, in the 
samples or standards. The assay was carried out as described in the protocol except that 
plates were washed manually. GCMS samples were analysed in collaboration with Dr N. 
Gopaul and Ms S. Dhir, in a method essentially described by Gopaul (2000). 
2.2.8 Effect of 8-epi-PGF2a in rat perfused hindquarters. 
Following stabilisation, the Wistar rat hindquarters were perfused with PSS with or without 
L-NAME (2.1 µmol) for 20 min before and during the administration of cumulative 
concentrations of 8-epi-PGF2a (0.1-300 nmol) 
2.2.9 Effect of vasodilators and vasoconstrictors in rat aortic rings. 
Rats were anaesthetised with pentobarbitone sodium (i. p. ) and exsanguinated by the 
removal of blood through the abdominal aorta. The thoracic aorta was removed and cleaned 
of adhering connective tissue and cut into 3 mm rings. The rings were mounted at random 
under a2g resting tension in organ baths filled with a PSS at 37°C (see above) and gassed 
with 95 % 02 and 5% CO2. The aortic rings were allowed to equilibrate for 1 hour, during 
which the PSS was changed at 15 min intervals. Tension was recorded from Grass FT03C 
isometric force transducers onto a MacLab recording system. 
Experimental protocols. Cumulative contraction curves to Phe (0.0001-10 µM) or 8-epi- 
PGF2a, (0.01-30 mM) were obtained depending on the experiment. ACh (10 µM) was added 
to assess the integrity of the endothelium. A Phe constrictor tone was induced, followed by 
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a cumulative relaxation curve to ACh (0.0001-10 µM). SNP (100 µM) was added at the end 
of the experiment to assess the vascular reactivity. 
In experiments assessing the acute action of insulin, rings were randomly exposed to 
insulin (100 nM), or its vehicle BSA (0.1 %), for 20 min. Then they were pre-contracted 
with noradrenaline (100 nM), a concentration that elicits approximately 90 % of the 
maximal response. After the pre-contraction stabilised endothelium-dependent 
vasorelaxation to ACh (1-1000 nM), and endothelium-independent vasorelaxation to SNP 
(SNP, 1-300 nM), were assessed in separate preparations. In other preparations, contraction 
to Phe (0.001-10 µM) was assessed following a 20 min pre-treatment with human insulin 
(100 nM), or its vehicle, in the presence or absence of L-NAME (300 µM). L-NAME was 
added 10 min prior to contraction with Phe. Insulin (100 nM), or its vehicle, was present 
throughout the experiment. 
2.2.10 Antioxidant and Pro-oxidant treatment regimes 
For antioxidant studies, male 9 week-old Zucker rats (Harlan, Blackthorn, Bicester, UK) 
were maintained for 4 weeks on either a standard chow diet (Special Diet Services, 
Witham, Essex, UK) or a chow enriched with probucol or Vitamin E ((±)-a-tocopherol 
acetate) - each antioxidant was in the chow at 0.5 % ww"1. Alternatively, the intracellular 
superoxide scavenger tiron was added to drinking water at 1%wv "1. 
For pro-oxidant studies, male 12 week-old Zucker rats (Harlan, Blackthorn, Bicester, UK) 
were treated daily with HQ (50 mg kg" i. p. ), BSO (50 mg kg-1 i. p. ) or HQ+BSO (each at 50 
mg kg-1 i. p. ) for 7 days. Control animals received sham injections of normal saline (2 mg 
kg-1 i. p. ) daily. HQ is a redox cycling compound that generates Of. Similarly, BSO is a 
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potent and selective irreversible inhibitor of reduced glutathione (GSH) synthetase and 
thereby results in the increased levels of ROS. 
For fructose studies, male 7 week-old Zucker rats (Harlan, Blackthorn, Bicester, UK) were 
given untreated or fructose (10 %) (fructofin C) treated drinking water for 6 weeks. After 4 
weeks of fructose treatment, pro-oxidant injections were started for 2 weeks as indicated 
above. 
Rats were allowed food and water ad libitum. Obese and lean littermates were fasted 
overnight before vascular function was assessed and blood collected from the Zucker rats. 
2.2.11 Measurement of plasma nitric oxide (Griess Assay) 
Nitric oxide release was determined by measuring the accumulation of its stable 
degradation products, nitrate (NO3") and nitrite (NOD. Firstly, nitrate was reduced to 
nitrite, by incubating the samples for 15 min at 37°C in the presence of NADH or NADPH- 
dependent nitrate reductase (1 U ml-'), NADPH (500 µM) and FAD (50 µM). When the 
nitrite reduction was complete, an additional step to degrade the excess NADPH was 
included to avoid its interference in the final reaction. This included the addition of lactate 
dehydrogenase (100 U ml-1) and sodium pyruvate (100 mM) at 37°C for 5 min. The total 
nitrite was then determined spectrophotometrically using the Griess reaction - used with N 
1-napthylethylenediamine dihydrochloride under acidic (phosphoric acid) conditions to 
convert sulphanilamide to the purple-coloured azo compound that was measured at 550 nm 
in an Anthos Labtech type 12605 microplate reader. 
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2.2.12 Measurement of plasma total antioxidant status (TAOS) 
The principle reaction of this microassay is the conversion of H202 to water which is 
coupled to the oxidation of 2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid (ABTS) 
to ABTS'+ (Arnao et al., 1996). Antioxidants present in the test samples will donate an 
electron to ABTS'+, reducing it back to ABTS. Hence total antioxidant status of the test 
plasma is proportional to its ability to inhibit ABTS' generation. The reaction mixture 
consisted of ABTS (2 mM), horse radish peroxidase (30 mU ml-1), H202 (0.1 mM), 
phosphate-buffered saline (10 mM, pH 7.4) and plasma. The reaction was initiated by the 
addition of H202 and conducted at 37°C. The increase in absorbance at 405 nm, reflecting 
the accumulation of ABTS", was determined after 6 min in an Anthos Labtech type 12605 
microplate reader. An ascorbate concentration curve was constructed and the data 
expressed as the ascorbate equivalent antioxidant concentration (AEAC). All 
determinations were made in triplicate. 
2.2.13 Measurement of plasma insulin 
Plasma insulin was determined using a commercial radioimmunoassay (RIA) kit (Linco 
Research Inc, Missouri, USA). Plasma, or known insulin standards, were added to rat 12sI- 
insulin and guinea pig anti rat insulin serum and incubated at 4°C for 24 hr. Competition 
between labelled tracer and unlabelled antigen for the antibody was stopped by the addition 
of an ice cold precipitating reagent containing goat anti-guinea pig IgG serum. The samples 
were vortexed and left to precipitate for 20 min at 4°C, before being centrifuged at 
3000 rpm for 30 min. The precipitated pellets were counted in a gamma counter (NE160, 
Nuclear Enterprises Ltd, Edinburgh, UK), and insulin concentrations in samples calculated 
from the standard curve, where (%) standard/total counts was plotted against its 
concentration. All determinations were made in duplicates. The limit of sensitivity of the 
assay is 0.1 ng m1'', and the limit of linearity is 10 ng ml-1. 
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2.2.14 Measurement of plasma glucose 
Plasma glucose was measured using a commercial photometric Trinder assay kit (Sigma 
Chemical Co. Poole, UK. ). The volumes and plasma dilution recommendations were 
modified from the manufacturer's instructions to determine glucose concentrations in a 
microtitre plate. The principle reactions in the assay are, firstly, the oxidation of glucose to 
gluconic acid and H202 by glucose oxidase. The H202 formed then reacts with 4- 
aminoantipyrine and p-hydroxybenzene sulfonate in the presence of peroxidase to form a 
quinoneimine dye, with an absorbance maximum at 505 nm. The colour intensity is directly 
proportional to the glucose concentration in the sample. The assay procedure for the 
microassay was to add the standards (1.25-40 mM) or plasma samples to a 96 well plate 
and quickly add the light sensitive trinder reagent. The plate was covered in foil, shaken 
and incubated at room temperature for 18 min. The plasma glucose concentration was 
determined by absorbance at 505 nm in an Anthos Labtech type 12605 microplate reader. 
Since turbid as well as haemolyzed plasma may give falsely high values, blank absorbance 
was determined for each plasma sample and these values were subtracted from the actual 
sample values. All determinations were made in duplicates. 
Standard (mM) 0 1.25 2.5 5 10 20 40 
% CV 2.52 5.23 3.47 4.64 4.41 5.89 5.63 
Table 2.1 Intra sample variation in the glucose standards (0-40 mM) in saline 
Plasma (mM) 0 5 10 
% CV 3.98 4.53 4.31 
Table 2.2 Inter assay variation in glucose spiked plasma samples (0-10 mM) 
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2.2.15 Measurement of plasma triglycerides 
Triglycerides were measured using a commercial photometric triglyceride assay kit - 
Triglycerides GPO-Trinder (Sigma Chemical Co. Poole, UK. ) which was carried out 
according to the kit instructions. Triglycerides, esters of fatty acids and glycerol do not 
circulate freely in plasma but are bound to proteins and transported as macromolecular 





Glycerol + ATP 00 
Glycerol + fatty Acids 
Glycerol-l-phosphate (G-1-P) + ADP 
Glycerol Phosphate Oxidase 
G-1-P +0 Dihydroxyacetone phosphate (DAP) + hydrogen peroxide (H202) 
Finally, a quineimine dye is produced by the peroxidase catalysed coupling of 4- 
aminoantipyrine (4-AAP) and sodium N-ethyl-N-(3-sulfopropyl) m-anisidine (ESPA) with 
H202 which shows an absorbance maximum at 540 nm. The increase in absorbance at 540 
nm is directly proportional to triglyceride concentration of the sample. The triglyceride 
(GPO-Trinder) reagent solution was warmed to assay temperature and added to a 
triglyceride standard or plasma. The sample was mixed and incubated at 37°C for 5 min. 
Following incubation the absorbance was measured at 540 nm in a spectrophotometer 
(Shimadzu UV-160, Howe, Oxon, UK). All determinations were made in duplicates. 
23 DATA ANALYSIS 
Data are presented as means±s. e. mean of n independent experiments, expect in the glucose 
assay method validation where s. d was used to calculate the coefficient of variation (% CV) 
for intra and inter assay variation (tables 2.1 & 2.2). Statistical analysis between paired 
means were assessed using Student's two-tailed, paired t-test and aP value of less than 
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0.05 was considered statistically significant. Multiple comparisons of unpaired meaned 
dose response curves from functional data shown by graphs were conducted by two way 
ANOVA followed by a Dunnett's test. All other multiple comparisons of unpaired means 
from functional data were conducted by one way ANOVA followed by a Dunnett's test. 
Data was analysed using Prism (GraphPad software Inc., U. S. A. ). Significance was 
accepted at the 5% level. ACh-induced changes in perfusion pressure are expressed as a 
percentage of the total vascular response (% SNP) in order to control for changes in the 
preparations. The figures are presented as means±s. e. mean. Error bars not represented are 
smaller than the symbol size used. 
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Chapter 3 
Development of methods for the 
investigation of endothelial function 
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3.1 INTRODUCTION 
Since the importance of endothelial function in the pathogenesis of diabetes remains 
unclear, a key goal of this work was to develop appropriate methods to assess endothelial 
function in rat models of diabetes. Many studies measuring forearm blood flow in type 2 
diabetic patients have shown impaired endothelium-dependent responses. However, studies 
with uncomplicated type 2 diabetic patients showed no difference in basal or agonist 
stimulated NO (Avogaro et al., 1997). This picture is further complicated by studies in 
animals with early diabetes that show an increased formation of endothelial-derived NO 
(Corbett et al., 1992; Tilton et al., 1993). Conflicting data in this area may be due firstly to 
the size of the vessel where a given measurement is taken. For example, NO is a key 
vasodilator in large arteries, but has a diminishing role as vessel calibre decreases 
(Urakami-Harasawa et al., 1997). Secondly, some measurements are made in more insulin 
sensitive areas than others - an aortic ring is less sensitive to insulin than a skeletal muscle 
bed. Thirdly, differences in in vitro and in vivo data will occur as blood borne factors and 
autonomic control will affect the measurement of endothelial function. The importance of 
using a variety of systems to measure endothelial function is therefore paramount to 
investigate its role in diabetes. 
Development of a rat model to assess blood flow and pressure simultaneously in vivo. 
Previous assessment of endothelial function in the rabbit ear artery using 
photoplethysmography (Weinberg et al., 2001) has shown NO-dependent changes in blood 
flow induced by ACh. Similar studies in humans showed NO-dependent changes in blood 
flow were impaired in type 2 diabetes patients (Chowienczyk et al., 1999). Development of 
a rat model would allow correlation of agonist-induced changes in blood flow in a small 
artery with overall changes in blood pressure. The blood flow measurements can be 
obtained using laser Doppler fluxmetry focused on the auricular ear artery. Principally, this 
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works by measuring frequency changes in a light beam that has been scattered in response 
to moving red blood cells. This method subsequently provides a measurement of red blood 
cell flow in a given volume, as the higher the frequency, the greater the amount of red 
blood cells. Hence a vasodilation of the ear artery results in less vascular resistance, and 
consequently an increased Doppler frequency. 
The model was additionally developed for its potential use as a non-invasive measurement 
of endothelial (dys)function so that animals could be used in long term studies. This would 
limit animal usage and allow better numerical data as infra variation analysis could be done. 
A further advantage of this approach is that the use of anaesthetic would be limited - it is 
well documented that anaesthesia can affect endothelial function (Castillo et al., 1999). 
Since any potential non-invasive method of endothelial function measurement would 
require drug administration via the tail vein, a comparison was made of tail verses jugular 
vein drug administration in respect of changes in arterial blood flow. 
Rat tail indirect blood pressure system provides a non-invasive method for blood pressure 
measurement and is therefore suitable for long term studies. Furthermore, this method is 
considered appropriate to use in parallel with non-invasive measurements of ear arterial 
blood flow, as blood pressure and blood flow could be measured simultaneously. The new 
system required testing in our laboratory, as rat body temperature and stress can affect the 
reliability of data. It was my aim to carry out the method at room temperature, because 
increasing the body temperature may alter endothelial function due to vasodilation. 
Previous studies have used rats that were warmed to 37°C, a practice that increased the 
blood flow to the tail and allowed the detection of a pulse. Additionally, rats need to 
become accustomed to being held in restrainers to reduce stress-induced constriction of 
their tails (Bunag & Butterfield, 1982). 
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The perfused rat hindquarters in situ is an ideal method for measurement of endothelial 
function in studies of diabetes, since the hindquarters have a large resistance vascular area 
that is insulin sensitive. This in situ preparation thus allows the direct measurement of 
endothelium-dependent mechanisms from changes in pressure and flow without the 
complications of autonomic nervous control and blood. For example, cardiovascular 
autonomic baroreceptor reflexes increase sympathetic activity in response to acute 
decreases in blood pressure in order to maintain homeostasis. Equally problematical is the 
sensitivity of blood borne factors, such as catecholamines, the activity of which can be 
increased by as much as 200 fold in blood-perfused systems. In addition, haemoglobin in 
the circulating blood may provide a constrictor vascular tone by binding some of the NO 
that is continually released from the endothelium (Martin et al., 1986). 
The haemodynamic relationship between blood flow, pressure and vessel tone (diameter) in 
both the perfused hindquarters in situ and ear blood flow experiments is described by 
Poiseuille's equation (Nichols & O'Rourke, 1998): Q=KD4 (Pl-P2) /L; where Q= volume 
flow of blood or perfusate per unit time, K is a constant, D the internal diameter of the 
vessel (which is dependent on vasodilation), and (PI-P2) is the pressure drop (or difference) 
along L (the length of the vessel). This was derived from the equation Pressure = Flow x 
Resistance (vessel diameter). There is some debate as to the type of perfusion model used. 
For example, flow can be kept constant and pressure changes recorded, or pressure can be 
kept constant and flow is varied according to the dilation of the preparation (Johnsson et 
al., 1991). Despite the reduction in oedema formation in the constant pressure models, the 
flow is a more preferred method as the delivery of drugs is more problematical in the 
constant pressure model, because the concentration at a particular flow cannot be predicted. 
Consequently, this more sensitive model can be harder to interpret. 
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3.2 METHODS 
3.2.1 Perfusion of the rat hindquarters in situ 
The surgical procedures used to set up this method are included in section 2.1.1 of the 
general methods chapter. 
In initial validation studies, the effluent outflow rate and basal perfusion pressure (PP) 
were determined at 30 min intervals over a perfusion period of 150 min in order to assess 
variation with time. In addition, vasoconstrictor reactivity was assessed over this time 
course by construction of a dose response curve for vasoconstriction to bolus doses of 
phenylephrine (Phe) (1-100 nmol). 
In basal endothelial function studies, the hindquarters received cumulative concentrations 
of Phe (0.3-1000 nmol min"') by infusion, with or without L-NAME (2.1 µmol) in the PSS, 
for 20 min before and during the Phe response curve. 
In agonist stimulated endothelial function studies, Phe eliciting approximately 85% of the 
maximal response (Wistar rat: 300 nmol min-) was infused at t=20 min to provide sub- 
maximal pre-constriction. After a stabilisation of induced vascular tone, bolus doses of 
ACh (0.001-30 nmol) or SNP (0.001-100 nmol) were injected to construct vasodilator dose 
response curves. 
In separate experiments, the effect of L-NAME on an ACh dose response curve was 
assessed at t=20 min in hindquarters preparations pre-constricted with Phe (300 nmol), in 
the presence or absence of L-NAME (2.1 . tmol) in the PSS. After a stabilisation of induced 
vascular tone, bolus ACh was administered as above. In these experiments, SNP (100 
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nmol) was injected to construct vasodilator dose response curves with respect to SNP (as an 
internal control and an estimation of the total vasodilation ability of the preparation). 
3.2.2 Haemodynamic measurements in vivo 
Blood pressure. Male Wistar rats were anaesthetised with thiopentone sodium (Intraval 
120 mg kg'', i. p. ). The trachea was cannulated to facilitate respiration and the rectal 
temperature was maintained at 37°C as described above. The right carotid artery was 
cannulated and connected to a pressure transducer (SensoNor 840, Norway) for the 
measurement of mean arterial blood pressure (MAP) and heart rate (HR) which were 
recorded for the duration of the experiment and displayed on a MacLab 16s recording 
system (AD Instruments, London, UK). The femoral vein was cannulated for the bolus 
administration of drugs, and the jugular vein for the infusion of drugs. 
Blood flow. In blood flow experiments, the surgical procedure for blood pressure 
measurements was completed before shaving the ear of the rat and placing a laser Doppler 
flow probe (Type P4; tip diameter 0.85 mm; Moor Instruments, Axminster, Devon, UK) on 
the ear auricular artery, or a branch of the artery (Fig. 3.1). Blood flow was also displayed 
on the MacLab recording system. Following surgery, a 30 min period of stabilisation was 
allowed before recording baseline haemodynamic parameters. 
ACh (0.001-10 nmol kg-1 i. v. ) and SNP (0.01-30 nmol kg-1 i. v. ) were administered to assess 
vasodilation and changes in blood flow mediated by endogenous or exogenous NO 
respectively. Separate experiments were performed to establish the role of NO in blood 
flow in the auricular artery of the ear. Agonist-stimulated NO responses were assessed by 
bolus ACh (1&10 nmol kg" i. v. ) responses. SNP (10 nmol kg" i. v. ) was administered for 
both the assessment of endothelial-independent NO vasodilation, and as an internal control. 
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L-NAME was administered initially as a bolus (50 mg kg" i. v. ), followed by a 10 min 
infusion (100 mg kg -1 hr 1 i. v. Moncada et al., 1991). Cardiovascular responses to bolus 
doses of ACh then SNP were then reassessed. 
ACh-induced vasodilation and changes in blood flow are expressed as a percentage of the 
total vascular response (% SNP) to control for probe movement during the experimental 
procedure. The vasodepressor activity and changes in blood flow are plotted as the area 
under the response curve with time as (mm Hg min-1) and (V s'1) respectively. 
Vasoconstrictor reactivity was assessed in vivo by construction of a dose response curve to 
bolus doses of Phe (0.1-100 nmol kg-1 i. v. ). In agonist stimulated endothelial function 
studies, bolus doses of ACh (0.01-10 nmol kg-1 i. v. ) or SNP (1-100 nmol kg-1 i. v. ) were 
injected to construct vasodilator dose response curves. 
3.2.3 Rat tail cuff blood pressure measurement 
Rats were placed in a restrainer, and a cuff was placed at the base of the tail. The rats were 
then allowed to acclimatize to their surroundings for 20-30 min prior to cuff inflation. 
Using a manual inflation bulb, the cuff was gently inflated to 250-300 mm Hg to occlude 
blood flow. A bleed valve was then opened to reduce the pressure over a 15 second period. 
The inflation pressure and the tail pulse pressure were recorded using a MacLab system 
(Hastings, Sussex, U. K. ). The recorded blood pressure measurement is the mean of 5 
individual readings taken 5 min apart. Analysis of the traces show that as the inflation 
pressure decreases a point will be reached where the pulse pressure will become apparent 
on the trace, this is read as the systolic pressure. As the inflation pressure decreases further, 




3.3.1 Development of an in situ hindquarters perfusion model. 
Initial validation studies. The effluent outflow rate decreased slightly over the initial 90 
min, with a sharp decrease occurring after this time (Fig. 3.3A). In contrast, basal perfusion 
pressure exhibited only a slight rise over 150 min (approximately 10 mm Hg) (Fig. 3.3C). 
Hindquarters basal perfusion pressure after t=20 min was 22.8±1.2 mm Hg (n=35). 
Vasoconstrictor responsiveness to Phe (10 nmol) moderately increased between t=30 and 
t=60 min and then remained reproducible until t=120 min, after which time there was a 
further significant increase in sensitivity (at t=150 min) (Fig. 3.3B). 
L-NAME enhances Phe-induced vasoconstriction. Basal perfusion pressure of the control 
preparations (28.0±1.7 mm Hg, n=7) was comparable to that of L-NAME (27.7±2.5 mm 
Hg, n=5) treated preparations (P>0.05). However, Phe (0.3-1000 nmol min 1) elicited 
graded increases in perfusion pressure that were shifted leftward in the presence of L- 
NAME (2.1 pmol) (Fig. 3.4A). 
ACh and SNP-induced vasodilation. Basal perfusion pressures in ACh (28.0±1.4 mm Hg, 
n=4) and SNP preparations (28.3±4.1 mm Hg, n=4) were elevated to sustained perfusion 
pressures by Phe (ED85,300 nmol min 1) (ACh preparations: 182.2±18.2 mm Hg, n=4; SNP 
preparations: 86.3±19.0 mm Hg, n=4). Vasodilator responses to ACh (0.0001-30 nmol) 
(Fig. 3.4B) and SNP (0.001-100 nmol) (Fig. 3.4C) elicited rapidly reversible, dose- 
dependent decreases in perfusion pressure. 
L-NAME inhibits ACh-induced vasodilation. Basal perfusion pressure in control 
preparations (28.3±2.9 mm Hg, n=6) was comparable with that of L-NAME treated 
preparations (32.8±2.5 mm Hg, n=6) (P>0.05). However, Phe elevated perfusion pressure 
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was greater in L-NAME (255.7±5.7 mm Hg, n=6; P<0.05) relative to control preparations 
(157.1±27.9 mm Hg, n=6). Furthermore, the ACh (0.0001-100 nmol) -induced 
vasorelaxation was impaired by the administration of L-NAME (2.1 p. mol) (P<0.05) (Fig. 
3.5). In contrast, the SNP (100 nmol) bolus dose elicited a greater vasorelaxation in the L- 
NAME (144.5±14.8 %, n=6; P<0.05) treated preparations compared to the control 
(87.4±13.9 %, n=6) preparations. 
3.3.2 Development of a non-invasive technique for ear artery blood flow measurement 
ACh and SNP -induced dose-dependent changes in MAP and blood flow. The 
administration of endothelium-dependent and -independent vasodilators provoked a 
decrease in MAP that was seen to be followed by a simultaneous increase in pulsatile blood 
flow in the ear artery (Fig. 3.1). Bolus administration of ACh dose-dependently elicited 
both a decrease in MAP and a simultaneous increase in blood flow in the auricular artery of 
the rat ear (Fig. 3.6) from baseline values of 126.28±5.76 mm Hg (n=12) and 4.42±0.16 V 
(n=12) respectively. Similarly, SNP (0.01-30 nmol kg-1) induced both an increase in blood 
flow and decrease in MAP in a dose-dependent manner (Fig. 3.7). However, administration 
of ACh or SNP did not alter the basal heart rate (HR) of 380.15±11.08 beats min' (BPM) 
(n=12). 
The correlation coefficient (r) for ACh (0.001-10 nmol kg-1) dose responses showed a 71 % 
(correlation P<0.05) similarity of blood flow to the MAP (n=6; data points included=36). 
However, a significantly greater relationship between flow and MAP of 88 % (correlation 
P<0.05) was observed in the dose responses to SNP (0.01-30 nmol kg-1) (n=6; data points 
included=22) (Fig. 3.8A; Fig. 3.8B) when the slopes were compared directly. ACh and 
SNP induced similar changes in MAP (P>0.05); changes in blood flow, however, were 
more sensitive to ACh than SNP (P<0.05, Two way ANOVA). 
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L-NAME inhibited ACh-induced changes in MAP but not blood flow. ACh-induced (1 & 
10 nmol kg') increases in ear artery blood flow were unaffected by L-NAME (Vehicle; 
n=5, L-NAME; n=6) (Fig. 3.9). In contrast, the decrease in MAP to ACh was significantly 
impaired by L-NAME (n=5-6) (Fig. 3.10). Furthermore, SNP-induced changes in basal 
blood flow (0.89±0.26 V, n=6), MAP (33.96±3.40 mm Hg, n=6), and HR (21.46±13.49 
BPM, n=5) (10 nmol kg'') were unaffected by L-NAME treatment (flow; 1.46±0.21 V, 
n=6, MAP; 31.97±8.9 mm Hg, n=6, HR; 2.76±4.56 BPM, n=5). Infusion of L-NAME 
alone decreased ear blood flow, but this was not statistically significant (absolute fall: 
4.4±0.5 V to 2.4±0.8 V, (n=6); area under the response curve: -343±149 V s-1 to 1285±822 
V s-1). Additionally, the increases in MAP (increase of 9.56±5.0 mm Hg, n=6) and the 
decrease in HR (decrease of 32.95±12.17 BPM, n=6) by L-NAME were not statistically 
significant. 
Route of administration altered ACh-induced changes in MAP but not blood flow. ACh- 
induced (10 nmol kg-1) increases in ear artery blood flow were unaffected by route of 
administration (femoral; n=6, tail; n=6) (Fig. 3.1 1A). In contrast, the decrease in MAP to 
ACh was significantly impaired when administered via the tail vein (n=6) (Fig. 3.11B). In 
addition, SNP-induced (10 nmol kg-1) changes in basal blood flow (n=6), MAP (n=6), were 
unaffected by route of administration. 
3.3.3 Non-invasive measurement of tail artery blood pressure. 
Basal measurement of MAP. The basal arterial blood pressure measurement using the non- 
invasive tail cuff was 117.85±5.3 mm Hg (n=5). Similarly, direct invasive MAP 
measurement was essentially the same 114.23±2.5 mm Hg (n=5) in anaesthetised rats (Fig. 
3.12). 
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Figure 3.1 Experimental setup and typical traces for the measurement of ear 
blood flow using laser Doppler fluximetry. Mean arterial blood pressure was 
measured using traditional pressure transducers. The traces show the A. blood pressure 
(. ) B. MAP C. blood flow (. ) following a bolus dose of acetylcholine. The computer 
recorded at 40 samples per second. 
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Figure 3.2 Typical trace using the tail cuff for indirect measurement of mean 
arterial blood pressure in the conscious rat. The traces show the occlusion and 
gradual release of the cuff pressure ( ) and simultaneous threshold then regular pulse 
rate (u). The arrow indicates where the mean arterial blood pressure value was 
measured. The computer recorded at 200 samples per second. 
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Figure 3.3 Initial validation studies of the Wistar rat perfused 
hindquarters in situ included the effect of perfusion time on: A. Effluent flow 
rate. B. Reactivity of preparation to Phenylephrine (10 nmol) -spiked responses. 
C. Basal perfusion pt-essure. Data are expressed as mcan±s. e. mean of 3 
determinations. 
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Figure 3.4 Assessment of endothelial function in the Wistar rat 
perfused hindquarters in situ. A. Basal nitric oxide vasodilator function 
was assessed by phenylephrine (Phe, 0.1-1000 nmol) cumulative dose 
responses in control (o) and L-NAME (2.1 p. mols equivalent to 300 p. M) (. ) 
treated preparations. Established vasoconstrictor tone by phenylephrine (300 
nmol) was reversed by the endothelium -dependent and -independent 
agonists B. Acetylcholine (ACh, 0.001-100 nmol) (") C. Sodium 
nitroprusside (SNP, 0.01-100 nmol) (A). Data are expressed as 
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Figure 3.5 Vasodilation to acetylcholine (ACh, 0.0001-100 nmol) in 
phenylephrine (300 nmol) pre-constricted Wistar rat perfused 
hindquarter in situ. Preparations were control (o) and L-NAME (2.1 gmols) 
( ) treated. ACh was standardised with respect to vasodilation to sodium 
nitroprusside (SNP, 100 nmol) Data are expressed as mean±s. e. mean of 4-6 
determinations. Statistical significance (*) using two way ANOVA was 
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Figure 3.6 Acetylcholine (ACh, 0.001-10 nmol kg-' i. v. ) -induced 
endothelium-dependent changes in mean arterial blood pressure (MAP) 
( ) or arterial blood flow (o) of the ear in the Wistar rat. Results are 
standardised with respect to vasodilation to sodium nitroprusside (SNP, 10 
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Figure 3.7 Sodium nitroprusside (SNP, 0.01-30 nmol kg"' i. v. ) -induced 
endothelium-independent changes in mean arterial blood pressure (MAP) 
(. ) or arterial blood flow (o) of the ear in the Wistar rat. Results are 
standardised with respect to vasodilation to sodium nitroprusside (SNP, 10 
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Figure 3.8 Correlation of (A). Acetylcholine (ACh, 0.001-10 nmol kg-1 
i. v. ) or (B). Sodium nitroprusside (SNP, 0.01-30 nmol kg-' i. v. ) -induced 
decrease in mean arterial blood pressure (MAP) and increase in ear 
arterial blood flow in the Wistar rat in vivo. Results are standardised with 
respect to vasodilation to SNP (10 nmol kg-1 i. v. ). Data are expressed as 






Figure 3.9 Acetylcholine (ACh, 1&10 nmol kg-1 i. v. ) -induced 
endothelium-dependent changes in mean arterial blood pressure (MAP) 
in vehicle (o) and L-NAME (100 mg kgl) (. ) treated Wistar rats in vivo. 
Results are standardised with respect to vasodilation to sodium nitroprusside 
(SNP, 10 nmol kg'' i. v. ). Data are expressed as mean±s. e. mean of 5-6 









Figure 3.10 Acetylcholine (ACh, 1&10 nmol kg"I Lv. ) -induced 
endothelium dependent changes in in ear arterial blood flow in vehicle 
(o) and L-NAME (100 mg kg'') (a) treated Wistar rats in vivo. Results 
are standardised with respect to vasodilation to sodium nitroprusside (SNP, 
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Figure 3.11 Acetylcholine (ACh, 10 nmol kg-' i. v. ) and sodium 
nitroprusside (SNP, 10 nmol kg-' i. v) -induced changes in in ear arterial 
blood flow and MAP when administered via the femoral ( ) or tail vein 
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Figure 3.12 Mean arterial blood pressure (MAP) in Wistar rats 
measured non-invasively using a tail cuff whilst conscious and invasively 
whilst anaesthetised. Data are expressed as mean±s. e. mean of 5 
determinations. Statistical significance (*) using a paired t-test was considered 
established at P<0.05. 
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3.4 DISCUSSION 
Blood flow and pressure model. I have developed a model that enables simultaneous 
measurement of blood pressure and ear artery blood flow in vivo using laser Doppler 
fluxmetry. This model allowed correlation of agonist-induced changes in blood flow in a 
small artery with overall changes in blood pressure. 
Initial studies showed the administration of endothelium-dependent and -independent 
vasodilators decreased MAP. This was followed by a simultaneous increase in pulsatile 
blood flow in the ear artery. The increase in flow was slightly time-delayed compared to the 
change in MAP and may reflect either the distribution time of the agonist to reach the sites 
of action, or autonomic control increasing blood flow in the ear artery as a consequence of 
decreased circulatory blood pressure. Another explanation for this time delay may be 
vascular tree variability where different receptors, endothelial mediators or signalling 
molecules are involved in vasodilation at various parts of the vasculature. Indeed, through 
the release of NO, organic nitrates are known to cause venous dilation and, at higher doses, 
arterial dilation. These variations in dilation demonstrate vasculature differences. Therefore 
the time delayed responses in my experiments are likely to be attributable to these 
differences. 
In a previous study of the rat ear artery by Sanae & Hayashi (1998), theophylline, an 
adenosine antagonist, induced increases in blood pressure, heart rate and blood flow. L- 
NAME inhibited the blood flow without any changes in blood pressure and heart rate. They 
suggested the increased flow was due to an independent cardiac effect, influenced by 
adrenergic and nitrergic pathways, as reserpine (a noradrenaline storage depleter) and 
propranolol (an adrenoceptor antagonist) reduced the vasodilation effects. This 
autoregulatory effect would be expected in the ear artery, since in the rat the ear is 
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important in the regulation of body temperature. However, increases in blood flow by ACh 
were not affected by reserpine, suggesting that the action of ACh was not through an 
autonomic mechanism in the ear. 
My data also supports the notion of vascular tree variability and not autonomic control, as 
dose-dependent changes in blood flow were more sensitive to ACh than SNP, whilst 
changes in MAP were comparable. This is unlikely to be due to ACh stimulating the release 
of higher concentrations of endogenous NO, or that guanylyl cyclase levels are higher in 
the ear artery than in large conduit arteries. This is because L-NAME did not inhibit ACh- 
induced increases in ear arterial blood flow, but significantly impaired the decrease in MAP 
to ACh. Furthermore, SNP-induced changes in ear blood flow, MAP and HR were 
unaffected by L-NAME treatment, suggesting the L-NAME inhibition was specific to ACh- 
induced changes in MAP, as would be expected. Additionally, L-NAME infusion did not 
significantly change basal blood flow, MAP, or HR, thereby indicating ACh caused an 
agonist-stimulated endothelium-dependent increase in blood flow that was NO- 
independent. This notion is further supported by the fact that if in these experiments 
arteriole vasodilation was solely mediated through the action of NO, then decreasing MAP 
would correlate with increasing blood flow, equally for ACh and SNP. However, the results 
showed a significantly weaker correlation between MAP and blood flow with ACh 
(r2=0.71) than with SNP (r2=0.88) -induced vasodilation, suggesting ACh may involve 
another mediator as well as NO to provoke the vasodilating effect. This other mediator, is 
one that also causes enhanced blood flow in the ear artery by an endothelial-dependent 
mechanism, as SNP was less sensitive. These findings perhaps show that the NO- 
independent action of ACh is more important in the ear artery of the rat than it is 
systemically. In support of this, studies using iontophoretically applied ACh or SNP to the 
dermal circulation of men (Noon et al., 1998) showed L-NAME had no effect, whereas 
aspirin inhibited ACh-induced vasodilation. However, L-NMMA inhibited the ACh- 
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stimulated decrease in blood flow in the brachial artery. The different changes observed in 
dermal and brachial artery blood flow support the notion of vascular tree variability. Other 
human brachial artery studies that support our data show ACh-stimulated increases in blood 
flow were inhibited by L-NMMA only at lower ACh concentrations (Bruning et al., 1993). 
This suggests a second mechanism of cholinergic vasodilation at higher ACh 
concentrations, possibly through the release of a relaxing factor other than NO. In studies of 
the dermal circulation of healthy men, prostanoids were implicated in the ACh-stimulated 
endothelium-dependent NO-independent increase in blood flow, as aspirin inhibited ACh- 
induced vasodilation (Noon et al., 1998). Further studies using a cyclo-oxygenase inhibitor 
such as indomethacin could be done to determine prostanoid involvement. 
The involvement of a secondary mediator stimulated by ACh may be dependent on the 
types of muscarinic receptors present on the endothelium of the vascular tissue involved. It 
has been shown that the release of EDHF is mediated by Mi receptors, and that NO is 
mediated by M2 receptors (Komori & Suzuki, 1987; Keef & Bowen, 1989). Endothelium- 
dependent hyperpolarisations induced by ACh have been identified in various blood vessels 
(Taylor et al., 1988; Chen et al., 1988) and appear to contribute more to relaxation of small 
vessels than large arteries (Mugge et al., 1991; Berman & Griffith, 1998; Feletou & 
Vanhoutte, 1999). This indicates a possible difference in the numbers of a particular 
receptor type in various blood vessels. Studies in the blood perfused rabbit hindquarter 
(Mugge et al., 1991) showed L-NMMA increased vascular resistance but did not inhibit 
ACh vasodilation. This suggests that basal tone in the hindquarters resistance vessels may 
be NO mediated, but that the agonist-stimulated vasodilation may be mediated by another 
mechanism. More importantly, studies in the larger femoral arteries in vitro showed ACh- 
induced relaxation to be inhibited by L-NMMA. However, EDHF and NO may not be the 
only factors in the small versus large artery ACh-induced vasorelaxation. For example, a 
cytochrome P450 metabolite of arachidonic acid may be responsible for L-NAME and 
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indomethacin resistant changes induced by ACh in the diameter of large epicardial 
coronary arteries in dogs (Ming et al., 1997). Though, the precise role of endothelium- 
derived relaxing factors such as, NO, prostacyclin and hyperpolarising factor(s) in this 
hyper-reactivity, remains to be established. 
It remains possible that ACh may have a direct action on vascular smooth muscle, or SNP 
may not be as able to access the smooth muscle as efficiently as agonist-stimulated NO, 
released to the sub-lumenal space. This is unlikely given that SNP was not more effective 
than ACh at increasing blood flow in the smaller vessels where the endothelium is 
fenestrated; a structure which allows for greater diffusion across the endothelial membrane. 
Either way, our study shows a novel coexistence of both a NO-mediated and NO- 
independent action of ACh regulating blood flow in the rat ear artery in vivo; a finding that 
is contrary to previous results obtained by photoplethysmography in the rabbit eat artery 
where ACh-induced changes in both MAP and flow that were NO-dependent. However, 
our results in the rat are consistent with an involvement of EDHF, and similar effects have 
been shown in vitro in smaller arterioles (Berman & Griffith, 1998). 
Since any potential non-invasive method of endothelial function measurement would 
require drug administration via the tail vein, we compared tail with jugular vein drug 
administration. Both routes provoked essentially the same increase in arterial blood flow, 
although ACh-induced decreases in MAP were reduced when administered via the tail vein 
compared to jugular vein, perhaps because the tail vein is further down the venous 
circulatory system. Overall, this system may be a suitable method in which to non- 
invasively assess endothelial function in small arteries and arterioles in the rat where repeat 
measurements of vascular/endothelial activity in the same animal are desirable over an 
extended period of time. 
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The second method analysed was the indirect rat tail blood pressure monitoring. Results 
show that the indirect tail cuff measurement was 117.85±5.3 mm Hg (n=5) and direct 
invasive MAP measurement was 114.23±2.5 mm Hg (n=5) whilst the same rats were 
anaesthetised. These data are not significantly different, suggesting that basal endothelial 
function may not be altered by anaesthesia with thiopentone (at least in our hands); 
although induction of anaesthesia with intravenous thiopental is often accompanied by 
hypotension. Studies have shown that thiopentone inhibits endothelium-dependent 
relaxation and nitrite production in aortic rings, indicating that thiopentone inhibits NOS 
(Castillo et al., 1999). Further evidence has been shown in vitro where activity of the 
enzyme iNOS was decreased by thiopentone (Galley & Webster, 1996). Interestingly, there 
was no correlation between the anaesthetised and conscious rat blood pressure, suggesting 
that the small difference between groups was arbitrary and was probably due to minor 
differences in animal variation and handling. Unfortunately, this model did not provide 
reproducible data blood pressure data from the obese Zucker rat. Indeed, a similar 
instrument, the photoelectric pulse sensor, has been refused registration with the FDA 
because it cannot be calibrated for skin pigmentation, skin thickness, etc (Stoelting Co, 
USA). This is of particular relevance in the Zucker rat as it has brown skin. 
Perfused hindquarters. A principal aim of this project was to develop a method to study 
endothelial function in an insulin sensitive tissue that provides a large resistance vascular 
area - the rat hindquarters. In initial validation studies, a fall in effluent outflow over time 
was seen. This was probably due to development of oedema that became increasingly 
evident after 90 min. Such changes may be due to vasodilation in the perfused hindquarters 
causing a decrease in vascular resistance, resulting in either a decrease in blood pressure 
and/or flow rate. However, this haemodynamic relationship also applies when water from 
the PSS accumulates in the interstitial compartment, contributing to oedema formation and 
an increase in vascular resistance. Oedema is known to contribute to high blood pressure 
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and vascular resistance in patients with cardiovascular disease. Oedema development was 
expected in my experiments as the PSS did not contain colloidal material necessary to 
maintain the osmotic balance. However, it is considered acceptable to carry out perfusion 
experiments for an optimal period or to decrease the perfusion flow rate (Guarner et al., 
1993) to avoid oedema. In my studies, the hindquarters basal perfusion pressure was stable 
for 90 min, suggesting that vascular resistance was not compromised. Reproducible 
vascular reactivity data was obtained between 60 and 120 min after the start of perfusion, 
therefore all our experiments were carried out within 90 min. 
In vasodilation studies, vascular reactivity is assessed using the endothelium-dependent NO 
and endothelium-independent dilators, ACh and SNP respectively. Both agonist-stimulated 
endothelium-derived and exogenous NO were effective in the reversal of established 
vascular contractile tone. When basal NO synthesis was inhibited by L-NAME, a leftward 
shift in the concentration response curve to Phe was observed and contractile tone was 
enhanced, suggesting NO had antagonised the Phe-induced contraction. Similarly, 
contractile tone was more effectively reversed by exogenous NO (SNP) in L-NAME treated 
preparations than in control preparations. However, agonist-stimulated endothelial- 
dependent vasorelaxation partially reversed the enhanced contractile tone in the presence of 
L-NAME. This may be because L-NAME had not completely inhibited NO synthesis. 
Previous reports have shown L-NAME produces almost 100 % inhibition of ACh- 
stimulated relaxation in vitro, but only approximately 75 % inhibition in vivo (Rees et al., 
1990). Therefore a partial vasorelaxation would be expected in an in situ model. 
Furthermore, this partial endothelium-dependent and enhanced endothelium-independent 
vasodilation may be greater in the absence of basal NO, as guanylyl cyclase would be 
under-stimulated which would lead to super-sensitivity. Super-sensitivity has been 
established in studies where the endothelium was removed (Moncada et al., 1991). 
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The in situ rat perfused hindquarters is thus an important preparation for the investigation 
of endothelial function in a pre-diabetic model of oxidant stress, such as the obese Zucker 
rat (see later), since it facilitates the assessment of endothelium-dependent vasodilator 
function in a physiological relevant vascular bed. It is important, however, to compare 




Investigation of insulin resistance, 
endothelial reactivity and oxidant stress 
in the obese Zucker rat 
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4.1 INTRODUCTION 
The WHO states that there is no generally accepted definition for the type 2 diabetes 
metabolic syndrome. However in working terms, it is the combination of hypertension, 
dyslipidaemia, insulin resistance, hyperinsulinaemia, glucose intolerance, and obesity, 
(particularly central obesity). Metabolic syndrome is an early stage of diabetes that 
indicates the individual is predisposed and is at high risk for diabetes; although changes in 
diet and exercise has been shown to slow the onset of disease in animal models (Becker- 
Zimmermann et al., 1982; Reaven et al., 1988). 
The Zucker rat (faffa) is an obese model of pre-diabetes - metabolic syndrome X, and is in 
many aspects a suitable model to investigate the relationship between metabolic syndrome, 
insulin resistance and diabetes. In 1985 Ionescu et al demonstrated that, at 13-14 weeks- 
old, obese Zucker rats had significantly higher basal glucose and insulin (10 fold) levels, 
and impaired glucose disposal compared to lean rats. In younger 6-7 week-old obese rats, 
levels of glucose were normal and insulin moderate (3 fold higher) compared to the lean 
rats; glucose disposal too was impaired compared to 6-7 week-old lean littermates but to a 
lesser extent than that seen in the 13 week-old rats. Not all investigators have found 
hyperglycaemia (Triscari et al., 1979). This may be due to a compensatory mechanism for 
insulin resistance that causes an increased ß-cell secretion of insulin, thereby preventing 
hyperglycaemia (a notion structurally indicated by hypertrophic and hyperplastic ß-cells 
(Ionescu et al., 1985). This is similar to most obese humans (Kraegen et al., 2001), and is 
therefore an important pre-diabetic model that can be used to study the early stages of 
insulin resistance prior to the development of frank diabetes. The additional components of 
the metabolic syndrome have also been investigated in the obese Zucker rat, and show 
raised triglycerides (Boulange et al., 1981), hyperlipidaemia, microalbuminuria and raised 
arterial blood pressure (Kasiske et al., 1985). 
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The initial hypothesis was that endothelial dysfunction, insulin resistance and oxidant stress 
would coexist in the 12 week-old Zucker rat, and these factors would contribute to the 
development of the metabolic syndrome and then to diabetes and its complications. The 
relationship between these pathologies, and how each could enhance the disease process of 
the other has not been determined. It may be that defects in insulin signalling contribute to 
the increased endothelial dysfunction and insulin resistance (Baron, 2002). Alternatively, 
increased levels of ROS (with or without the above pathologies) react with NO and hence 
reduce basal and induced endothelial vasodilation. This impaired endothelial function, and 
its resultant decreased vasodilation, can contribute to the decreased post prandial glucose 
disposal. Interestingly, it has been demonstrated that, in individuals with type 2 diabetes, 
post prandial glucose levels may be better predictors of glycaemic control than fasting 
plasma glucose (Avignon et al., 1997). It has been estimated that most exposure to excess 
glucose occurs in post prandial periods. Many epidemiological studies suggest that post- 
prandial hyperglycaemia, even in the absence of fasting hyperglycaemia, is an independent 
risk factor for the development of macro- and microvascular complications associated with 
diabetes (Curb et al., 1995; Lowe et al., 1997). This was probably due, at least in part, to 
hyperglycaemia causing non-enzymatic protein glycation. The relative contribution of post- 
prandial and fasting glucose to protein glycation is, however, not known. Some studies 
have shown enhanced lipid peroxidation associated with post-prandial hyperglycaemia 
(Ceriello et al., 1998). This may be due to autoxidation of glucose, AGE-formation, 
glycation of enzymatic antioxidants and/or stimulation of the polyol pathway. It may be 
that by normalizing post-prandial glucose and the oxidative load, the ensuing diabetic 
complications can be decreased. 
Endothelial function, oxidant stress and insulin sensitivity were assessed in the same age 
matched obese group. Studies of endothelial function in the obese Zucker rat have 
generated conflicting results in some cases, showing both increases and decreases in 
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endothelial function. Supporting findings of increased endothelial function studies, have 
shown that obese Zucker rats have exaggerated intracellular Ca2+ responses to vasoactive 
agents (Abel & Zemel, 1993). This difference may simply be age related. Alternatively it 
may also be an indication of the stage of the disease progression, as Sexl et al (1995) 
showed enhanced endothelial function in 12 week obese rats and normal function in 24 and 
36 week-old obese rats. Other studies, however, have shown NOS activity in skeletal 
muscle samples to be greater in lean than in obese rats (Young & Leighton, 1998), 
unfortunately the age of the rats was not stated. 
In some of these studies, endothelial function measurements had focused on aorta and other 
arterial vessels from the obese Zucker rat. The insulin sensitive hindquarters perfusion 
system would, however, be more suitable model to understand a relationship between 
insulin resistance and endothelial function. This is because it is an insulin sensitive tissue 
and also because the microcirculation contains the greatest amount of the total animal blood 
volume. Therefore changes in pulse pressure can have significant effects on endothelial cell 
permeability and the redistribution of blood plasma into adjacent fluid compartments in the 
skeletal muscle. This can lead to alterations in the transport of substrates and waste 
products between blood and cells, and may therefore be important in the uptake of glucose 
in these insulin sensitive tissues. Studies would also concentrate on the involvement of NO 
in obese Zucker rat endothelial function in perfused hindquarters. The use of L-NAME in 
the functional studies can then be compared to the indirect biochemical evidence for NOS 
activity using the Griess method. The Griess method measures nitrite/nitrate - metabolites 
of NO that are stable in the plasma before their excretion in the urine. 
Oxidative stress has been suggested as a significant contributing factor in the development 
of endothelial dysfunction and insulin resistance (Nourooz-Zadeh et al, 1997; Perticone et 
al, 2001). Elevated levels of 8-epi-PGF2a have been detected in type 2 diabetic patients 
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(Gopaul et. al, 1995), implying increased levels of ROS. Other studies have shown a 
doubling in plasma lipid peroxides in type 2 diabetic subjects compared to control 
(Nourooz-Zadeh et al, 1997), and a reduction in total plasma antioxidant capacity (Ceriello 
et al., 1997). Indeed, increased oxidant stress has been shown in obese Zucker rats - in liver 
studies, obese Zucker rat livers contained significantly less GSH, tocopherol, and catalase, 
compared to leans. In addition, pre-treatment with vitamins C and E completely corrected 
the decreases in GSH, tocopherol, and catalase (Soltys et al., 2001). Other studies have 
shown vascular O2 ' levels were elevated in obese compared to the lean rats, and that 
functionally, treatment of cremaster muscles of obese rats with the 02"* scavengers can 
improve arteriolar dilation to ACh and SNP (Frisbee & Stepp, 2001). 
Oxidative stress in the Zucker rat was assessed by measurement of 8-epi-PGF2a,, and TAOS 
in the rat plasma (Laight et al., 1999A; 1999B). 8-epi-PGF2a, is the most studied F2- 
isoprostane and is present in human plasma, urine (Morrow et al., 1999), tissues and 
endothelial cells (Gopaul et al., 1994). 8-epi-PGF2a, is a specific marker of lipid 
peroxidation, whereas TAOS measurements incorporate the antioxidant status of many 
plasma solutes such as ascorbate, glutathione, urate and albumin. TAOS is measured from 
plasma samples and it estimates the protective anti-oxidative ability present in the plasma. 
The plasma contains free radical scavengers such as vitamin C and E which can be rapidly 
consumed while scavenging ROS. In addition to scavenging ROS, plasma can reduce 
oxidised forms of antioxidants back to the active form. For example, GSH regenerates 
vitamin C, which, in turn, regenerates vitamin E. It follows that the total plasma antioxidant 
capacity is the result of interactions between many different compounds. Interestingly, 8- 
epi-PGF2a, is a potent vasoconstrictor in the kidney (Fukunaga et al., 1993), lungs 
(Banerjee et al., 1992; Kang et al., 1993), coronary (Kromer & Tippins, 1996) and retinal 
(Lahaie et al., 1998) vessels at nanomolar concentrations. It was therefore appropriate to 
test for vasoconstrictor effect in our vascular preparations - hindquarters and aortic rings. 
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Plasma levels of 8-epi-PGF2a are increased in type 2 diabetic patients (Gopaul et al., 1995). 




4.2.1 Insulin resistance in the obese Zucker rat 
High plasma insulin in obese Zucker rats. The basal plasma insulin levels in the obese 
(5.93±1.4 ng mU', n=6) were significantly higher than that of the lean (0.46±0.09 ng mL t, 
n=5; P<0.05) Zucker rat. 
After bolus glucose (0.5g kg"' i. v. ) administration, plasma insulin was increased in the 
obese (AUC was 221.05±20.5 ng mI: 1 min', n=4) compared to lean (AUC was 46.71±7.5 
ng mL"t min-1, n=5; P<0.05) Zucker rats, and remained higher in the obese for the duration 
of the timecourse (24 min) (Fig. 4.1A). 
High plasma glucose in obese Zucker rats. Basal plasma glucose levels in the obese 
(5.15±0.6 mM, n=7) were higher than those of the lean (3.09±0.2 mM, n=7; P<0.05) 
Zucker rat. 
After glucose (0.5g kg-1 i. v. ) administration during the glucose tolerance test, plasma 
glucose was increased in the obese (AUC was 297.23±19.38 mM min'', n=7) compared to 
lean (AUC was 222.69±8.1 mM min-1, n=7; P<0.05) Zucker rats, and remained higher in 
the obese for the duration of the timecourse (24 min) (Fig. 4.1B). 
4.2.2 Endothelial reactivity in the Zucker rat perfused hindquarters 
Mean body weight was greater in 13 week-old obese (413.6±15.2 g, n=5) relative to lean 
animals (280.2±4.2 g, n=5; P<0.05). Basal perfusion pressure in obese preparations 
(28.5±6.1 mm Hg, n=5) was comparable with that of lean preparations (38.1±5.8 mm Hg, 
n=5). Similarly, Phe-elevated perfusion pressure in obese preparations (144.2±20.5 mm Hg, 
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n=5) did not differ from that of lean Zucker rat preparations (129.6±6.0 mm Hg, n=5; 
P>0.05). 
Enhanced endothelial vasodilator function in obese Zucker rats. Vasodilator responses to 
ACh (0.0001-10 nmol) were enhanced (P<0.05) in obese relative to lean animals (Fig. 4.2; 
table 4.1), while maximal vasodilation to SNP (100 nmol) was similar (obese: 59.6±9.8 %, 
n=5; lean 51.9±2.6 %, n=5; P>0.05). When responses to ACh (0.0001-10 nmol) were 
standardised with respect to SNP (100 nmol) as an assessment of hindquarters endothelial 
function, the data still showed a significantly greater vasodilation in the obese relative to 
lean animals. 
When assessed as pD2 (i. e. the negative logio of the concentration eliciting the half-maximal 
response), the obese (pD2=11.03±0.19, n=5) showed a slight (3-fold) increase in the 
sensitivity of vasodilation to ACh relative to lean (pD2=10.53±0.13, n=5; P=0.05) 
preparations. Similarly, when responses to ACh (0.0001-10 nmol) were standardised with 
respect to SNP (100 nmol), the pD2 values were the same to two decimal places. 
L-NAME inhibited ACh-induced vasodilation. Basal perfusion pressure in control 
preparations (lean: 27.9±3.2; obese: 29.0±1.4 mm Hg, n=5) was comparable with that of L- 
NAME treated preparations (lean: 24.7±1.8; obese: 27.0±2.3 mm Hg, n=5; P>0.05). 
Similarly, Phe elevated perfusion pressure was comparable in L-NAME (lean: 153.0±32.6; 
obese: 174.0±32.1 mm Hg, n=5; P>0.05) relative to control preparations (lean: 155.3±8.1; 
obese: 157.3±8.6 mm Hg, n=6). The ACh (0.0001-10 nmol) -induced vasodilation was 
significantly greater in the obese compared to the lean. Additionally, this enhanced 
vasodilation in the obese was maintained with the administration of L-NAME (2.1 µmol), 




Treatment pD2 Emax pD2 E,,, 
Control 10.88+0.06* 131.06+13.9 10.51+0.04 102.4+16.6 
NAME 10.42+0.05*t 75.1+5.9*t 10.20+0.06t 46.7+8.4t 
Table 4.1 Vasorelaxation to ACh (0.0001-10 pM) in Phe pre-contracted obese and 
lean Zucker rat perfused hindquarters in the presence and absence of L-NAME (2.1 
. tmol). E, r. was reached at 1 µM. Data are expressed as mean±s. e. mean of 4-5 
determinations. *P<0.05 with respect to corresponding treatment in the lean group; 
tP<0.05 with respect to corresponding control group. 
High blood pressure in obese Zucker rats. The mean arterial blood pressure was raised in 
13 week-old obese (136.0±3.6 mm Hg, n=8) compared to lean (116.4±6.7 mm Hg, n=8; 
P<0.05) Zucker rats (Fig. 4.4). In this group body weight was greater in obese 
(477.88±13.2 g, n=8) relative to lean animals (298.9±8.4 g, n=8). 
Low blood volume in obese Zucker rats. The administration of Evans blue caused a small, 
non-significant rise in obese MAP (1.7±1.6mm Hg, n=8) and decrease in lean MAP (- 
1.4±1.6 mm Hg, n=8). Evans blue obeys Beer Lambert law between 1.5-25 mg 1; 1. The 
slope of the standard curve (0.5-32 mg L'1) constructed was linear (r2= 0.99, slope = 
0.5726±0.001 mg L'1 cm abs'1). 
The haematocrit, or packed cell volumes were comparable in the obese (44.09±1.07, n=8) 
and lean (46.5±0.99, n=8; P>0.05) Zucker rats. There was a correlation between weight and 
blood volume in both obese (r2=0.85) and lean (r2=0.75). Interestingly, the results showed a 
decreased blood volume per 100 g body weight in the obese (4.2±0.10 cm3 100 g'1, n=8) 
Zucker rat compared to the lean (6.0±0.15 cm3 100 g"1, n=8; P<0.05) (Fig. 4.5). 
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High plasma nitrate/nitrite levels in obese Zucker rats. Plasma nitrate/nitrite levels in the 
obese (33.39±2.6 µM, n=3) were higher than that of the lean (20.93±1.9 µM, n=6; P<0.05) 
Zucker rat (Fig. 4.6). 
4.2.3 Oxidant stress in the obese Zucker rat 
High plasma 8-epi-PGF2a levels in obese Zucker rats. Plasma 8-epi-PGF2a levels in the 
obese (3.7±0.4 ng mL'1, n=5) were higher than that of the lean (0.7±0.2 ng m: 1, n=5; 
P<0.05) Zucker rat (Fig. 4.7). 
High plasma TAOS levels in obese Zucker rats. Plasma TAOS levels in the obese 
(46.85±1.1 ng mL"1, n=4) were higher than that of the lean (42.67±0.4 ng mL'1, n=6; 
P<0.05) Zucker rat (Fig. 4.8). 
Vasoconstriction to 8-epi-PGF2a in the rat perfused hindquarters. Cumulative infusions 
of 8-epi-PGF2a (0.1-3000 nmol) in the presence of L-NAME (2.1 µmol) elicited 
concentration-dependent, sustained increases in perfusion pressure (pD2=5.6±0.77, n=3) 
(Fig. 4.9A). In the absence of L-NAME, 8-epi-PGF2a did not produce measurable 
contractile responses. 
Vasoconstriction to 8-epi-PGF2a in rat aortic rings. 8-epi-PGF2a (0.1-3000 nmol) elicited 
concentration-dependent and sustained increases in tension. When assessed as pD2 values, 
the L-NAME (pD2=2.8±0.15, n=4) cumulative concentration curve was enhanced 
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Figure 4.1 Glucose tolerance test (g. t. t) in 13 week-old lean (Ei) and 
obese (. ) Zucker rats A. Comparison of plasma insulin (AUC, 0-24 min). B. 
Plasma glucose (AUC, 0- 24 min). Data are expressed as mean±s. e. mean of 4- 
7 determinations. Statistical significance lean vs. obese (*) was considered 
established at P<0.05 using a students t-test. 
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Figure 4.2 Vasodilation to acetylcholine (ACh, 0.0001-10 nmol) in 
lean (Q) and obese ( ) Zucker rat perfused hindquarters in situ. ACh 
responses were standardised with respect to vasodilation to sodium 
nitroprusside (SNP, 100 nmol) Data are expressed as mean±s. e. mean of 5 
determinations. Statistical significance (*) using two way ANOVA was 
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Figure 4.3 Vasodilation to acetylcholine (ACh, 0.0001-10 nmol) was 
assessed in phenylephrine (100 nmol) pre-constricted Zucker rat 
perfused hindquarters in situ. Comparison of A. Obese B. Lean control (o) 
with L-NAME ( ) treated preparations. ACh responses were standardised 
with respect to sodium nitroprusside (SNP, 100 nmol) Data are expressed as 
mean±s. e. mean of 4-5 determinations. Statistical significance (*) using two 
way ANOVA was considered established at P<0.05. 
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Figure 4.4 Mean arterial blood pressure (MAP) in anaesthetised 13 
week-old lean and obese Zucker rats. Data are expressed as 
mean±s. e. mean of 8 determinations. Statistical significance (*) using an 









Figure 4.5 Assessment of blood volumes in lean and obese 13 week- 
old Zucker rats. Data are expressed as mean±s. e. mean of 8 determinations. 
Statistical significance (*) using an unpaired student t-test was considered 









Figure 4.6 Plasma nitrate/nitrite levels in lean and obese 13 week-old 
Zucker rats. Data are expressed as mean+s. e. mean of 3-6 determinations. 
Statistical significance (*) using an unpaired student t-test was considered 






Figure 4.7 Plasma levels of 8-epi prostaglandin F,,, (8-epi-PGF,,, ) in 13 
week-old lean and obese Zucker rats. Data are expressed as mean±s. c. mean of 
5 determinations. Statistical significance (*) using an unpaired student t-test was 






Figure 4.8 Plasma total antioxidant status (TAOS) expressed as 
ascorhate equivalent antioxidant concentration (AEAC) in 13 week-old 
lean and obese Zucker rats. Data are expressed as mean±s. e. mcan of 5 
determinations. Statistical significance (*) using an unpaired student t-test 
was considered established at P<0.05. 
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Figure 4.9 Biological effects to 8-epi prostaglandin Fla (8-epi-PGF2a) 
in Wistar rats show respectively contraction and vasoconstriction in: A. L- 
NAME (2.1 µmols equivalent to 300 mM) pre-treated perfused hindquarters 
in situ. B. Control (o) and L-NAME (. ) treated aortic rings. Data are 
expressed as mean±s. e. mean of 3-4 determinations. Statistical significance 
(*) using two way ANOVA was considered established at P<0.05. 
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4.3 DISCUSSION 
Fasting plasma insulin and glucose levels were significantly higher in the obese than in the 
lean littermate. Additionally, after glucose administration (during the glucose tolerance 
test), plasma insulin and glucose were significantly increased in the obese compared to the 
lean Zucker rats, and remained higher in the obese for the duration of the time course. This 
data compares to previous studies in obese rats, which, in contrast to lean rats, exhibited 
fasting hyperinsulinaemia and hyperglycaemia in addition to insulin resistance and a poor 
glucose disposal (Ionescu et al., 1985). Insulin resistance in the obese Zucker rats has been 
shown in liver and adipose tissue (Terrettaz & Jeanrenaud, 1983), and, most interestingly, 
in skeletal muscle (Crettaz et al., 1980). These results will be of particular importance in 
understanding the effect of insulin in the rat hindquarters (Chapter 5). 
In the perfused hindquarters of the Zucker rat, endothelium-dependent, but not 
endothelium-independent vasodilation was enhanced (3-fold) in the obese relative to its 
lean littermate. This suggests that enhanced vasodilation to ACh did not simply reflect a 
general increase in vascular smooth muscle vasodilator reactivity in obese animals, but 
instead represents a selective enhancement in endothelial vasodilator function. This was the 
first demonstration of enhanced endothelial function in obese Zucker rats in situ, and 
supports earlier in vitro studies (Auguet et al., 1989; Cox & Kikta, 1992; Turner et al., 
1995; Growcott et al., 1995; Sexl et al., 1995; Turner & White, 1996; Kaw et al., 1998). 
The precise role of endothelium-derived relaxing factors remains to be established. It has 
been suggested that enhanced transmembrane Ca2+ influx might trigger NO synthesis in the 
obese rats (Sexl et al., 1995), after experiments in rat aortic rings showed enhanced 
relaxation to ACh and the calcium ionophore-A23187 in obese compared to lean Zucker 
rats - an effect that was inhibited by L-NAME. In other studies, enhanced responses to the 
vasoconstrictor noradrenaline in Zucker rat aortic rings were reported to be due to abnormal 
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functioning of voltage sensitive Ca2+ channels in vascular smooth muscle (Ouchi et al., 
1996). If the channels are activated constantly, increased intracellular Ca2+ may stimulate 
NOS. However, in the hindquarters perfusion system, L-NAME (2.1 tmol) significantly 
impaired maximal vasodilation in both lean and obese Zucker rats (though the obese 
retained a more enhanced vasodilation to ACh in the presence of L-NAME compared to the 
lean). This may suggest an EDHF or prostaglandin involvement. Recent studies by our 
group have shown a non-NO, non-prostanoid component of endothelial vasorelaxation in 
obese Zucker rat aortic rings (Kaw et al., 1999) that was blocked by the depolarising agent 
potassium chloride (increased extracellular K+ can inhibit EDHF-induced vasorelaxation; 
Garland et al., 1995). Other studies in the cremasteric arterioles have shown a small 
decrease in ACh-induced vasorelaxation in the presence of indomethacin (Frisbee & Stepp, 
2001), but this still does not account for the large vasorelaxation not inhibited by a 
combination of L-NAME and indomethacin. EDHF is the most likely candidate for this 
effect, as studies in streptozotocin-induced diabetic rats have shown endothelial responses 
dependent upon EDHF were impaired in femoral arteries and mesentery respectively (Wigg 
et al., 2001; Makino et al., 2000). In addition, it is now generally accepted that EDHF has a 
greater role in the smaller vessels compared to NO; the hindquarters is a highly 
vascularised tissue bed populated with many small resistance vessels. 
Comparison of endothelial function in the perfused hindquarters with in vivo measurements 
in 13 week-old Zucker rats anaesthetised rats showed the obese to have higher blood 
pressure than the lean (Ambrozy et al., 1991; Pamidimukkala & Jandhyala, 1996; Laight et 
al., 1998). It would be expected that blood pressure would be lower in the obese relative to 
the lean Zucker rat as endothelium-dependent vasodilation was enhanced in situ. This 
paradoxical endothelial hyperactivity and high blood pressure suggests the influence of 
blood borne factor(s) or autonomic controls may be responsible for hypertension in obese 
Zucker rats. 
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Blood borne factors such as endothelin have potent vasoconstrictor activity in vivo (see 
review, Haynes & Webb, 1998). The urinary excretion of endothelin and pre-proendothelin 
mRNA was shown to be increased in obese compared to lean Zucker rats (Turner et al., 
1997). Functionally, insulin has been shown to exaggerate endothelin-l-evoked Ca2+ 
responses (Hopfner et al., 1998). This is an important finding, as the obese Zucker rat is 
hyperinsulinemic. Evidence for higher sympathetic tone in the obese Zucker rat has also 
been reported by Pamidimukkala & Jandhyala, (1996). Their studies showed comparable 
blood pressures in conscious rats, but when anaesthetised the obese rats had higher blood 
pressures than their lean littermates. Autonomic ganglionic blockade reduced the obese rat 
blood pressure to a level comparable to that of the lean Zucker rat (Pamidimukkala & 
Jandhyala, 1996). Therefore autonomic activation probably contributes to the hypertension 
observed in the obese Zucker rat. The baroreflex system responds to acute hypotension by 
increasing sympathetic tone to resistance as well as capacitance vessels, which increases 
blood pressure and venous return respectively. Elevated sympathetic activity has been 
shown to contribute to hypertension in hyperglycaemic obese Zucker rats in telemetry 
studies (Carlson et al., 2000). However, the obese Zucker rat has been shown to have 
decreased peripheral catecholamine levels too (Levin et al., 1981; Pacak et al., 1995). It is 
thought that these differences are attributed to organ specific changes in sympathetic 
activity (Pacak et al., 1995). 
The blood volume studies confirmed that the obese Zucker rat had a significantly decreased 
blood volume compared to the lean Zucker rat, as previously reported (Schirardin et al., 
1979). Reduced blood volume has in some studies been implicated in hypertension 
(Gresson et al., 1973; Bianchi et al., 1981), where it was suggested that vasoconstriction 
would reduce the blood volume and that the increased muscle vascularisation in the lean 
could allow higher blood volumes. Additionally, a greater correlation between weight and 
blood volume was seen in the obese compared to the lean Zucker rat -a scenario 
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previously reported in genetically hypertensive rats (Huff & Feller, 1955). Reduced blood 
flow and blood volume has been reported in the adipose tissue of the obese Zucker rat, 
suggesting obese tissues are poorly perfused compared to that of the lean. If this is the case, 
any blood borne factors that constrict or deplete vasodilating factors may be even more 
damaging in the obese rat. 
The idea that a key mechanism of endothelial dysfunction is NO inactivation by free 
radicals may be supported by the higher plasma nitrite/nitrate levels in obese rats. This 
supports also data where raised levels of nitrite/nitrate were found in type 2 diabetic 
patients (Catalano et al., 1997). If there is a greater agonist-induced NO response (as 
observed in the perfused hindquarters) in the obese Zucker, this NO may be quickly 
inactivated in vivo but then appear as a metabolic end product in the plasma as 
nitrate/nitrite. Studies have shown that the glomerular filtration rate measured using inulin 
clearance was normal in 12-14 week rats (Kasiske et al., 1985). However, as the obese 
Zucker rat is hyperphagic and nitrate is also a dietary metabolic end-product, caution may 
be needed with these results, even though the Zucker rats were fasted prior to blood 
collection. Furthermore, it may reflect synthesis of NO by the neuronal and inducible forms 
of NOS. 
Higher 8-epi-PGF2« levels in the obese compared to the lean Zucker rat confirmed the 
greater level of oxidant stress in this animal. Along with higher plasma TAOS levels in 
obese Zucker rats, this suggests a higher antioxidant status is perhaps already primed due to 
increased oxidant stress. Although it appears paradoxical that the obese Zucker rat has 
endothelial hyperreactivity with concomitant oxidant stress (Halliwell, 1993; Giugliano et 
al., 1995; Harrison & O'Hara, 1995), studies have previously reported a mechanism for a 
ROS-mediated enhancement in agonist-stimulated endothelial function involving altered 
Ca2' signalling (Graier et al., 1996,1997). This has been suggested to account for the 
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anomaly of endothelial hyperreactivity associated with early type 1 diabetes (Wascher et 
al., 1994; Graier et al., 1996). It is therefore possible that a similar scenario in the obese 
Zucker rat may account, at least in part, for endothelial hyperreactivity in this animal. 
It is also worth considering that 8-epi-PGF2a was measured in circulating plasma in vivo 
and not in the endothelial cells of the hindquarters that were perfused in situ. This suggests 
high levels of blood borne oxidant stress markers were present in the obese Zucker rat. 
Such increased oxidant stress due to 02"* and other ROS could bind and cause NO 
inactivation. This is consistent with the hypothesis that a key mechanism of endothelial 
dysfunction is NO inactivation by free radicals (Diederich et al., 1994; Pieper et al., 1996). 
In the young (13 weeks-old) obese Zucker rat, high ROS generation may be compensated 
for by increased NO synthesis following agonist-stimulation. In the older (52 weeks-old) 
Zucker rat, chronic oxidant stress may then contribute to the impaired endothelium- 
dependent vasodilation observed in other studies (Halliwell, 1993; Giugliano et al., 1995; 
Harrison & O'Hara, 1995). It is conceivable that increased plasma levels of 8-epi-PGF2 in 
humans with type 2 diabetes (Gopaul et al., 1995) may be present before vascular 
complications. Indeed other markers of oxidative stress, TBARS and copper/zinc SOD 
have also been shown to be increased in the obese Zucker rat where hyperglycaemia, 
hypertension and inflammation have been absent (Poirier et al., 2000). 
F2-isoprostane-containing phospholipids show distortion of the fluidity and integrity of 
plasma membranes, and may therefore interfere with normal physiological processes 
(Morrow et al., 1992). These findings are consistent with endothelial dysfunction involving 
the alteration of transmembrane signalling mechanisms and Ca2+ homeostatic mechanisms 
that cause an increase in the release of paracrine factors (Schilling & Elliott, 1992). The 
physiological role of 8-epi-PGF2a, and related prostanoids is unknown. However, my 
studies confirmed a vasoconstriction by 8-epi-PGF2a in aortic rings and the hindquarters 
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(Fukunaga et al., 1993; Banerjee et al., 1992; Kang et al., 1993). L-NAME treatment 
enhanced vasoconstriction, suggesting that NO inactivation by ROS, and the direct 
vasoconstriction by 8-epi-PGF2a produce additive endothelial damage. 
The data in this chapter show the 13 week-old obese Zucker rat with a hyper-endothelial 
response, probably due to an increased NO action suggested by higher plasma nitrate/nitrite 
levels. This may be a compensation response to the increased sympathetic drive and 
oxidant stress present in the obese Zucker rat that are realised by raised 8-epi-PGF2a, and 
TAOS measurements. The increased redox stress may lead to increased vasoconstriction in 
vivo, indirectly by the inactivation NO and directly by 8-epi-PGF2a, -induced constriction. 
The raised plasma insulin and glucose levels and a poor glucose disposal observed in the 
obese Zucker rats may be also be indicative of poor NO responses in vivo. Indeed, impaired 
glucose disposal rates have been shown in eNOS knockout mice (Shankar et al., 2000). If 
in these studies increased ROS causes inactivation of NO, then glucose disposal may be 
impaired, resulting in higher insulin and eventually higher glucose levels. Conversely, 
hyperglycaemia in addition to increased NO and ROS levels may also lead to disruption of 
cellular signalling and in turn endothelial function. The relationship between insulin and 
NO in the Zucker rat however remains inconclusive. Studies on cultured vascular 
endothelial cells isolated from 12 week-old Zucker rats have demonstrated that insulin 
increased levels of eNOS mRNA and protein, and increased eNOS activity in lean but not 
in insulin-resistant obese littermates (Kuboki et al., 2000). It follows that insulin is an 
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Initial findings that suggested insulin was involved in vasodilation appeared in patient 
studies where insulin administration caused marked hypotension associated with 
hypoglycaemia (Miles & Hayter, 1968). More recently studies have shown that insulin can 
induce hypotension in subjects where glucose levels were kept constant. One of the first 
studies to support the vasodilator function of insulin was by Liang (1982), who showed it 
decreased vascular resistance and increased muscle blood flow. Further studies in 
normotensive humans have demonstrated an insulin sensitive redistribution of blood flow 
to more insulin sensitive sites (Baron et al., 1993). The mechanism of insulin-mediated 
vasodilation remains unclear, but is likely to be via insulin's modulation of NO-dependent 
vasodilation (Steinberg et al., 1994). There is also evidence of a positive relationship 
between basal vascular endothelial NO production and insulin sensitivity in healthy human 
volunteers (Petrie et al., 1996). Insulin stimulated production of NO is through activation of 
phosphatidylinositol 3-kinase (PI 3-kinase) (Zeng & Quon, 1996), via IRS proteins in the 
insulin signalling pathway. However, insulin also stimulates cGMP production directly 
(Kahn et al., 1998), and can augment NO-induced cGMP production in vascular smooth 
muscle cells (Kahn et al., 2000). 
There is paradoxical evidence of insulin-induced vasoconstriction from studies in 
sympathectomised rats (Edwards & Tipton, 1989). Here, insulin increased blood pressure in 
control, but not in sympathectomised or hexamethonium treated rats, suggesting insulin- 
induced vasoconstriction is modulated by the sympathetic nervous system. Indirect 
vasoconstrictor function of insulin has been shown by its ability to desensitise vascular 
responsiveness to noradrenaline at ß-adrenoceptors. Studies reported that the ß- 
adrenoceptor G proteins may be phosphorylated in response to insulin, leading to reduced 
signalling (Hadcock et al., 1992). 
120 
In later studies, insulin potentiated a noradrenaline-induced tone in the rabbit facial artery 
by activation of protein kinase C and tyrosine kinase (Henrion & Laher, 1994). This 
suggests insulin can also tilt the vascular balance back toward greater vasoconstriction 
when sympathetic mediators are raised. More chronic studies of insulin's action have 
shown increased gene expression (Oliver et al., 1991) and release (Hattori et al., 1991) of 
the potent vasoconstrictor endothelin-1 from endothelial cells. 
In diabetic disease, the notion that insulin induces vasodilation and that this is impaired in 
diabetics is most possible. As a vasodilator effect of insulin is potentially a critical factor to 
its metabolic function, i. e. the efficient disposal of glucose at insulin sensitive sites. It can 
also be hypothesised that defective insulin-induced vasodilation due to insulin resistance 
will further impede insulin's metabolic function. Certainly the NO-dependent enhancement 
of endothelium-dependent vasodilation by insulin, which has been observed experimentally 
in vivo (Steinberg et al., 1994; Scherrer et al., 1994) may be abnormal in diabetes 
(Steinberg et al., 1996). It should be noted, however, that, increased sympathetic tone 
inducing VSM relaxation via a-adrenoceptor stimulation is detrimental to glucose disposal 
in resistance and small conductance arteries of the skeletal muscle. Chronic sympathetic 
stimulation, such as that observed in the Zucker rat (Pamidimukkala & Jandhyala, 1996), 
can cause desensitisation of the adrenoceptor and in turn alter glucose disposal. 
The aim of these studies was, firstly to investigate the action of insulin in a macrovascular 
and microvascular preparation as NO-induced vasodilator responses in diabetics are known 
to be impaired in both conduit and resistance vessels (Diederich et al., 1994). Secondly, an 
attempt was made to understand if insulin resistance or the impaired glucose tolerance seen 
in the obese Zucker contributed to endothelial dysfunction and whether this could then in 




5.2.1 Initial validation studies investigating concentration and incubation times of 
insulin in Wistar rat aortic rings. 
Incubation with insulin (100 nM) for 20 min increased the endothelium-dependent 
vasorelaxation to ACh compared to BSA treated paired rings (Fig. 5.1A; Table 5.1). A 10 
min treatment with insulin (100 nM) had no significant effect, while a 30 min treatment 
was determined to be no more effective than a 20 min treatment. Therefore 20 min was 
chosen for subsequent studies. With respect to pre-treatment, 20 min with insulin (10 nM) 
was without effect (P>0.05) (Fig. 5.1B; table 5.2), whereas a 20 min with insulin (100 nM 
and 1000 nM) caused a similar increase in endothelium-dependent vasodrelaxation - 
therefore 100 nM was adopted in subsequent studies. In contrast to ACh, endothelium- 
independent vasorelaxation to SNP (n=6) vehicle control (pD2 =7.60+0.12, n=6) was not 
affected by insulin (100 nM) (pD2 7.78+0.08, n=6; P>0.05). 
Insulin (nM) 
0 10 100 1000 
pD2 7.16±0.13 7.09±0.22 7.13±0.12 7.14±0.11 
E. (%) @ 1µM 70.0±5.4 67.7±8.7 78.6±5.9 84.9±2.9 
Table 5.1 Vasorelaxation to ACh (0.0001-10 µM) in Phe pre-contracted Wistar rat 
aortic rings following treatment with insulin (10,100 & 1000 nM) or its vehicle (BSA 
0.1 %) for 20 min. Data are expressed as mean±s. e. mean of 4-5 determinations. 
5.2.2. Effects of insulin on the contractile reactivity in Zucker rat aortic rings 
Insulin (100 nM) did not significantly change the Phe elicited contractions from that of the 
BSA vehicle responses, either in the presence or absence of L-NAME, in lean and obese 
Zucker rats (Fig. 5.2; table 5.3). Phe-induced contractions were similar in lean and obese 
rings, whether BSA or insulin treated (P>0.05). However, treatment with L-NAME induced 
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slight leftward shift in both insulin and BSA treated rings from obese and lean rats 
respectively (P<0.05), and only slightly increased the E, a,, values from obese Zucker rats 
(Fig. 5.2; table 5.3). 
Insulin Control 
Time (min) pD2 E (%) pD2 Emax (%) 
10 7.28±0.11 81.9±4.3 7.17±0.11 83.2±2.9 
20 7.51±0.11 86.4±4.1 7.31±0.12 79.2±3.4 
30 7.44±0.10 92.8±1.2 7.30±0.11 85.6±2.3 
Table 5.2 Timecourse for insulin (100 nM) or its vehicle (BSA 0.1%) in Phe pre- 
contracted Wistar rat aortic rings effects on vasorelaxation to ACh (0.0001-10 PM). 
Data are expressed as mean±s. e. mean of 6-8 determinations. E. was reached at 1 [M. 
Obese Lean 
Treatment pD2 Emax (%) pD2 E.. (%) 
BSA 7.09±0.1 2.3±0.07 7.38±0.12 2.3±0.09 
Insulin 7.23±0.08 2.3±0.06 7.32±0.13 2.0±0.08 
BSA + NAME 7.99±0.14*`W 2.4±0.07 7.47±0.15 2.3±0.01 
Insulin + NAME 8.11±0.11 *'y 2.6±0.07 7.64±0.11 2.3±0.08 
Table 5.3 Vasoconstriction to Phe (0.01-10 pM) following 20 min treatment with 
insulin (100 nM) or its vehicle (BSA 0.1%) in the presence or absence of L-NAME 
(300 µM) in obese and lean Zucker rat aortic rings. Data are expressed as 
mean±s. e. mean of 4-5 determinations. E. was reached at 3 µM. *P<0.05 with respect to 
corresponding treatment in the lean group; tP<0.05 with respect to corresponding BSA 
group; `'P<0.05 with respect to corresponding treatment in the absence of L-NAME. 
5.2.3 Effects of insulin on the vasodilator reactivity in Zucker rat aortic rings 
ACh-induced vasorelaxation was slightly greater in the lean compared to the obese Zucker 
rats (P>0.05). Insulin enhanced this relaxation in the obese but not the lean group (Fig. 5.3; 
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table 5.4). This resulted in a greater ACh-induced vasorelaxation in obese compared to lean 
rings where insulin was present (P<0.05). SNP-induced vasorelaxation was unaffected by 
treatment with insulin in both lean and obese (P>0.05). However, pD2 values were different 
between lean and obese treated with insulin (P<0.05) (table 5.5). 
Obese Lean 
Treatment pD2 Emax pD2 E. 
BSA 7.05±0.05 85.3±2.1 7.24±0.06 89.6±1.5 
Insulin 7.37±0.11*t 92.3±2.8 7.15±0.06 90.0±2.2 
Table 5.4 Vasorelaxation to ACh (0.0001-10 µM) in Phe pre-contracted obese and 
lean Zucker rat aortic rings following 20 min treatment with insulin (100 nM) or its 
vehicle (BSA 0.1 %). Data are expressed as mean±s. e. mean of 5-7 determinations. E1 was 
reached at 1 pM. *P<0.05 with respect to corresponding treatment in the lean group; 
tP<0.05 with respect to corresponding BSA group. 
Obese Lean 
Treatment pD2 Emax pD2 Emax 
BSA 7.23±0.06 94.7±1.2 7.24±0.06 96.8±1.2 
Insulin 7.22±0.05* 93.6±1.4 7.45±0.08 95.9±1.6 
Table 5.5 Vasorelaxation to SNP (0.01-100 µM) in Phe pre-contracted obese and 
lean Zucker rat aortic rings following 20 min treatment with insulin (100nM) or its 
vehicle (BSA 0.1 %). Data are expressed as mean±s. e. mean of 4-6 determinations. E,.,, was 
reached at 3 µM. *P<0.05 with respect to corresponding treatment in the lean group. 
5.2.4 Effects of insulin on contractile reactivity in Zucker rat perfused hindquarters 
Insulin had no effect on basal perfusion pressure (PP) in obese (BSA: 70.8±6.7, n=3; 
insulin: 60.5±1.4 mm Hg; n=3, P>0.05) or lean rats (BSA: 65.6±3.7 mm Hg, n=4; insulin: 
87.1±13.8 mm Hg; n=4, P>0.05). Similarly, insulin had no effect on L-NAME-elevated PP 
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in obese (BSA: 61.2±3.5 mm Hg, n=4; insulin: 59.5±4.4 mm Hg; n=3, P>0.05) or lean rats 
(BSA: 95.9±30.6 mm Hg, n=3; insulin: 69.9±2.2 mm Hg; n=3, P>0.05). 
Phe-induced comparable constrictions in insulin (100 nM) and BSA treated hindquarters in 
the obese, but not lean, Zucker rats. The pD2 values showed a significant decrease in Phe- 
induced constrictions by insulin. Changes in E X, however, were unaffected (Fig. 5.4; table 
5.6). In the presence of L-NAME, insulin provoked an enhanced Phe-induced constriction 
in the obese (P<0.05), but depressed the responses in lean preparations (P>0.05) (Fig. 5.4; 
table 5.6). Insulin and BSA treated preparations showed a leftward shift in Phe-induced 
constrictions when treated with L-NAME in both lean and obese hindquarters. 
Obese Lean 
Treatment pD2 EnaX pD2 Emax 
BSA 7.20±0.02 197.3±4.4 7.21±0.02 208.6±6.5 
Insulin 7.15±0.08 215.8±7.5 7.02±0.021 217.3±4.8 
BSA + NAME 7.89±0.01 *W 200.1±7.2 8.25±0.02'P 209.2±9.7 
Insulin + NAME 8.20±0.16t'ß 217.7±8.4 8.13±0.02t`ß 193.5±4.3`v 
Table 5.6 Vasoconstriction to Phe (0.01-100 nmol) infusions in obese and lean 
Zucker rat perfused hindquarters in situ following 20 min treatment with insulin (100 
nM) or its vehicle (BSA 0.1%) in the presence or absence of L-NAME (300 9M). Emax was 
reached at 100 nmol in L-NAME treated and at 3 pmol in untreated preparations. Data are 
expressed as mean±s. e. mean of 3-4 determinations. *P<0.05 with respect to corresponding 
treatment in the lean group; tP<0.05 with respect to corresponding BSA group; `WP<0.05 
with respect to corresponding treatment in the absence of L-NAME. 
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5.2.5 Effects of insulin on vasodilator reactivity of the Zucker rat perfused 
hindquarters 
Insulin had no effect on basal perfusion pressure (BPP) in obese or lean animals (P>0.05), 
or on the Phe infusion-elevated PP (P>0.05) (table 5.7). 
Basal PP Phe elevated PP 
Treatment vehicle Insulin vehicle Insulin 
Obese BPP (mm Hg) 30.3±2.7 27.5±3.2 129±19.8 157.6±14.7 
Lean BPP 33.3±1.5 31.4±3.6 160.0±11.6 163.7±19.2 
Table S. 7 Basal and Phe elevated perfusion pressures in lean and obese Zucker 
rats following insulin (100 nM) or its vehicle (BSA 0.1 %) infusion. Data are expressed 
as mean±s. e. mean of 9-12 determinations. 
Vasodilation to ACh was impaired by insulin in obese and lean animals (P<0.05) (Fig. 5.5; 
table 5.8). A rightward shift of the ACh curve and blunted E,. was seen in the obese rats, 
and a smaller rightward shift was seen in the lean rats (P<0.05). In contrast, obese and lean 
vasodilation to SNP was unaffected by insulin (P>0.05) when compared by two way 
ANOVA (table 5.9). However pD2 values show vasodilation to SNP was impaired by 
insulin in the obese and enhanced in the lean animals (P<0.05) (table 5.9). 
Obese Lean 
Treatment pD2 E pD2 E 
BSA 10.65±0.02* 49.7±3.1 10.84±0.03 41.3±2.3 
Insulin 10.18±0.04*t 44.3±3.9 10.43±0.03t 44.8±2.8 
Table 5.8 Vasodilation to bolus dose ACh (0.0001-10 nmol) in Phe pre-constricted 
obese and lean Zucker rat perfused hindquarters in situ following 20 min treatment 
with insulin (100 nM) or its vehicle (BSA 0.1%). E. was reached at 10 nmol. Data are 
expressed as mean±s. e. mean of 5-7 determinations. *P<0.05 with respect to corresponding 
treatment in the lean group; tP<0.05 with respect to corresponding BSA group. 
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OBESE LEAN 
Treatment pD2 E pD2 E. 
BSA 8.76±0.05* 42.7±2.3 8.57±0.01 43.5±3.1 
Insulin 8.63±0.02*f 44.7±4.3 8.82±0.021 40.0±3.0 
Table 5.9 Vasodilation to bolus dose SNP (0.01-100 nmol) in Phe pre-constricted 
obese and lean Zucker rat perfused hindquarters in situ following 20 min treatment 
with insulin (100 nM) or its vehicle (BSA 0.1%). Data are expressed as mean±s. e. mean 
of 4-5 determinations. E was reached at 100 nmol. *P<0.05 with respect to 
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Figure. 5.1 Relaxation to acetylcholine (ACh) in the isolated Wistar 
rat aorta: Effect of insulin. A. Comparison of vehicle ( ) and insulin 
concentrations 10 (o), 100 (. ) and 1000 (o) nM. B. Comparison of mean 
vehicles (u) and insulin (100 nM) incubation times 10 (o), 20 (0), and 30 (0) 
min. Data are expressed as mean±s. e. mean of 5-8 determinations. Statistical 
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Figure 5.2 Effects of insulin (100 nM) and its vehicle BSA (0.1 %) on 
phenylephrine (Phe, 0.001-3 µM) cumulative concentration responses in 
13 week-old lean and obese Zucker rat aortic rings. Comparison of A. 
obese rats B. lean rats treated with BSA (co), and insulin (. ), BSA+L-NAME 
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Figure 5.3 Effects of insulin (100 nM) and its vehicle BSA (0.1 %) on 
acetylcholine (ACh, 0.001-1 µM) cumulative concentration responses in 
13 week-old lean and obese Zucker rat aortic rings. Comparison of A. 
obese rats or B. lean rats treated with BSA (o) and insulin (. ). Data are 
expressed as mean±s. e. mean of 6-7 determinations. Statistical significance (*) 
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Figure 5.4 Effects of insulin (100 nM) and its vehicle BSA (0.1 %) on 
phenylephrine (Phe, 0.3-3000 nmol) cumulative dose responses in control 
and L-NAME (2.1 pmols equivalent to 300 pM) treated preparations in 
13 week-old lean and obese Zucker rats perfused hindquarters in situ. 
Comparison of A. obese rats and B. lean rats treated with BSA (a), insulin 
( ), BSA+L-NAME (o) or insulin+L-NAME (. ). Data are expressed as 
mean±s. e. mean of 3-4 determinations. Statistical significance (*) using two 
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Figure 5.5 Effects of insulin (100 nM) and its vehicle BSA (0.1 %) on 
acetylcholine (ACh, 0.0003-10 nmol) dose responses in 13 week-old lean 
and obese Zucker rats perfused hindquarters in situ. Comparison of A. 
obese rats B. lean rats treated with BSA (o) and insulin (. ). Data are 
expressed as mean±s. e. mean of 5-7 determinations. Statistical significance (*) 
using two way ANOVA was considered established at P<0.05. 
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5.3 DISCUSSION 
Initial studies in rat aortic rings provided for the optimum insulin concentrations and 
timecourse for all further studies. After timed incubations (10-30 min) with insulin (100 
nM), the 20 min interval was chosen for subsequent experiments. Concentration ranging 
(10-1000 nM) showed 100 nM to cause a maximal increase in endothelium-dependent 
vasorelaxation and was therefore adopted in subsequent studies. It is important to note that 
endothelium-independent vasorelaxation responses were not significantly affected by 
insulin (100 nM), indicating an endothelial-dependent action of insulin. The high 
pharmacological concentration of insulin required in these studies for an endothelial- 
dependent effect may be due to variability in tissue responsiveness to insulin outside the 
normal in vivo metabolic environment and/or heterogeneity in the density of vascular 
insulin receptors (Zeng & Quon, 1996; Muggeo et al., 1977; Bar et al., 1979). It may also 
be due to differences in the species specificity, as the insulin used in these experiments was 
recombinant human - said to be effective on all mammalian cells as there is little difference 
in rat and human insulin homology. However, a study has shown that insulin receptors of 
mammals, but not those of rodents, share the same epitope(s) (Tong et al., 1994). This 
suggests that the human insulin used in these experiments may not have efficiently 
stimulated the rat insulin receptors. Alternatively, it is possible that the vascular effects of 
insulin may be at least in part mediated by the insulin-like growth factor receptor system, 
for which insulin exhibits a somewhat lower potency (Walsh et al., 1996; Sowers, 1996). 
In rat aorta studies, insulin had no effect on Phe elicited contractions compared to BSA, 
even in the presence of L-NAME, in either obese or lean Zucker rings. Treatment with L- 
NAME induced a leftward shift in both insulin and BSA treated rings from the obese and 
lean rats. However, this shift was significantly greater in the obese, perhaps suggesting 
there was a greater basal NO release in the obese. Additionally, insulin enhanced the ACh- 
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induced relaxation in the obese but not the lean group, resulting in a greater vasorelaxation 
in the obese compared to the lean rings where insulin was present. These findings suggest 
that the obese has a greater basal NO release in the aorta, which is more sensitive to insulin- 
induced mediation. It may be that the obese has a higher basal NO release due to the 
hyperinsulinaemia in vivo. Studies by Baron (1994) showed that increases in skeletal 
muscle blood flow were dependent on the exposure time to insulin. Here, insulin mediated 
a NO-induced vasodilation over a 4-9 hour exposure. However, although this time period 
may be physiologically consistent with metabolism in normal animals, when compared to 
the hyperphagic obese Zucker rats, this exposure is small. The obese Zucker rat may be 
effectively in an almost permanent post prandial state and therefore exhibit continual NO- 
mediated vasodilation due to constantly evoked insulin release. It could then be reasoned 
that the insulin mediated NO-induced vasodilation is a physiological factor in glucose 
disposal, a process that is particularly active in the obese rat. The increased ACh-induced 
vasorelaxation in the presence of insulin may then be a further upregulation of this 
physiological process. 
Vasorelaxation to SNP in both lean and obese rats, was unaffected by insulin treatment 
when the aortic ring response curves were compared by 2 way ANOVA. However, the pD2 
values showed a significant difference between lean and obese response after treatment 
with insulin. This difference was due to a greater SNP-induced relaxation in the lean, as the 
obese relaxations were completely unaffected by insulin treatment. This difference may be 
due to a non-specific effect of insulin in the lean rats which causes the vascular smooth 
muscle to be more sensitive to NO-induced vasodilation, possibly via insulin's stimulation 
cGMP production itself (Kahn et al., 1998). However, if this was the case one would expect 
the ACh-induced vasorelaxation to also be enhanced by insulin, and it was not. Again this 
would suggest less NO was released/synthesised in the vasculature of the lean, as there was 
not an enhanced response. Alternatively, insulin may have mediated a vasoconstriction to 
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compensate for this increased vascular smooth muscle sensitivity via another non-specific 
endothelium-independent mechanism. 
In contrast to the aortic ring data, the hindquarter perfusion preparations showed there was 
no difference between control and insulin treated Phe-induced vasoconstriction responses in 
the lean and obese rats. However, in the presence of L-NAME, the obese vasoconstriction 
curve to Phe was shifted further leftwards in insulin treated as opposed to control 
preparations. This suggests that NO, when not inhibited by L-NAME, compensates for the 
increased constriction evoked by insulin treatment. This may be possible if insulin has a 
dual role, causing both vasodilation through a NO-dependent pathway and constriction 
through another pathway. Numerous studies have shown that insulin causes acute 
vasodilation through a NO-dependent pathway (Taddei et al., 1995). However, insulin has 
also been shown to potentiate vasoconstriction to noradrenaline (Henrion & Laher, 1994) 
through a specific pathway involving tyrosine kinase and PKC activation in rabbit facial 
arteries. In addition, insulin has been shown to increase plasma noradrenaline by causing 
sympathetic nerve terminal spillover (Yki-Jarvinen & Utriainen, 1998). This may not be 
applicable in the hindquarters perfused preparation, as the CNS is severed the nerve 
terminals are, however, still present in situ. 
Vasodilation to ACh was more significantly impaired by insulin in the obese compared to 
lean rat preparations. It may be argued that this would be expected as the vasodilation was 
greater in the control preparations in the obese than in the lean ones (although this is not 
consistently represented - pD2 values are comparable, probably due to the increased Ea" in 
the obese) and therefore any inhibition would be marked. It may also suggest further 
evidence of the involvement of the dual vasoconstrictor mechanism. Though, as SNP- 
induced vasodilation was unaffected by insulin in both obese and lean preparations, this 
would exclude a non-specific effect of insulin and point to insulin-evoked blunting of ACh- 
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stimulated NO biosynthesis/release in the hindquarters of the obese Zucker rat. This 
impaired insulin mediated vasodilation is consistent with findings from diabetic patient 
studies in vivo (Johnstone et al., 1993). However if the pD2 values are considered this 
impaired ACh vasodilation may be an endothelial-independent effect on VSM. It is 
interesting that if this is an endothelial-independent effect by insulin that it inhibits 
vasodilation in obese and enhances vasodilation in the lean. In addition, these in situ 
experiments have revealed that in the absence of insulin, there is an enhanced basal NO 
release in the hindquarters. Therefore insulin is not only a poor of mediator of NO-induced 
vasodilation in diabetics subjects, but it probably abrogates basal NO-induced vasodilation 
as well. 
In summary, the macrovascular and microvascular preparations used in these studies have 
revealed that basal NO release was enhanced in the obese compared to the lean rats. 
However, agonist-induced vasodilation was enhanced only in the obese hindquarters, which 
was abrogated by the addition of insulin. In contrast, the agonist-induced vasodilation was 
similar in lean and obese rings, but was significantly enhanced in the obese by insulin. The 
different responses from the macro or microvascular preparations show the importance of 
using insulin sensitive vascular beds for the investigation of insulin mediated vasoactive 
responses. More importantly, insulin has been shown to differentially regulate systemic and 
skeletal muscle vascular resistance (Baron & Brechtel, 1993). The skeletal bed and organs 
that require glucose uptake are subjected to greater blood redistribution and shunting, as 
their metabolic needs are more crucial than a large conduit vessel. 
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Chapter 6 
Modulation of endothelial function, 
oxidant stress and insulin resistance by 
antioxidant and pro-oxidant treatment in 
the obese Zucker rat 
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6.1 INTRODUCTION 
In diseases associated with oxidant stress, the balance between NO and Oi ' in the vascular 
wall is likely to be perturbed, which can contribute to an insulin resistance state. The 
enhanced vascular levels of Of present in disease can directly damage the vasculature 
itself, and additionally can inactivate NO (Gryglewski et al., 1986) leading to the formation 
ONOO- - thus promoting further endothelial dysfunction. The balance of free radicals in 
the vasculature is finely tuned so that any excess or shortage will lead to dysfunction (Fig. 
6.1). 
The relationship between oxidant stress, endothelial function and insulin resistance in the 
obese Zucker rat remains unclear. However, using a number of structurally diverse 
antioxidants added to the diet, and pro-oxidant administration it was possible to modulate 
the oxidant status and measure any concomitant changes in endothelial function and insulin 
resistance. In insulin sensitive tissues, oxidative stress associated with diabetes mellitus is 
likely to impair insulin action and depress endothelial function, promoting insulin 
resistance and cardiovascular complications. Indeed, defective endothelial function at 
insulin sensitive sites may contribute to poor insulin-stimulated glucose disposal (Baron et 
al., 1995). This chapter investigates in the obese Zucker rat endothelial function, insulin 
resistance and oxidant stress, and their responses to dietary antioxidants (probucol, vitamin 
E and tiron) and pro-oxidants (HQ and BSO). 
Vitamin E consists largely of alpha tocopherol (Fig. 6.2). It is considered an essential 
nutritional element, although its exact function is unknown. As a lipophilic antioxidant, 
vitamin E protects polyunsaturated fatty acids in membranes and other cellular structures 
from attack by free radicals, and protects red blood cells against haemolysis. Vitamin E acts 
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Figure 6.1 Representation of the balance between nitric oxide 
(NO) and superoxide anion (02~) in the vascular wall: 
disturbances in disease. 
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present in membranes and lipoproteins. It does this by binding and capturing peroxyl 
radicals (chain reaction intermediates) and thus breaking the chain reaction that causes lipid 
peroxidation. It should be noted that protection against oxygen radical damage appears to 
be important for the development and maintenance of nerve and muscle function. Vitamin 
E may also act as a cofactor in some enzyme systems. It is bound to beta lipoproteins in 
blood and stored in all body tissues, especially fatty tissues. Although a large number of 
claims for vitamin E have been made, it has not been proven effective as a treatment for, or 
preventative measure against, diabetes or arteriosclerosis. Studies have shown reductions in 
8-epi-PGF2c and 11-dehydro-thromboxane B2 to normal levels with vitamin E 
supplementation in type 2 diabetic patients (Davi et al., 1999). Similarly, Vitamin E 
supplementation was found to effectively decrease both serum C-reactive protein and 
interleukin-6 in both type 2 diabetics and healthy controls (Devaraj & Jialal, 2000). In 
another study, type 1 diabetic children were given vitamin E, which resulted in increased 
glutathione levels and decreased malondialdehyde to normal values. It was concluded that 
antioxidant supplementation may help lower the risk of vascular disease in type 1 diabetic 
patients (Jainn et al., 2000). Similar studies in type 2 diabetic patients have shown vitamin 
E treatment increased levels of glutathione, whilst decreasing free radical by-products 
substantially (Sharma et al., 2000). More interestingly, studies have shown that 
pharmacological doses of vitamin E can improve insulin action in type 2 diabetics (Paolisso 
et al., 1993). 
Probucol (Fig. 6.2) is a cholesterol lowering drug with antioxidant properties. It has been 
shown that probucol may inhibit the oxidation and tissue deposition of LDL cholesterol, 
thereby slowing atherogenesis (Parthasarathy et al., 1986). It has been used clinically as an 
adjunct to dietary measures in patients with primary hypercholesterolemia. Probucol is a 
dimer of hydroxytoluene, which is an antioxidant itself. Probucol's antioxidant properties 
stems from its two hydroxyl groups that allow it to reduce free radicals into a non-reactive 
140 
form. It also acts as a lipophilic chain breaking antioxidant. It has been demonstrated that 
probucol is able to protect LDL from oxidation (Parthasarathy et al., 1986). Probucol has 
also been found to inhibit atherosclerotic lesion formation in hyperlipidaemia rabbits, 
through its antioxidant properties rather than its lipid lowering properties (Steinberg et al., 
1988). In human clinical studies, antioxidant supplementation is related to decreased 
oxidation of LDL and decreased manifestation of atherosclerosis. However, these effects 
may not be due to inhibition of the initiating events of atherosclerosis (Diaz et al., 1997). 
Post mortems of patients who suffered from atherosclerosis indicate that atherosclerotic 
lesions were established in childhood (Stary, 1989). Consequently, antioxidants are thought 
to slow the development of atherosclerotic lesions, rather than inhibit their formation. 
Tiron (fig. 6.2), a water-soluble scavenger of Oi ', was also used, since increased 02 
contributes to impaired NO mediated relaxation; many studies have shown that tiron both 
improves vascular endothelial function (Arimura et al., 2001; Didion et al., 2002) and 
decreases the generation of OZ ' in vivo (Laight et al., 1998). 
Pro-oxidants are compounds that induce oxidative stress by spontaneous or enzymic 
generation of ROS, or by inhibition of antioxidants. Hydroquinones belong to the quinine 
class of redox cycling compounds that undergo one electron reductions in the presence of 
enzymes such as mitochondrial NADH, microsomal NADPH and flavoenzymes. Quinone 
redox cycling is associated with rapid conversion of 02 to 02", and therefore this class of 
reagents are useful pro-oxidant research compounds. Previous studies have shown HQ to 
blunt the NO vasorelaxant responses in many different animal tissues such as aortic strips 
(Moncada et al., 1986), rabbit coronary arteries (Bing et al., 1987) and cat cerebral arteries 
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BSO is a potent, selective and irreversible inhibitor of GSH synthetase (Griffith, 1999). 
Glutathione is a sulphur containing compound that is an essential co-factor for many 
antioxidant enzymes in the body, including glutathione peroxidase. Higher levels of 
glutathione are desirable, indicating a larger supply for the body to incorporate into 
antioxidant enzymes. GSH is a very effective reducing agent and an important scavenger of 
ROS. It is present in the mitochondria, endoplasmic reticulum and nucleus. The liver is the 
main source of GSH synthesis, from where it can be transported via the blood to the tissues 
(Gamalay & Klyubin, 1999). Glutathione peroxidase reduces hydroperoxides in a reaction 
that generates oxidized GSH (glutathione disulfide, GSSG), which is subsequently recycled 
to GSH by glutathione reductase. 
2GSH+H202 -01- GSSG+2H2O 
GSSG + NADPH + H+ -º 2 GSH + NADP 
Glutathione maintains Fe3+ and cysteinyl residues in haemoglobin in the reduced state and 
reacts rapidly with OH', ONOO", and 02 '. Studies in animals suggest that vitamin E 
supplementation helps increase glutathione levels, possibly by assisting in the 
neutralization of free radicals, thus decreasing the oxidative stress on the body. BSO 
decreases GSH levels in the kidney, liver, pancreas, muscle and plasma, and evokes 
increased levels of ROS. It has been demonstrated that 5 hours after the administration of 
BSO, GSH was reduced by 40 % in liver samples of treated rats. Studies showed no 
measurable affect by BSO in rat aortic rings (Cuzzocrea et al., 1998; Laight et al., 1999C). 
Although not capable of altering vasoregulation in its own right, BSO has been shown to 
aggravate the detrimental effect of HQ on vasodilation in rat aortic rings (Laight et al., 
1999). 
Markers of oxidant stress are raised in type 2 diabetes, which is indicative of increased 
levels of ROS (Gopaul et al., 1995). Furthermore, a reduction of antioxidant defences has 
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also been observed in both diabetic patients (Collier et al., 1990; Vijayalingam et al., 1996) 
and pre-diabetic rats (Gunnarsson et al., 1998). The marker of oxidant stress, 8-epi-PGF2a, 
was used in these studies to establish the antioxidant or pro-oxidant action in vivo of the 
drugs used and to compare the changes in 8-epi-PGF2a levels with changes in diabetic 
pathology. It is known that increased oxidant stress causes cell damage (Halliwell, 1994) 
and even cell death. Increased oxidant stress in type 2 diabetes may contribute to its 
complications and, more importantly, be involved in the primary onset of the disease. By 
using end products of lipid peroxidation, a number of methods can be employed to assess 
oxidative stress in plasma and tissue. 
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6.2 RESULTS 
6.2.1 Effect of antioxidants on endothelial function, oxidant stress and insulin 
resistance in the Zucker rat. 
Plasma insulin and glucose levels are altered by antioxidant diets. Obese basal plasma 
glucose and insulin levels were elevated relative to lean levels (P<0.05), and were slightly 
reduced after dietary vitamin E, tiron and probucol (P>0.05) (Fig. 6.3). In contrast, basal 
lean plasma glucose levels was elevated by dietary vitamin E, (P<0.05) but not tiron or 
probucol. Basal lean insulin levels were not affected (P>0.05) (Fig. 6.3). 
Following bolus glucose (0.5 g kg-1 i. v. ) administration, both the plasma glucose and 
insulin responses were greater in obese animals (Fig. 6.4). Dietary vitamin E in obese 
animals reduced insulin AUC (P<0.05), without an effect on glucose AUC (P>0.05). In 
contrast, dietary vitamin E, tiron and probucol appeared to elevate glucose and insulin AUC 
in lean animals. Although statistical significance was not attained, more n numbers may 
have given significance. Comparisons of the insulin/ glucose ratio showed a similar profile 
to that of insulin AUC - impairment in glucose disposal in obese compared to lean rats, and 
improvement with antioxidant treatment in obese but not lean groups (Fig. 6.4C). 
Antioxidant diet had no effect on body weight, however the obese rats were significantly 
heavier than the lean animals (P<0.05) (table 6.1). 
Antioxidant diet had no effect on basal and Phe -induced PP. Basal PP in obese and lean 
preparations were not affected by dietary vitamin E, tiron or probucol (P>0.05) (table 6.2). 
Similarly, Phe-elevated perfusion pressures in obese and lean preparations were not 
significantly altered by dietary vitamin E, tiron or probucol (P>0.05) (table 6.2). 
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Treatment control Vitamin E tiron Probucol 
Obese 413.6±15.2* 428.2±8.6* 448.2±10.7* 455.2±9.3* 
Lean 280.2±4.2 280.6±6.3 282.2±17.3 305.0±7.4 
Table 6.1 Body weights (g) of lean and obese Zucker rats following 4 weeks of 
dietary treatment. Data are expressed as mean±s. e. mean of 3-6 determinations. *P<0.05 
with respect to corresponding treatment in the lean group. 
(mm Hg) Treatment 
Basal PP control Vitamin E tiron Probucol 
Obese 28.5±6.1 29.9±5.4 32.4±2.7 26.18±2.7 
Lean 38.1±5.8 25.5±2.3 24.4±2.0 30.6±2.0 
Phe-elevated PP control Vitamin E tiron Probucol 
Obese 144.2±20.5 144.8±13.0 113.6±16.5 132.0±5.0 
Lean 129.6±6.0 141.6±13.3 126.6±7.5 142.1±15.2 
Table 6.2 Basal and Phe elevated PP in lean and obese Zucker rats following 
dietary treatments. Data are expressed as mean±s. e. mean of 3-6 determinations. 
Endothelial hyperactivity is altered by antioxidant diets. Vasodilator responses to ACh 
(0.0001-10 nmol) were enhanced in obese relative to lean animals (P<0.05 2W ANOVA) 
(Fig. 6.5), while pD2 and E.. a,, values were similar in the obese and lean Zucker rats 
(P>0.05). Similarly, the maximal vasodilation to SNP (100 nmol) was comparable between 
lean and obese (table 6.3). 
Comparison between treatment groups showed that vitamin E significantly blunted 
vasorelaxation in both the lean and obese rats (Fig. 6.5A; 6.5B; table 6.4). This effect was 
associated with a decrease in the magnitude of vasodilator responses to ACh (0.0001-10 
nmol) in obese (P<0.05 2W ANOVA) compared to the level of vasorelaxation in the lean 
hindquarters preparations (P>0.05 2W ANOVA). Dietary treatment with tiron (Fig. 6.5C; 
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6.5D) and probucol (Fig. 6.5E; 6.5F) both induced a greater vasodilation in the lean and 
obese rats. Significance was reached by probucol in the obese group, and by tiron in lean 
group (P<0.05,2W ANOVA). 
Treatment 
Em (%) control Vitamin E tiron Probucol 
Obese 37.2±3.6 45.3±6.1 41.2±2.6 41.7±1.7 
Lean 41.5±3.0 48.1±6.5 37.4±4.0 40.5±1.9 
Table 6.3 Vasodilation to SNP (100 nmol) following dietary treatment in lean and 
obese Zucker rats. Data are expressed as mean±s. e. mean of 3-6 determinations. 
In contrast to endothelium-dependent responses, maximal vasodilation to SNP was not 
significantly enhanced (P>0.05) following 4-week dietary vitamin E, and unchanged in 
tiron and probucol obese and lean hindquarters preparations. Similarly, using pD2 and E 
values, comparison of the curves were not significantly different in either the control or 
treatment groups. 
Treatment 
E,,, aX (°10) control Vitamin E tiron Probucol 
Obese 134.6±6.7 105.1±5.8 123.8±5.3 148.8±9.6 
Lean 115.5±5.3 84.3±9.4 127.7±16.5 121.7±9.6 
pD2 control Vitamin E tiron Probucol 
Obese 10.37±0.07 10.34±0.15 10.75±0.12 10.55±0.07 
Lean 10.39±0.07 10.21±0.21 10.57±0.13 10.39±0.16 
Table 6.4 Effect of 4-week dietary vitamin E, tiron or probucol on vasodilation to 
ACh (0.0001-10 nmol) standardised with respect to vasodilation to SNP (100 nmol) in the 
perfused hindquarters in situ of obese and lean Zucker rats. Data are expressed as 
mean±s. e. mean of 3-6 determinations. 
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Lower 8-epi-PGF2a plasma levels in antioxidant treated Zucker rats. Plasma levels of 8- 
epi-PGF2a were increased (by about 5 fold) in the obese relative to the lean (P<0.05) 
Zucker rats (Fig. 6.6). Treatment with Vitamin E and probucol but not tiron, decreased 
plasma 8-epi-PGF2 levels in obese (P<0.05) to levels comparable with their lean 
littermate. Dietary antioxidant treatments showed no effect in the lean (P>0.05) Zucker 
rats. 
6.2.3 Effect of pro-oxidants on endothelial function, oxidant stress and insulin 
resistance in the Zucker rat. 
Plasma insulin and glucose levels are altered by pro-oxidant treatment. Obese basal 
plasma insulin levels were elevated relative to the lean (P<0.05). However, the lean groups 
treated with HQ and BSO alone showed a further decrease in insulin levels compared to the 
control rats (Fig. 6.7A). Basal plasma glucose levels were comparable in the lean and 
obese rats. However, pro-oxidant treatments with HQ, BSO and HQ+BSO caused an 
increase in the levels of glucose when compared with lean (P<0.05) (Fig. 6.7B). 
Following bolus glucose (0.5 g kg-1 i. v. ) administration, plasma insulin responses were 
greater in untreated obese animals compared to the lean rats; although statistical 
significance was not reached, possibly due to a large variation between animals in the 
group - again more n numbers may have reduced this variation (P>0.05) (Fig. 6.8A). Pro- 
oxidant treatments slightly increased insulin AUC in the obese groups to cause a difference 
in the lean and obese treatment groups when compared individually (P<0.05 students t- 
test). 
Plasma glucose was significantly elevated in the obese compared to the lean rats. However, 
treatment with pro-oxidants decreased the obese glucose levels to a level comparable with 
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their lean treatment equivalent (Fig. 6.8B). Comparisons of the insulin/glucose ratio 
showed slightly higher levels in the obese compared to the lean. Though HQ+BSO 
treatment increased the obese ratio significantly. Differences were also significant in the 
lean and obese treatment groups HQ and HQ+BSO (Fig. 6.8C). 
Pro-oxidant treatment had no effect on body weights of 13 week-old obese Zucker rats. 
Lean and obese rats were not affected by pro-oxidant treatments. Obese rats were greater 
(P<0.05) than that of the corresponding lean Zucker rat weights (table 6.5). 
Treatment Control HQ BSO HQ+BSO 
Obese 432.7±10.7* 421.4±14.2* 433.2±6.7* 413.5±10.8* 
Lean 270.0±11.1 260.0±6.6 277.0±10.4 260.5±4.6 
Table 6.5 Body weights (g) of lean and obese Zucker rats following pro-oxidant 
treatment. Data are expressed as mean±s. e. mean of 4-6 determinations. *P<0.05 with 
respect to corresponding lean group. 
Pro-oxidant treatment had no effect on basal and Phe-induced PP. Basal PP was not 
affected by pro-oxidant treatments in obese preparations (P>0.05) (table 6.6). Similarly, 
lean basal PPs were comparable to the obese, and were unaffected by pro-oxidant treatment 
(P>0.05). Phe-induced PP in obese preparations were not affected by pro-oxidant 
treatments (P>0.05). Lean and obese basal PPs were comparable and unaffected by pro- 
oxidant treatment (P>0.05) (table 6.6). 
Endothelial hyperactivity is impaired by pro-oxidant treatment. Vasodilator responses to 
ACh (0.0001-10 nmol) were enhanced (P<0.05) in obese relative to lean animals (see Fig. 
3.11; table 6.7). This difference was abolished following pro-oxidant treatment with HQ, 
BSO, and HQ+BSO (P>0.05) (Fig. 6.9; table 6.7). The abolition of the ACh-induced 
hyperreactivity in the obese was associated with both a decrease in the magnitude of 
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vasodilation when treated with HQ (P<0.05) and HQ+BSO (P<0.05), and with small but 
significant increases in lean responses (HQ: P<0.05; HQ+BSO: P<0.05). BSO alone did 
not change the responses in lean or obese rats (P>0.05). 
(mm Hg) Treatment 
Basal PP Control HQ BSO HQ+BSO 
Obese 27.7±3.1 33.5±3.9 30.3±8.8 35.8±4.5 
Lean 31.2±2.5 31.3±3.8 46.4±9.6 28.2±1.5 
Phe-elevated PP Control HQ BSO HQ+BSO 
Obese 140.8±18.3 176.5±11.0 134.9±18.1 167.7±15.6 
Lean 175.0±13.5 201.5±23.2 209.2±54.1 165.7±22.6 
Table 6.6 Effect of pro-oxidant treatment on basal and Phe-elevated PP in lean 
and obese Zucker rat perfused hindquarters in situ. Data are expressed as 
mean±s. e. mean of 4-6 determinations. 
Treatment 
E,,, a,, (% SNP) Control HQ BSO HQ+BSO 
Obese 132.6±6.3* 121.6±5.5 127.2±12.3 107.1±3.4t 
Lean 111.9±3.6 120.2±8.9 114.4±3.7 115.8±2.5 
pD2 Control HQ BSO HQ+BSO 
Obese 10.95±0.06* 10.70±0.02t`ß 11.07±0.04 10.74±0.01tß' 
Lean 10.69±0.01 10.59±0.01 10.58±0.02 10.81±0.02 
Table 6.7 Effects of pro-oxidant treatment on vasodilation to ACh (0.0001-10 
nmol) standardised with respect to vasodilation to SNP (100 nmol) in the perfused 
hindquarters in situ of obese and lean Zucker rats. Data are expressed as 
mean±s. e. mean of 4-6 determinations. *P<0.05 with respect to corresponding lean group; 
tP<0.05 with respect to obese control; ̀ WP<0.05 with respect to lean control. 
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Higher 8-epi-PGF2Q plasma levels in pro-oxidant treated Zucker rats. Plasma levels of 8- 
epi-PGF2a were increased in the obese (5.46±1.0 ng m; 1, n=6) relative to the lean 
(2.70±0.3 ng m; ', n=6; P<0.05) Zucker rats (Fig. 6.10). Pro-oxidant treatment increased 
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Figure 6.3 Measurement of basal plasma insulin (ng mL-1) and glucose 
(mM) in 13 week-old lean (. ) and obese (. ) Zucker rats treated with sham, 
Vitamin E, Tiron and Probucol. Data are expressed as mean±s. e. mean of 5-6 
determinations. Statistical significance was compared using a student t-test, 
*P<0.05 with respect to the equivalent lean control group, or using one way 
ANOVA, 'YP<0.05 with respect to the control treatment group. 
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Figure 6.4 Glucose tolerance test (g. t. t) in 13 week-old lean ( ) and 
obese ( ) Zucker rats following a4 week dietary treatment of vitamin E, 
Tiron or probucol. A. Comparison of plasma insulin (AUC, 0-24 min). B. 
Plasma glucose (AUC, 0- 24 min). C. Insulin/Glucose ratio (AUC, 0-24 min). 
Data are expressed as mean±s. e. mean of 3-6 determinations. Statistical 
significance was compared using a student t-test, *P<0.05 with respect to the 
equivalent lean control group, or using one way ANOVA, `YP<0.05 with 
respect to the equivalent lean control group. 
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Figure 6.5 Effects of 4 week dietary anti-oxidant treatment on 
vasodilation to acetylcholine (ACh, 0.001-10 nmol) in 13-week old lean 
and obese Zucker rats perfused hindquarters in situ. Control lean (o) and 
obese (o) rats are compared to lean (. ) and obese (. ) treatment groups: A-B, 
vitamin E, C-D, tiron and E-F, probucol. ACh responses were standardised 
with respect to vasodilation to sodium nitroprusside (SNP, 100 nmol). Data 
are expressed as mean±s. e. mean of 3-6 determinations. Statistical 








Figure 6.6 Plasma levels of 8-epi-prostaglandin F,,, (8-epi-P('3F, ) 
in 
lean ( ) and obese ( ) Zucker rats: effects of 4 week dietary treatment 
with vitamin E, tiron or prohucol. Data are expressed as mean±s. e. mean of 
4-6 determinations. Statistical significance was compared using a student t- 
test, *P<0.05 with respect to lean control group, or using one way ANOVA, 
9'P<0.05 with respect to obese control group. 
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Figure 6.7 Measurement of basal plasma insulin (ng mUi) and glucose 
(mM) in 13 week old lean (. ) and obese (a) Zucker rats treated with sham, 
HQ, BSO and HQ+BSO in combination. Data are expressed as 
mean±s. e. mean of 4-6 determinations. Statistical significance was compared 
using a student t-test, *P<0.05 with respect to the equivalent lean control, or 
using one way ANOVA, I) P<0.05 with respect to the control treatment group. 
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Figure 6.8 Glucose tolerance test (g. t. t) in 13 week-old lean ( ) and 
obese ( ) Zucker rats following a one week treatment of hydroquinone 
and buthionine sulfoxamine combination (HQ+BSO) (50 mg kg-' i. p. 
daily). A. Comparison of plasma insulin (AUC, 0-24 min). B. Plasma glucose 
(AUC, 0- 24 min). C. Insulin/Glucose ratio (AUC, 0-24 min). Data are 
expressed as mean±s. e. mean of 4-6 determinations. Statistical significance 
was compared using a student t-test, *P<0.05 with respect to the equivalent 
lean control group, or using one way ANOVA, `}'P<0.05 with respect to the 
equivalent control treatment group. 
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Figure 6.9 Effects of hydroquinone and buthionine sulfoxamine 
combination (HQ+BSO) (50 mg kg-1 i. p. daily) for one week on 
vasodilation to acetylcholine (ACh, 0.001-10 nmol) in 13 week-old lean 
and obese Zucker rat perfused hindquarters in situ. Comparison of A. 
obese B. lean control (o) and obese HQ+BSO ( ) treated. ACh responses 
were standardised with respect to vasodilation to sodium nitroprusside (SNP, 
100 nmol). Data are expressed as mean±s. e. mean of 4-6 determinations. 











Figure 6.10 Plasma levels of 8-epi prostaglandin Fla in 13 week-old lean 
(a) and obese ( ) Zucker rats treated with sham, hydroquinone (HQ) and 
buthionine sulfoxamine (BSO) alone or in combination (HQ+BSO) (50 mg 
kg"I i. p. daily). Data are expressed as mean±s. e. mean of 6 determinations. 
Statistical significance was compared using a student t-test, *P<0.05 with 
respect to lean control group, or using one way ANOVA, 'PP<0.05 with 
respect to obese control group. 
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6.3 DISCUSSION 
Antioxidant treatment The elevated plasma insulin and glucose levels seen in the obese 
compared to the lean rats were not reduced with antioxidant treatment. However, in 
response to a glucose load, the elevated insulin levels in the obese rats were decreased by 
antioxidant treatment. The responses in the lean animals were unaffected by antioxidant 
treatment. The plasma insulin levels from the obese rats were elevated to an unexpected 
level (24 ng ml; ') compared (6-12 ng m; 1) seen in the previous studies. The increased 
insulin levels were only seen in the obese rats and may be due to animal variation and not 
insulin analysis or plasma storage. The result do show relative differences between the 
treatment groups and therefore the data can provide useful understanding of the action of 
antioxidant treatment in this particular batch of animals. These results would imply that the 
obese rats have higher basal insulin levels, necessary to overcome the increased glucose 
ingested due to their hyperphagia. The increased basal insulin level is sufficient to maintain 
relatively normal plasma glucose levels, which are comparable to its lean littermate. 
However, following a glucose load, the obese rat produced relatively more insulin to 
dispose of the glucose administered, thus revealing insulin resistance. Antioxidant 
treatment decreased the need for this greater production of insulin in the obese rat, perhaps 
by improvement in endothelial function at the skeletal muscle. 
The enhanced endothelium-dependent vasodilation in the obese compared to the lean 
Zucker rat was abolished following 4-week dietary vitamin E. Plasma 8-epi-PGF2a, levels 
were decreased in the obese Zucker rat. This data suggests the increased compensatory 
endothelium-dependent vasodilation was no longer required following vitamin E treatment. 
As the dietary vitamin E treatment did not enhance vasodilation to SNP, it can be 
understood as an endothelium-dependent effect. This is in agreement with other studies 
where Vitamin E prevented impairment of the vascular endothelium, and even reversed 
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endothelial dysfunction in animal models of vascular disease (Stewart-Lee et al., 1994; 
Andersson et al., 1994; Laight et al., 1996; Konneh et al., 1995; Laight et al., 1997). This 
antioxidant action on endothelial function may be due partly to the protection of 
endothelium-derived NO from inactivation by ROS (Gryglewski et al., 1986; Laight et al., 
1998), and partly that agonist-stimulated endothelial vasodilator function is modulated by 
oxidant tone differently in lean and obese Zucker rats. In any event, the apparent need for 
endothelial hyperfunction in the obese was removed by vitamin E. Another explanation for 
the observed effect may be that ROS cause a net upregulation of agonist-stimulated 
endothelium-dependent vasodilation in the obese Zucker rat, whilst inactivating the NO that 
is subsequently synthesised. It has been demonstrated that oxidative stress may affect 
specific receptors and intracellular signalling cascades (Flavahan, 1992; Stewart-Lee et al., 
1994,1995). The upregulation of ROS is certainly an interesting speculation, as leptin has 
been shown to cause direct vasodilation through an endothelium-dependent mechanism 
(Lembo et al., 2000), as well as to increase oxidative stress in human endothelial cells. It 
may be that ROS are second messengers in leptin-induced signalling in endothelial cells, 
and contribute to the direct endothelium-dependent vasodilation by leptin. Furthermore, 
hyperleptinaemia may contribute to chronic oxidant stress in endothelial cells and to 
vascular pathology (Bouloumie et al., 1999). It is important to note that while an 
upregulation in the synthesis/release of endothelium-derived relaxing factors such as 
prostacyclin or NO cannot be ruled out in the adaptive response to this elevated oxidant 
tone, there may also be a non-prostanoid, non-NO component of vasodilation. In this 
respect, a possible hyperpolarising factor-derived mechanism has been described in the 
isolated aorta of the obese Zucker rat (Kaw et al., 1999). 
In contrast, endothelium-dependent vasodilation was significantly improved by probucol 
but not by tiron. Furthermore, the measured oxidant stress correlated with the endothelial 
function in that probucol, but not tiron, significantly decreased plasma 8-epi-PGF2a,. These 
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results are somewhat contrary to the reduced vasodilation seen with vitamin E treatment. 
However, previous studies by Keaney et al., (1994; 1995) have also shown vitamin E to 
worsen, and probucol to preserve endothelial function in cholesterol fed rabbits. One 
explanation for this could be, in addition to its antioxidant activity, probucol's 
hypocholesterolaemic activity. This secondary role of probucol is not clearly understood 
but may involve either an immunolmodulatory activity (Wagberg et al., 2001) or Ca2+ 
blocking effect which is thought to be involved in reduction of fatty streak formation in 
atherosclerosis. It would seem probable that in a hyperlipidaemic Zucker rat, any slight 
decrease in early atheroma would increase vascular pliability. One study has even showed 
probucol to block a Ca2+ sensitive K+ channel, an effect that would also increase 
vasodilation in the hindquarters (Howland et al., 1984). In terms of the vascular balance 
hypothesis, probucol may act in a similar fashion to vitamin E, in decreasing the O2 ' levels 
and thereby decreasing the need for NO compensation. However, this secondary role of 
probucol improves vascular function through another mechanism, where agonist stimulated 
endothelial-dependent vasodilation is improved even when NO levels are decreased. The 
lack of effect seen with tiron, shows in both endothelial function and in reduction of 8-epi- 
PGF2a,, and is probably due to its hydrophilic nature. Reduction in lipid peroxidation is 
clearly via lipid soluble drugs that can enter the cell membrane and act in situ. However, 
tiron would have had some action to mop up the ROS generated in the plasma and 
intracellularly. Unfortunately though, tiron was not potent enough to generate a functional 
response in the hindquarters. 
Overall, the efficacy of the antioxidants, in modulating hindquarters endothelial vasodilator 
hyperreactivity in the obese Zucker rat suggests that this improvement in insulin resistance 
is related to differences in the regulation of agonist-stimulated endothelium-dependent 
vasodilation by oxidant tone in lean and obese animals in vivo. However, in the absence of 
defects in endothelial-dependent function in the obese Zucker rat, either in vivo or in situ, 
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which may conceivably reflect a compensatory enhancement of endothelial function in the 
face of oxidant stress, the ability of the antioxidants treatments to affect further 
improvements in function is probably limited. Therefore pro-oxidant interventions were 
also done to raise oxidant stress in the obese Zucker rat in vivo and to expose endothelial 
dysfunction, in the hope of a better understanding of the vascular implications of oxidant 
stress in this model of insulin resistance. 
Pro-oxidant treatment (HQ+BSO) increased plasma insulin and glucose levels in the obese 
Zucker rats. Glucose disposal was measured as insulin/glucose ratio (a parameter indicative 
of insulin sensitivity) to estimate the glucose-insulin feedback mechanism after fasting. It is 
similar to the widely accepted homeostasis model approach (HOMA), where the 
calculation: fasting insulin x fasting glucose /22.5 equals a HOMA score. This score 
correlates well to independent measures of insulin resistance and beta-cell function using 
the euglycaemic clamp technique (Bonora et al., 2000). In these studies, the glucose 
disposal (insulin/glucose ratio) was also increased in the obese rats, suggesting a metabolic 
deterioration that worsens the already present insulin resistance in the obese rats. 
Metabolic deterioration was accompanied by changes in endothelial function and oxidant 
stress. Pro-oxidant treatment . with HQ and HQ+BSO abolished the hyperreactivity of 
endothelial-dependent responses to ACh in obese relative to lean Zucker rats. This effect in 
obese rats was associated with a decrease in the magnitude of vasodilator responses to ACh 
with HQ and HQ+BSO treatment. However, respective lean Zucker rat responses showed 
small but significant increases in reactivity. This abolished endothelial hyperreactivity by 
HQ treatment in the obese Zucker rat supports other functional studies in vascular rings that 
showed HQ can impair ACh-induced relaxation (Furchgott, 1984; Lubbe et al., 1992), and 
enhance Phe-induced contraction (Kaw et al., 1998). This would be expected, as HQ is 
known to generate Of, and was also recently reported to have NO scavenging properties 
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(La et al., 1999). Therefore increased levels of 02', or even HQ itself could bind NO 
produced by endothelial cells, thereby reducing vasorelaxation. In addition, the increased 
levels of Oi ' could react with the already high levels of NO to form ONOO- (Gryglewski, 
1986), thereby promoting further endothelial dysfunction through cell damage. Indeed, as 
would be expected, the 8-epi-PGF2a, levels were also increased by pro-oxidant treatment. 
However, lean rats showed an increased vasoreactivity with pro-oxidant treatment. It may 
be that obese rats had reached their maximum oxidant status and could not counteract the 
excess free radical generation. For example, untreated obese Zucker rats may have elevated 
endogenous cellular antioxidants such as SOD, catalase, and glutathione. Indeed, previous 
studies have shown increased activity of catalase, glutathione peroxidase and SOD in 
endothelial cells following exposure to HZO2, suggesting the presence of inducible 
antioxidant defences (Lu et al., 1993). It may be that following chronic pro-oxidant 
treatment, these endogenous antioxidant pathways become exhausted. Experiments of cell- 
mediated oxidation of LDL have shown that the propagative phase of lipid peroxidation 
begins when more than 50 % of the initial chain-breaking antioxidants are depleted (Bowry 
et al., 1992). Alternatively, the lean animals may display an enhanced vasorelaxation as 
compensation for the pro-oxidant treatment; comparable to what is seen in the control 
obese rats. This suggests that lean rats are able to cope with the increased turnover of 
oxidants from HQ+BSO treatment by not only maintaining basal levels of 8-epi-PGF2a, as 
these were unchanged by pro-oxidant treatment, but by even enhancing endothelial 
function. These results suggest ROS upregulation of agonist-stimulated endothelium- 
dependent vasodilation in the lean Zucker rat. However, the ROS upregulation in the obese 
Zucker rat was too much for the antioxidant defences to cope with resulting in endothelial 
impairment. 
Clearly a major difficulty in diabetes research is using suitable systems which model 
disease. However, the pro-oxidant treated obese Zucker rat exhibits a number of 
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characteristic features of type 2 diabetes, such as hyperglycaemia and glycosuria (data not 
shown as glucose urine sticks were used - Diabur-test® 5000, Roche, UK). This suggests a 
causative link between oxidant stress and type 2 diabetes, at least in this model. This was 
unlikely to be related to metabolic deterioration (insulin hyposecretion) due to HQ+BSO 
toxicity at the level of the endocrine pancreas as the toxicological markers of renal, muscle, 
exocrine pancreas, and liver damage were previously assessed in our lab and shown to be 
normal (Vetlab, Horsham, UK). Pathological morphology of the endocrine pancreas was 
also normal. Decreased insulin levels in plasma can be used as an indicator of pancreatic 
damage, but this was actually increased in both the pro-oxidant treated lean and obese 
fasting insulin samples and in the obese glucose stimulated insulin samples (Fig. 6.7A; 
6.8A). Interestingly, it is known that insulin resistance also correlates with 
hyperleptinaemia, a possible candidate to link oxidative stress and endothelial dysfunction 
in type 2 diabetes. 
Oxidant insult due to vascular O2 ' and other ROS generation mechanisms, NO inactivation, 
increased turnover of antioxidants and the induction of antioxidant enzymes may play a 
pivotal role in aggravation of metabolic dysfunction. Specifically, the fasting glycaemia 
and exaggerated fasting hyperinsulinaemia observed in these animals. Increasing oxidant 
stress and the resulting enhancement then fall of endothelial function (a `bell shaped' 
response; Fig. 6.11) seems to prevail throughout these experiments, indicating the strong 
compensatory mechanisms involved in maintaining blood pressure and flow in response to 
diet. Figure 6.11 shows that increasing amounts of oxidants initially cause endothelial 
hyperfunction, probably by a compensatory increase in NO production, or alternatively by 
02"-induced enhancement of cellular responses. Finally, when the level of oxidant stress is 
increased further, the endothelial hyperfunction starts to diminish and endothelial function 
measurements are seen as "normal" and comparable to the lean littermate prior to the frank 
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dysfunction. Overall, assessment of the role of oxidant status on endothelial function and its 
contribution to metabolic dysfunction in type 2 diabetes needs further investigation. 
In summary, there is evidence to link insulin resistance, oxidant stress and altered 
endothelial function in the obese Zucker rat, a model of pre-diabetes. Oxidant stress alters 
normal endothelial function by reducing vasodilation and increasing vasoconstriction of the 
vasculature. This in turn can impair glucose disposal. The obese Zucker rat compensates for 
this vascular imbalance by enhanced agonist-induced NO-dependent vasodilation. 
However, by increasing oxidant stress, the obese Zucker rat is unable to cope and 
modulated endothelial function results. The involvement of other environmental factors, 
such as diet, in mediating the vascular and metabolic pathology of the Zucker rat is 








Figure 6.11 Hypothetical representation of changes in 
endothelial function in relation to the oxidant stress status of 
the obese Zucker rat. 
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Chapter 7 
Effect of fructose on endothelial 
function, oxidant stress and insulin 
resistance in the pro-oxidant treated 
obese Zucker rat 
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7.1 INTRODUCTION 
Previous chapters have shown that hyper endothelial function and impaired glucose 
tolerance in the obese Zucker rat was worsened by increased ROS-induced by pro-oxidant 
treatment. It was thought that, if the pro-oxidant-induced endothelial dysfunction and 
insulin resistance evoked in the obese rats was due to diminished antioxidant defences, then 
further environmental insult should worsen the dysfunction. Among potential dietary 
environmental factors, fructose is mainly of interest because of its ability to bypass the 
control steps of glycolysis, leading to an uncontrolled influx into glycolysis that results in 
metabolic changes characteristic of type 2 diabetes (i. e. insulin resistance). It is also 
interesting that the fructose content in our diets is becoming increasingly higher. Over the 
past 20 years high fructose corn syrup has become a widely used sweetener, especially in 
non-diet soft drinks. It is not understood if this increasing use of fructose in the population 
has any relationship to the rising prevalence of type 2 diabetes. Numerous studies in normal 
rats have shown that fructose feeding can cause hyperinsulinaemia, insulin resistance, and 
hypertriglyceridaemia (Zavaoni et al., 1980; Tobey et al., 1982). In addition, increased 
blood pressure (Hwang et al., 1987) and, more recently, defective endothelium-dependent 
relaxation (Verma et al., 1996) has been shown in this model. Therefore, if a normal rat can 
be made to develop type 2 diabetes it would follow that a genetically obese and pro- 
oxidant-induced insulin resistant rat would be even more susceptible to additional 
deterioration and frank type 2 diabetes. 
There is convincing evidence that hyperglycaemia significantly promotes the development 
of diabetic complications such as retinopathy and neuropathy. High plasma glucose levels 
may contribute more to this major damage associated with diabetic complications when 
metabolised to fructose, as glucose metabolised via the polyol pathway results in the 
formation of intracellular fructose. Fructose is known to accelerate the production of AGE 
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products more than glucose. However, in hyperglycaemic conditions, glucose is first 
converted to sorbitol via aldose reductase, then from sorbitol to fructose via sorbitol 
dehydrogenase. Even with high levels of fructose in diet, the blood level of fructose is only 
10 % of that of glucose. However, since the glycation index is 10 times that of glucose, 
dietary fructose may significantly add to normal glycation that occurs with aging. Fructose 
also enhances carbonyl stress through the formation of dicarbonyl compounds such as 3- 
deoxyglucosone (3DG), an intermediate in AGE formation (Thornalley et al., 1984; Sakai 
et al., 2002). 
Metabolism of fructose differs in muscle and liver (Fig. 7.1). Muscle contains only 
hexokinase, which can phosphorylate fructose to Fructose-6-Phosphate, a direct glycolytic 
intermediate. The liver contains mostly glucokinase, a glucose specific enzyme, in addition 
to other enzymes required to utilize fructose for glycolysis. Hepatic fructose is first 
phosphorylated by fructokinase, yielding fructose- l-phosphate. Aldolase can then utilise 
both frucotse-1,6-biphosphate and fructose-1-phosphate as substrates, to generate 
dihydroxyacetone phosphate (DHAP) and glyceraldehydes. The DHAP is converted by 
triose phosphate isomerase to glycerol-3-phosphate that enters glycolysis. This circumvents 
phosphofrucotse kinase controls, so fructose can thus flood the TCA cycle causing 
increased lipid synthesis in the liver. Fortunately, humans cannot absorb sufficient fructose 
to cause a fatty liver; also the metabolism of fructose from the diet is too rapid to allow it to 
accumulate in the blood. Fructose can cause marginal increases in blood lipids, uric acid, 
blood insulin, and blood glucose, and worsens already impaired glucose tolerance. 
Some of these metabolic effects of fructose are attributed to its rapid hepatic uptake and the 
fact that it bypasses the phosphofructokinase regulatory step in glycolysis (Mayes, 1993) 
and this unregulated glycolysis will lead to increased fat synthesis. Acute overloading of 
the liver with fructose results in sequestration of inorganic phosphate in fructose-1- 
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phosphate. The metabolism of fructose results in increased xanthine oxidase activity and 
glyceraldehyde production (which can generate free radicals). It may be that the liver is 
exposed to oxidative stress following fructose consumption and this may be a possible 
mechanism to partly explain the induced liver abnormalities. 
The fructose fed rat is a well established convenient, non-obese in vivo model of insulin 
resistance and type 2 diabetes (Tobey et al., 1992; Faure et al., 1997). Consequently, it can 
be seen to simulate what happens in humans, i. e. a disorder created by feeding 
abnormalities. Rats fed fructose either in the drinking water or the chow for a number of 
weeks (usually between 2-6 weeks) exhibit characteristic hyperglycaemia, insulin 
resistance and impaired endothelial function (Prasad et al., 1998). Additionally, this model 
has increased triglycerides plasma, and significantly raised levels of malondialdehyde and 
glycation products, indicating oxidative stress and glycation stress (Faure et al., 1997). The 
mechanism underlying endothelial function and its relationship to oxidant stress in these 
rats is not however understood. Since we have good evidence to associate oxidative stress, 
insulin resistance and endothelial function in the pro-oxidant treated obese Zucker rat, we 
wished to further examine our hypothesis in another established model of diabetes, i. e. the 
fructose fed rat. We reasoned this to be an important additional measure in the validation of 
oxidative stress hypothesis. 
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Figure 7.1 Entry of fructose into the glycolytic pathway in both 
hepatocytes and muscle. 
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7.2 RESULTS 
7.2.1 Effect of fructose and pro-oxidant treatment on insulin resistance in the obese 
Zucker rat. 
Body weight was greater in obese relative to lean animals (P<0.05) (table 7.1). The 
fructose only lean and obese groups showed only a slight (30-50 g) increase in weight 
compared to control and pro-oxidant treatments (P>0.05). 
Fructose & 
Treatment Control Fructose HQ+BSO 
HQ+BSO 
Obese 406.4± 8.6* 451.7±10.2* 399.3±19.5* 380.0±18.7* 
Lean 278.8±7.3 314.3±10.3 303.6±7.7 301.4±6.9 
Table 7.1 Body weights (g) of lean and obese Zucker rats following a fructose diet 
and pro-oxidant administration. Data are expressed as mean±s. e. mean of 5-7 
determinations. *P<0.05 with respect to corresponding treatment in the lean group. 
Plasma insulin and glucose levels were altered by pro-oxidant treatment and fructose 
diet. Obese basal plasma glucose and insulin levels were elevated relative to lean levels 
(P<0.05) in all groups with the exception of the fructose fed only group. Here fasting 
glucose levels were similar in the lean and obese groups (Fig. 7.2). Fructose treatment 
elevated basal plasma insulin levels in lean (P<0.05) but not obese rats (P>0.05). Similarly, 
basal glucose levels were significantly increased by HQ+BSO treatment but not HQ+BSO 
in combination with fructose, in lean but not obese rats (Fig. 7.2). 
Following bolus glucose (0.5 g kg" i. v. ) administration, both plasma glucose and insulin 
were greater in obese animals (Fig. 7.3) this was similar in all groups. Treatment with 
HQ+BSO alone caused increased insulin levels in the obese compared to their obese 
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control group. Comparisons of the insulin/ glucose ratio showed a similar profile to that of 
insulin and glucose AUC, i. e. impairment in glucose disposal in obese compared to lean 
rats and no significant changes with pro-oxidant treatment in obese and lean groups (Fig. 
7.3C). 
7.2.2 Effect of fructose and pro-oxidant treatment on endothelial function in the obese 
Zucker rat. 
Comparison of pD2 values from ACh-induced vasorelaxation showed a greater relaxation in 
the obese aortic rings compared to lean (P<0.05). Vasorelaxation was significantly 
impaired in the obese treated with HQ+BSO treatment alone, and in combination with 
fructose (P<0.05), but not by fructose alone (P<0.05) (Fig. 7.4; Table 7.2). 
Treatment 
Fructose & 
E (%) Control Fructose HQ+BSO 
HQ+BSO 
Obese 95.8±1.8 94.7±1.6 91.7±2.3 93.1±0.9 
Lean 90.1±2.0 86.6±2.8 88.1±2.7 90.5±1.5 
Fructose & 
pD2 Control Fructose HQ+BSO 
HQ+BSO 
Obese 7.50±0.03* 7.45±0.03* 7.16±0.03'P 7.25±0.02' 
Lean 7.18±0.03 7.26±0.01'P 7.16±0.01 7.28±0.01'P 
Table 7.2 Effects of combined fructose and pro-oxidant treatment on vasodilation 
to ACh (0.0001-10 nM) in aortic rings of obese and lean Zucker rats. Data are 
expressed as mean±s. e. mean of 4-7 determinations. *P<0.05 with respect to corresponding 
lean group; `vP=0.05 with respect to lean or obese control group. 
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In contrast, the lean vasorelaxation was enhanced by fructose treatment, even in 
combination with HQ+BSO. Interestingly, the obese aortic rings were only comparable to 
the lean rings following pro-oxidant treatment, with or without fructose. However, when 
E values were compared, there was no difference between groups. Vasorelaxations in the 
presence of L-NAME were significantly and maximally inhibited in all groups. 
Treatment 
Fructose & 
E. (g) Control Fructose HQ+BSO 
HQ+BSO 
Obese 2.40±0.18t 2.47±0.07t 2.45±0.24t 2.66±0.13t 
Lean 2.65±0.161 2.74±0.22t 2.77±0.141 2.61±0.08t 
Fructose & 
pD2 Control Fructose HQ+BSO 
HQ+BSO 
Obese 7.00±0.06*t 6.79±0.04t 6.76±0.06'Pt 6.85±0.06t 
Lean 6.74±0.04t 6.82±0.05t 6.89±0.041 6.97±0.06`ßt 
Table 7.3 Effects of combined fructose and pro-oxidant treatment on 
vasocontraction to Phe (0.0001-10 nM) in aortic rings of obese and lean Zucker rats. 
Data are expressed as mean±s. e. mean of 5-7 determinations. *P<0.05 with respect to 
corresponding lean group; 'PP<0.05 with respect to the equivalent lean or obese control; 
tP<0.05 with respect to the equivalent L-NAME treated lean or obese control. 
Comparison of Phe elicited concentration responses using pD2 values showed a leftward 
shift in the contraction response of the obese relative to lean (P<0.05) (Fig. 7.4; table 7.3). 
However, this was not mirrored by an increase in Ems, which was actually smaller in the 
obese (P>0.05). The presence L-NAME caused a leftward shift in both lean and obese 
contraction curves, normalising these differences between lean and obese Zucker rats 
(P<0.05) (Fig. 7.4; table 7.4). Treatments with HQ+BSO alone caused significant increases 
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in Phe-induced contractions in obese but not lean rats. However, the lean rats showed 
increased contractions with fructose & HQ+BSO combined treatment (P<0.05). The 
presence of L-NAME again evoked a leftward shift in all treatments groups (P<0.05), 
resulting in comparable contractions. Additionally, comparison of the E,,, a, values showed 
no differences between treatment groups in lean or obese rat aortic rings. In the presence of 
L-NAME, all groups had increased E. values (P<0.05), but were all comparable within 
the pro-oxidant treatment groups (Fig. 7.4; table 7.4). 
II Treatment 
Fructose & 
E (g) Control Fructose HQ+BSO 
HQ+BSO 
Obese 3.8±0.1 3.9±0.2 3.8±0.2 3.9±0.2 
Lean 3.8±0.2 4.0±0.2 4.0±0.1 3.9±0.2 
Fructose & 
pD2 Control Fructose HQ+BSO 
HQ+BSO 
Obese 7.54±0.10 7.51±0.08 7.48±0.09 7.58±0.11 
Lean 7.55±0.10 7.52±0.09 7.58±0.10 7.36±0.04 
Table 7.4 Effects of combined fructose and pro-oxidant treatment on 
vasocontraction to Phe (0.0001-10 nM) in the presence of L-NAME (300 µM) in aortic 
rings of obese and lean Zucker rats. Data are expressed as mean±s. e. mean of 6-7 
determinations. 
Comparison of SNP-induced vasorelaxation using E,. values showed similar results in the 
lean and obese rat aortic rings. This vasorelaxation was blunted by fructose in the lean 




E. (%) Control Fructose HQ+BSO 
HQ+BSO 
Obese 100.2±0.6 99.9±1.0 99.9±1.0 100.8±0.8 
Lean 100.2±0.7 97.1±1.1`{' 98.7±0.6 100.1±0.5 
F (%) in the 
Fructose & 
presence of Control Fructose HQ+BSO 
HQ+BSO 
L-NAME 
Obese 100.7±1.8 98.3±0.6 96.7±1.3 97.5±0.8 
Lean 97.7±1.2 97.5±0.9 96.5±0.7 96.0±0.9 
Table 7.5 Effects of combined fructose and pro-oxidant treatment on vasodilation 
to SNP (100 nM) in aortic rings of obese and lean Zucker rats. Data are expressed as 
mean±s. e. mean of 6-7 determinations. ''P<0.05 with respect to the lean control. 
Enhanced vasodepressor activity to ACh and SNP following fructose and HQ+BSO 
combination treatment in obese Zucker rats in vivo. Vasodepression to bolus dose ACh 
(0.01- 10 nmol kg-1 i. v. ) was comparable in lean and obese rats on control diet, but became 
greater in the obese relative to the lean rats after fructose and HQ+BSO combination 
treatment (P<0.05 2W ANOVA) (Fig. 7.5). Similarly, vasodepression to bolus dose SNP 
(0.1- 100 nmol kg" i. v. ) was comparable in the lean and obese rats on control diets, and 
was not significantly greater in the obese relative to the lean following treatment. 
High mean arterial blood pressure in obese Zucker rats. Mean arterial blood pressure in 
the obese control and treatment groups was higher than that of the lean (P<0.05) Zucker rat 
groups (Fig. 7.6). Pro-oxidant and fructose treatment showed no effect on the blood 
pressure in either group. 
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High plasma nitrate/nitrite levels in obese Zucker rats. Plasma nitrate/nitrite levels in the 
obese control and treatment groups were higher than those of the lean (P<0.05) Zucker rat 
groups (Fig. 7.7). In the obese rats, fructose and HQ+BSO treatments showed only a slight 
increase in plasma nitrate/nitrite levels compared to the controls and fructose in 
combination with HQ+BSO (P>0.05). In the lean Zucker rat groups HQ+BSO was reduced 
compared to the lean untreated (P<0.05). 
7.2.1 Effect of fructose and pro-oxidant treatment on oxidant stress in the obese 
Zucker rat. 
Plasma levels of 8-epi-PGF2 were only slightly increased in the obese relative to the lean 
Zucker rats, an increased n number may have attained significance (Fig. 7.8). Treatment 
with HQ+BSO, but not fructose or fructose combined with HQ+BSO, increased plasma 8- 
epi-PGF2a levels in obese (P<0.05). Dietary antioxidant treatments showed no effect in the 
lean (P>0.05) Zucker rats. 
High plasma triglyceride levels in obese Zucker rats. Plasma triglyceride levels in the 
obese control and treatment groups were higher than that of the lean (P<0.05) Zucker rat 
























Figure 7.2 Measurement of basal plasma insulin (ng mL-1) and 
glucose (mM) in 13 week-old lean ( ) and obese (. ) Zucker rats treated 
with sham, fructose, and IIQ+ßS0 alone and in combination. Data are 
expressed as mean±s. e. mcan of 5-7 determinations. Statistical significance 
was compared using a student t-test, *P<0.05 with respect to the equivalent 
lean control, or using one way ANOVA, "'P<0.05 with respect to the control 
treatment group. 
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Figure 7.3 Glucose tolerance test (g. t. t) in 13 week-old lean and obese 
Zucker rats treated with sham, fructose, hydroquinone and huthionine 
sulfoxamine (HQ+BSO) (50 mg kg-' i. p. daily), and fructose (HQ+BSO) in 
combination. Data are expressed as mean±s. e. mean of 4-7 determinations. 
Statistical significance was compared using a student t-test, *P<O. 05 with 
respect to the equivalent lean control, or using one way ANOVA, "'/'<0.05 
with respect to the control treatment group. 
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Figure 7.4 Effects of pro-oxidant and fructose treatment on contraction 
and relaxation responses in aortic rings in 13 week-old lean and obese 
Zucker rats. Rats were treated with sham (o), fructose (m), hydroquinone and 
buthionine sulfoxamine (HQ+BSO) (o), and fructose (HQ+BSO) in combination 
("). Contraction responses to phenylephrine (0.03- 10 µ M) alone in obese (A) 
and lean (B) rats, and in the presence of L-NAME (300 µM) in obese (C) and 
lean (D) rats. Vasorelaxation responses to acetylcholine (ACh, 0.0003-3 µM) in 
obese (E) and lean (F) rats. Data are expressed as mean±s. e. mean of 4-7 
determinations. Statistical significance (*) using 2 way ANOVA was considered 
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Figure 7.5 Effects of pro-oxidant and fructose treatment on 
vasodilator and vasoconstrictor responses in 13 week-old lean and obese 
Zucker rats in vivo. Rats were treated with sham (o), fructose (. ), 
hydroquinone and buthionine sulfoxamine (HQ+BSO) (o), and fructose 
(HQ+BSO) in combination ("). Graphs show vasodilator responses to 
acetylcholine (ACh, 0.001-10 nmol kg-1) in obese (A) and lean (B) rats, and 
sodium nitroprusside (SNP 1-100 nmol kg-1) in obese (E) and lean (F) rats and 
vasoconstrictor responses to phenylephrine (0.1- 100 nmol kg-1) in obese (C) 
and lean (D) Zucker rats Data are expressed as mean±s. e. mean of 4-7 
determinations. Statistical significance (*) using 2 way ANOVA was 
considered established at P<0.05. 
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Figure 7.6 Mean arterial blood pressure (MAI') in anaesthetised 13 
week-old lean (. ) and obese (. ) Zucker rats treated with sham (Q), 
fructose, hydroyuinone and huthionine sulfoxamine (HQ+BSO), and fructose 
(HQ+BSO) in combination. Data are expressed as mean±s. e. mean of 6-7 
determinations. Statistical significance was compared using a student t-test, 




Figure 7.7 Plasma nitrate/nitrite levels in lean and obese 13 week-old 
Zucker rats treated with sham, sham, fructose, and hydroquinone and 
buthionine sulfoxamine (HQ+BSO) alone and in combination (50 mg kg-' i. p. 
daily). Data are expressed as mean±s. e. mean of 3-6 determinations. Statistical 
significance was compared using a student t-test, *P<0.05 with respect to the 
equivalent lean control, or using one way ANOVA, "P<0.05 with respect to 
the control treatment group. 
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Figure 7.8 Plasma levels of 8-epi prostaglandin F,,, in 13 week-old 
lean (n) and obese (. ) Zucker rats treated with sham, fructose, and 
hydroquinone and buthionine sulfoxamine (HQ+BSO) alone and in 
combination (SO mg kg-' i. p. daily). Data are expressed as mean±s. e. mean of 
4-7 determinations. Statistical significance was compared using a student t- 
test, *P<0.05 with respect to the equivalent lean control. 
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Figure 7.9 Fasting plasma triglyceride levels in lean and obese 13 
week-old Zucker rats treated with sham, fructose, and hydroquinone and 
buthionine sulfoxamine (HQ+BSO) alone and in combination (50 mg kg-' i. p. 
daily). Data are expressed as mean±s. e. mean of 5-7 determinations. 
Statistical significance was compared using a student t-test, *P<0.05 with 
respect to the equivalent lean control, or using one way ANOVA, "'P<0.05 
with respect to the control treatment group. 
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7.3 DISCUSSION 
Obese basal plasma glucose and insulin levels were significantly elevated relative to lean 
levels. Interestingly, plasma glucose was increased in the obese HQ+BSO treatment group, 
a condition that was normalized with the pro-oxidant and fructose combination. Similarly, 
following the glucose load, both the glucose and insulin responses were greater in obese 
compared to lean animals. There was a significant increase in insulin levels in the 
HQ+BSO treated obese compared the control obese. However the HQ+BSO combination 
with fructose feeding did not further impair the increased insulin response, but 
paradoxically decreased it. This suggests an apparent protective effect of fructose rather 
than impairment as originally expected. However, the lean rats only showed an increase in 
fasting plasma insulin levels following treatment with fructose only. Fasting plasma 
glucose and glucose disposal was not shown to be affected by fructose or pro-oxidant 
treatment in the lean rats. Pro-oxidant treatment was not expected to increase the insulin 
resistance parameters tested in this study as previous studies (chapter 6) have not shown 
impairment in the lean rats. This was thought to be due to their ability to compensate for 
this increased stress. 
Comparison of ACh-induced vasorelaxation was significantly greater in the obese aortic 
rings compared to lean. This finding has been shown by other groups (Sexl et al., 1985) and 
supports the enhanced vasodilation found in the obese hindquarters. The obese 
vasorelaxation was significantly impaired by HQ+BSO treatment alone. However, this was 
not the case with HQ+BSO in combination with fructose. This again suggests that fructose 
may indeed protect against pro-oxidant damage, at least in this model. All these responses 
were in similarly contracted rings, as the Phe elicited contraction curves were not different 
between the treatment groups of either the obese or lean rats. However, the Phe 
contractions were increased in the obese aortic rings compared to the lean using pD2 value 
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comparisons. Though if this increased contraction was to affect the ACh-induced 
relaxations it would cause impairment, as the more contracted a tissue is, the higher the 
concentration of vasodilatory agonist required to overcome the contraction. The SNP- 
induced vasorelaxations were similar in the lean and obese rat aortic rings, and therefore 
any changes measured in the obese are endothelial-dependent. 
Blood pressure studies showed vasodepressor activity to ACh and SNP was enhanced 
following fructose and HQ+BSO combination treatment in obese Zucker rats in vivo. 
Vasodepression to bolus dose ACh and SNP was comparable in lean and obese rats on 
control diet, but became greater in the obese relative to the lean rats after fructose and 
HQ+BSO combination treatment. This data suggests a protective role for fructose in pro- 
oxidant treated rats. Furthermore, as mean arterial blood pressure was unaffected by 
treatments in either lean or obese groups, agonist-induced changes could not simply be 
greater due to higher basal pressures. The obese control and treatment groups did have 
significantly higher blood pressures than those of the lean Zucker rat groups. However, this 
did not cause an increased agonist-induced response in the obese. 
Interestingly, plasma nitrate/nitrite levels in the obese control and treatment groups were 
higher than those of the lean Zucker rat groups. This was not unexpected given the 
increased ACh-induced endothelial-dependent vasodilation seen in the obese rats. 
However, in these rats, fructose and HQ+BSO treatments showed a only slight increase in 
plasma nitrate/nitrite levels compared to untreated and those treated with fructose and 
HQ+BSO in combination. These results support findings from previous insulin resistance 
and endothelial-dependent studies. In addition, the lean pro-oxidant treated group showed 
decreased levels of nitrate/nitrite, suggesting that the NO balance is affected by pro-oxidant 
treatment, but not enough to impair endothelial function. Finally, oxidant stress 
measurements showed treatment with HQ+BSO, but not fructose or fructose and HQ+BSO 
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in combination, increased plasma 8-epi-PGF2a levels in the obese rats. The lean plasma 8- 
epi-PGF2a levels remained unaffected by pro-oxidant treatment; this has been seen in 
previous experiments (chapter 6). The plasma 8-epi-PGF2 levels in this study were 
analysed using an ELISA method unlike the previous chapters where GCMS was used. It is 
interesting to note that similar levels were obtained in this study compared to the previous 
findings. 
The protective role of fructose shown in these studies needs further investigation and this 
data needs to be confirmed; particularly as the lean Zucker rat only responded to the 
fructose diet with increased fasting insulin and triglyceride levels, and no changes in 
endothelial function or oxidant stress were shown. Changes in endothelial function and 
oxidant stress have previously been shown in Wistar rats following a fructose treatment 
(Dai & McNeill, 1995; Faure et al., 1997). In addition, studies in the Zucker rat have shown 
increased insulin and triglycerides as well as increased blood pressure in fructose fed lean 
Zucker rats (Verma et al., 2001). Interestingly, this study also showed that fructose 
increased insulin levels in the obese Zucker rat but that there was no effect on blood 
pressure. These results are supportive of my data in that a fructose diet in the obese rats was 
shown to have a protective effect on aortic ring vasodilation and no effect on blood 
pressure. Unfortunately, in my studies the obese rats did not develop a worsened 
hyperinsulinaemia. However, another study in the obese Zucker rats that supports my data 
has shown that small amounts of oral fructose reduced post prandial glycaemia (Wolf et al., 
2002). It may be that my results did not show fructose alone induced increases in insulin 
and triglyceride levels in the obese rat because both parameters were already high. 
Alternatively, it may be that fructose promotes diabetes in the absence of oxidant stress in 
normal albino animals, but is protective when levels of oxidant stress is high or levels of 
antioxidants are low. 
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This data appears to be the first demonstration of fructose feeding protecting against the 
deterioration of metabolic disease leading to frank diabetes, at least in the model described. 
It is important to note that previous studies have shown that a fructose diet protects against 
the complications of diabetes such lethal reperfusion injury to sinusoidal endothelial cells in 
rat livers (Currin et al., 1996). In addition, high fructose levels have been shown to protect 
against LPS-induced sepsis damage (Harris et al., 1999). It was speculated that this may be 
due to the high circulating levels of endogenous triglyceride rich lipoproteins, which are 
components of a non-adaptive innate immune response to endotoxin-induced by fructose. 
Interestingly, triglyceride levels were increased in the obese rats in our studies (Fig. 7.9). 
Also, increased levels were seen in the lean rats with fructose diet alone. In addition, Harris 
et al., showed increased levels of NO released from endothelial cells. When the induced 
NO was non-selectively inhibited, the fructose-induced protection against endotoxemia in 
vivo was completely abolished. Similarly, hepatocytes were protected from TNFa-induced 
toxicity by fructose in vivo and in vitro (Latta et al., 2000), though ATP depletion by 
fructose was suggested as the primary metabolic cause of their results. Fructose does not 
block ATP synthesis nor deplete organic substrates for glycolysis or mitochondrial energy 
generation. It is thought that fructose acts as a sink for the cellular phosphate pool, as it is 
rapidly phosphorylated in order for it to enter into glycolysis. Interestingly, a study has 
shown that by increasing ingestion of fructose in healthy subjects, levels of uric acid 
increased (MacDonald et al., 1978). This supports the theory that fructose causes the 
depletion of hepatic adenine nucleotides and that the purine component of these appears as 
uric acid. Indeed the authors show a significant correlation between serum fructose and uric 
acid concentrations. For each 1g fructose /kg bodyweight a 0.6 mg/100 mL increase in uric 
acid resulted. Uric acid is an antioxidant in vivo that scavenges peroxyl radicals, HO' and 
ONOO-. Therefore in my experiments this increased uric acid concentration may have 
scavenged the basal radical production in the obese Zucker rats and even the pro-oxidant 
challenge which in turn prevented endothelial dysfunction. Most interestingly, whilst 
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preventing oxidant-induced endothelial dysfunction, fructose treatment may have also 
prevented in the obese, the insulin and triglyceride increases seen in the lean rats. 
Other explanations for the protection by fructose include intracellular acidification as a 
result of glycolysis. However, it has been shown that its protection is pH-dependent in the 
hepatocyte (Nieminen et al., 1990). Another likely theory proposed is the protection against 
oxidative injury by ferric iron (Fe 3+) chelation (Valeri et al., 1997). Fructose and tagatose 
were shown to protect hepatocytes against oxidative cell injury by the formation of stable 
complexes with Fei+. Effective iron chelation would prevent iron catalysed formation of 
HO' and prevent pro-oxidant-induced toxicity. For example the Fenton reaction is the 
reaction involved in the biological generation of HO'. The reaction involves O2 ' which 
reduces Fe 3+ to Fe2+ and then subsequent reduction of H202 re-oxidizes the Fe 2+ with the 
concomitant generation of HO': 
OZ '+ Fe 3+ --ý O2 + Fe 2+ 
Fe2+ + H202 -> Fe 
3+ + HO- + HO' 
Interestingly, these studies showed that toxicity from both cocaine and nitrofurantoin was 
dependent on the presence of intracellular Fei+, and that deferoxamine protected against 
injury (Valeri et al., 1997). The authors considered whether Fe 3+ chelation is the factor in 
fructose protection, and whether decreased intracellular Fe 3+ would prevent the rapid 
oxidation of GSH. This has been shown in reverse in studies where fructose inhibited 
reoxygenation-induced apoptosis by decreasing ROS via stabilisation of the glutathione 
pool (Frenzel et al., 2002). These studies showed that pre-treatment with BSO abolished 
the effects of fructose. There may be a dual role for intracellular Fe 3+ in fructose protection 
as it has also been shown that Fe 3+ is required for uric acid to protect against ONOO-. In 
conclusion, our studies show a protective role by fructose to prevent the onset of frank 
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diabetes. However, it remains clear that a more complete understanding of the 





The models developed for my research included one for blood flow measurements in the rat 
ear -a potential model of non invasive endothelial function. This model was particularly 
interesting as it provided in vivo data that supported in vitro studies which showed the 
existence of an EDHF involvement in small resistance vessels (Urakami-Harasawa et al., 
1997). However, there were a number of problems with the methodology which restricted 
the time and effort afforded to this method's development, hence its absence in the later 
chapters. Firstly, the probe was rather large and bulky in comparison to the small delicate 
ear of the rat. This impeded the ability to position the tip (only 0.85 mm itself) carefully on 
the same vessel resulting in large variations in each experiment. Secondly, slight 
movements from the rat ear, such as a very deep breath, caused the probe position to move. 
If the probe was smaller and more delicate it could be secured to a sticky backing such as 
those used in rabbit ear photoplethysmography studies and this would avoid the movement. 
The results shown have accounted for the movement in the studies by using SNP as an 
internal control, though a number of rats were not included in the data sets as, due to many 
hours of anaesthetic and repeated dosing of ACh, they were near to being volume loaded. 
Future studies in this model could therefore be achieved if tiny probes were used with 
gentle adhesive and with a small pliable wire that could transmit signals from the probe to 
the recorder. 
EDHF involvement in the resistance vessels is certainly an area of great interest. 
Preliminary evidence from our laboratory showed a non-NO non-prostanoid relaxation of 
obese Zucker rat aortic rings (Kaw et at., 1999) indicating that EDHF is an important factor 
in endothelial dysfunction in the Zucker rat, making this potential non invasive in vivo 
model a valuable tool for investigation of the role of EDHF in diabetes. 
The perfusion model was a reproducible and simple preparation. It allowed investigation 
into the insulin sensitive beds and resistance vessels that are most important in the 
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investigation of type 2 diabetes. An example of the importance of preparation choice was 
seen, in that very different results were achieved in the parallel studies of the acute effects 
of insulin in the rat aortic rings and hindquarters preparation (chapter 5). This shows how 
the site of investigation is particularly significant in diabetes studies. In hindsight, studies in 
the fructose chapter should have been done in the hindquarters preparation as the data 
would have probably provided a greater correlation between endothelial function and 
oxidant stress. As far as future development of this model is concerned, glucose uptake 
from the hindquarters might be measured. This measurement would provide another 
important physiological parameter similar to the euglycaemic clamp technique - the gold 
standard in glucose disposal measurements. Radioactive tracers of glucose then could be 
used in the PSS, and glucose content in the muscles and effluent measured following the 
experiment. Preliminary studies have been carried out and present a promising 
experimental model for future studies. The limitation of the perfused hindquarters 
preparation was the time restriction, in that 90 min was used as a maximum time for the 
experimental procedure. This prevented the use of slow onset and duration agonists. It 
would have been interesting to measure the effects of insulin in this model after long 
duration of perfusion for e. g. 4 hours in order to parallel the studies of that Baron and 
Steinberg that were carried out on human subjects. 
The blood pressure cuff provided a good model for non-invasive measurement of 
endothelial function for use in chronic studies. Unfortunately, this method could not be 
used in any further experiments due to the pigmentation of the Zucker rat's tail. However, 
the tail cuff has been tested and is ready for use in future studies in other rodent models. 
The existence of oxidant stress, endothelial function and insulin resistance was investigated 
in the pre-diabetic obese Zucker rat. As the insulin resistant syndrome is only in its early 
stages in the 13 week-old obese Zucker rat, the extent of oxidant stress and endothelial 
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dysfunction was uncertain. The presence of oxidant stress, endothelial function and insulin 
resistance was investigated prior to characterising the relationship between them and their 
involvement in disease progression by the use of pharmacological intervention. 
T Fasting glucose T Fasting insulin 
J. Glucose disposal 
T Endothelial function 
T 8-epi-PGF2a 
T Nitrate/nitrite 
T Blood pressure I Blood volume 
Table 8.1 Characterization of insulin resistance, endothelial function and oxidant 
stress in the 12-13 weeks-old obese Zucker rat. 
Oxidant stress, endothelial hyperfunction and insulin resistance were exhibited in the 12-13 
week-old obese Zucker rat without any pharmacological intervention (Table 8.1). These 
results together could suggest enhanced oxidant stress contributes to insulin resistance and 
compensatory enhanced endothelial function. This may happen through damage to the 
insulin receptors or their signalling pathways, for example by the production of AGE or 
NAD(P)H-redox imbalances. Endothelial hyperfunction ex vivo may be a compensatory 
mechanism to the increased OZ ' present in vivo in this obese rat. However, the fasting 
glucose in the obese Zucker rat was increased compared to the lean, but was within a 
normal range of <6mM and was therefore not strictly hyperglycaemic. Hyperglycaemia- 
induced damage to insulin receptors and the endothelium is therefore unlikely. 
Alternatively, together these results could suggest that insulin resistance contributes to the 
enhanced endothelial function as a part of a compensatory mechanism, which counteracts 
the poor glucose disposal - hence minimal fasting hyperglycaemia in the obese Zucker rat. 
In addition, the insulin resistant syndrome could lead to oxidant stress through increased 
levels of post prandial plasma glucose. The insulin resistant syndrome is usually associated 
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with increased blood pressure and poor endothelial function in vivo due to an increased 
sympathetic output. This would in turn increase the need for enhanced endothelial function. 
An enhanced sympathetic drive would also reduce the observed insulin and NO -derived 
vasodilation as it would antagonise the balance in preference of constriction. Studies using 
the euglycaemic clamp technique support this notion, and one review (Fagius, 2003) 
showed that in healthy subjects, insulin infusion to levels corresponding to a postprandial 
state caused a sustained moderate increase in muscle sympathetic nervous activity. A 
peripheral vasodilation was also observed despite the enhanced sympathetic vasoconstrictor 
command; blood pressure remained stable (Anderson et al., 1991). Another, similar study 
described supraphysiological insulin levels that induced an increase in muscle sympathetic 
nervous activity, which was also without a hypertensive reaction (Berne et al., 1992). 
Insulin mediated vasodilation on muscle vessels, exerted via NO release opposes the effect 






Figure 8.1 Paradigm of insulin resistance, endothelial function and oxidant stress. 
Finally, although unlikely, these results could suggest that endothelial dysfunction may be 
responsible for insulin resistance. For example, the enhanced generation of NO may lead to 
sympathetic nervous system compensation and a balance tipped toward vasoconstriction 
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that will impair glucose uptake. In addition, if the NO pathway is constantly stimulated by 
other mediators, then insulin's small vasodilatory effect may be lost in the large overall 
vasodilation or balanced by sympathetic constriction. Impaired endothelial function can 
also lead to increased 02-' generation. It has been shown that the NOS enzyme can generate 
02 ' instead of NO when the cells lack cofactors such as arginine and BH4. This would most 
likely be when the cell is "over-worked" by the constant high generation of NO. 
Studies of the obese Zucker rat suggest that the pathological progression is via central 
nervous system and autonomic nervous system dysfunction that results in insulin over 
secretion and dysregulation of insulin counter regulatory hormones. Certainly, this 
compares with studies in young 6-7 week-old obese rats, where levels of insulin were 
approximately 3 fold higher compared to the lean rats. These obese rats' glucose disposal 
was impaired too (Ionescu et al., 1985). Evidence to suggest the involvement of autonomic 
dysfunction in early type 2 diabetes in humans was recently shown in heart rate variability 
studies using E. C. G (Laitinen et al., 1999). These studies showed that in the offspring of 
insulin resistant subjects, but not in controls or the offspring of type 2 diabetic patients with 
insulin secretion phenotype (low C-peptide levels), that an insulin infusion significantly 
increased the low/high frequency ratio (an index of autonomic balance) to a higher value, 
indicating sympathetic predominance. The paradigm of what leads to this is still uncertain. 
It is, however, known that insulin resistance is the common factor in the syndrome X 
pathology, and that oxidant stress and endothelial dysfunction probably leads to the 
complications of the diabetic disease where they are not shown to be causative factors 
themselves. 
Investigation of the effects of insulin on endothelium-dependent vasodilation in the 
hindquarters and aortic rings from the obese Zucker rat gave quite contrasting results. The 
hindquarters of the obese Zucker rat with already enhanced endothelial function showed 
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less vasodilation in the presence of insulin, whereas the aortic rings showed an enhanced 
relaxation in the presence of insulin. This tissue variability may help explain the selective 
action of insulin in the diabetic disease progression. The literature reports insulin mediates 
increased muscle blood flow in healthy subjects, a process that is impaired in type 2 
diabetic patients (Steinberg et al., 1996). This impaired action of insulin in the insulin 
sensitive tissues may be a factor in the early stage of disease in insulin resistant subjects; 
the macrovasculature at this stage may remain undamaged. It may be that macrovascular 
damage is the consequence of later disease and diabetic complications such as 
hypertension. Both my results from the investigation of the acute effect of insulin are from 
ex vivo preparations, therefore the increased blood pressure present in the obese Zucker rat 
is probably not due to hyperinsulinaemia itself as its aorta elicited insulin-induced dilation. 
This further suggests the involvement of enhanced sympathetic output. The use of a novel 
insulin bound NO donor drug would be useful to separate these sites of action and observe 
the whole effect in vivo. 
It may be that ANS dysfunction is the initiator of the disease and that the pathophysiology 
of the obese Zucker rat arising from CNS disorders leading to insulin resistance could apply 
to humans. Diabetics have an insulin resistant, pre-diabetic state for some years prior to 
exhibiting type 2 diabetic disease. It follows therefore, similarly to the obese Zucker, that 
humans may require the "insult" from other environmental factors to push insulin resistance 
to frank diabetes; the increased processed food and sugar intake in our diet may progress 
the disease in those individuals susceptible. 
Treatment with pharmacological tools such as pro-oxidants, antioxidants and fructose led to 
an understanding that environmental factors may be important, in that the changes in the 
oxidant balance caused modulation of both endothelial function and insulin resistance in the 
obese Zucker rat in vivo. As insulin resistance was affected too, it may be that oxidant 
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stress can be a causative factor in the progression from insulin resistance to type 2 diabetes 
at least in this model. This relatively new model of type 2 diabetes (pro-oxidant treated 
Zucker rat) showed the influence of oxidant status to change both endothelial function and 
insulin resistance together, suggesting there may be a relationship between them. 
The antioxidant treatment gave positive evidence for the use of vitamin E in the early 
stages of diabetes, possibly by slowing the progression of the disease. Although this area of 
vitamin intake is extremely controversial, there is evidence of insulin depleting vitamin E 
supplies in circulating lipids regardless of the presence of insulin resistance (Galvan et al., 
1996). It would therefore follow that in hyperinsulinemic states, increased vitamin E would 
be used. This data sits alongside other evidence for the benefits of antioxidant therapy in 
type 2 diabetes, whilst the physiological and pathological balance of the oxidant status 
remains debatable. 
As for the protective effect by fructose in these studies, it can only be said that there was no 
increase in oxidant stress. Therefore impairment of endothelial function and worsened 
insulin resistance would not have been expected. However, the mechanism by which 
fructose induced protection is unclear. Increased triglycerides as a protective mechanism 
would contradict the fatty acid-induced insulin resistance hypothesis (Goldstein, 2002), as 
increased insulin resistance would have been expected. A feasible mechanism is that 
fructose forms stable complexes with Fe3+ and prevents the Fe 2+ catalysed formation of 
OH' via the Fenton reaction. This would prevent increased oxidant stress and therefore 
decrease the pro-oxidant-induced toxicity. These results reinforce that notion of an oxidant 
balance as a fructose diet has been shown to increase oxidant stress in normal animals and 
yet can protect in diabetic disease. 
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In summary, I developed models for the assessment of endothelial function that are 
especially useful in diabetes research - the in situ perfused hindquarters and an in vivo ear 
blood flow model. Endothelial function and oxidant stress were then investigated in the 
obese Zucker rat -a model of insulin resistance. Subsequently, endothelial dysfunction and 
oxidant stress were found to coexist with insulin resistance in this 13 week-old pre-diabetic 
rat model. My studies went on to show that oxidants not only contribute to endothelial 
function and therefore the complications associated with type 2 diabetes, but that they may 
also be a causative factor in progression to frank type 2 diabetic disease. Finally, dietary 
insult with fructose showed, paradoxically, protection against oxidant-induced damage in 
the obese animal with pre-diabetes. These studies have shown that the oxidant balance is 
finely tuned (especially in the case of dietary fructose) and that much research is required 
before it is understood if oxidant stress, and its resultant damage to endothelial function, 
together with its aggravation of insulin resistance, is a significant cause of this very 
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